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Yersinia pestis, the infective agent of bubonic and pneumonic plague, is classified 
as a category A agent of bioterrorism. YopM, a protein toxin of Y.  pestis, is necessary for 
full virulence in a systemic plague mouse model with ambient-temperature grown 
bacteria. We used this model to identify the cells undermined by YopM. Natural killer 
(NK) cells were previously reported to be lost in spleen and blood in a YopM-associated 
way; however, NK cell depletion was found not to occur in liver, and ablation of NK 
cells had no effect on bacterial growth, indicating that NK cells are redundant for the 
YopM-mediated virulence mechanism. In mice either ablated for Gr1
+
 cells or lacking 
the chemokine receptor CCR2, wildtype growth was at least partially restored to the 
ΔyopM Y. pestis in both spleen and liver. In a mouse model of bubonic plague, CCR2 also 
was shown to be required for the ΔyopM Y. pestis to show wildtype growth in skin. These 
data pointed towards Gr1
+
CCR2
+
 cells, which include polymorphonuclear leukocytes 
(PMNs), inflammatory monocytes and inflammatory dendritic cells (iDCs), as key 
cellular components in controlling the in vivo growth of the ΔyopM Y. pestis. Recruitment 
of Gr1
+
CCR2
+
 cells into both organs was not YopM-dependent, except iDCs, whose 
influx from blood into spleen was blocked by the YopM-producing Y. pestis parent strain, 
but not the ΔyopM mutant. Ablation of PMNs, another main subset of Gr1+CCR2+ cells, 
relieved the growth limitation of the ΔyopM Y. pestis in liver, but not in spleen. Taken 
together, the data imply that YopM disables the recruitment of CCR2
+
Gr1
+
 iDCs into 
spleen but compromises the function of CCR2
+
Gr1
+
 PMNs in liver. These results were 
recapitulated when the infecting ambient-temperature-grown bacteria received 3 hours of 
incubation at 37°C. However, the appearance of the yopM mutant phenotype was 
postponed at least 24 hours, indicating that some virulence property of Y. pestis that was 
induced by the temperature transition compensated for the loss of YopM in
 
the yopM 
strain at an early stage of the infection. In general, these findings provide a framework for 
focusing future research to identify YopM’s direct molecular targets. 
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 1 
Chapter One: Introduction 
 
A. Plague and Yersinia pestis natural history 
a) Natural history and major clinical forms of plague 
Plague, a deadly infectious disease caused by the gram negative bacterium, Yersinia 
pestis, has caused widespread loss of human life during recurrent pandemics. Three 
pandemics in human history were recorded. The first pandemic, named the Justinian 
plague (541–767 A.D.) killed 100 million people in Europe and Asia. The second 
pandemic, named the Black Death (1346-19th century), spread over 3 major continents 
including Asia, Europe and Africa and reduced the world's population from 450 million 
to between 350 and 375 million. The third pandemic began in China in 1855 and for the 
first time was recognized to be transmitted by two different sources: bubonic plague 
transmitted through infected rats and fleas and pneumonic plague with direct person-to-
person transmission. This modern plague became a global threat after the bacteria from 
the high-mortality 1894 epidemic in Hong Kong were disseminated by marine shipping 
to Hawaii and finally reached San Francisco. After more than one century of effort since 
Alexandre Yersin and Shibasaburo Kitasato isolated the bacterium of the Hong Kong 
epidemic, plague is believed to be curable and only draws some historical interest. 
However, plague's geographic range has expanded greatly, and Y. pestis poses new threats 
in previously unaffected regions, including the western United States (Figure 1.1). 
Epidemics still occur frequently in developing countries where people live in unsanitary, 
rat-infested environments, for example, the 1994 pneumonic plague outbreak in India and 
ongoing outbreaks in South America and Africa (92, 106, 315) . The concern about the 
 2 
potential use of Y. pestis as a bioterrorism weapon is increasing because Y. pestis can be 
used in an aerosol attack that causes an outbreak of pneumonic plague. Further, because 
of the delay between exposure to Y. pestis and becoming sick, infected people could 
travel over a large area and possibly spread the bacteria to others, which makes 
controlling the disease more difficult. A bioweapon carrying Y. pestis is possible because 
the bacterium is available and could be isolated and grown in quantity in a laboratory, 
even though manufacturing an effective weapon using Y. pestis would require advanced 
knowledge and technology. 
Clinically, there are three major forms of plague, bubonic, pneumonic and septicemic. 
Bubonic plague is a rodent-associated, flea-borne zoonosis. Xenopsylla cheopis (the 
oriental rat flea) is considered the classic vector because of its role in the last pandemics. 
However, over 31 species of flea have been proven to be vectors of plague, and their 
importance in Y. pestis transmission depends on the region. For example, Oropsylla 
montana (the rock squirrel flea) is more potent than X. cheopis in the western US (245). 
When a flea leaves its dead host and bites a human, the bacteria will enter into the 
skin tissue through regurgitated blood from the flea (Figure 1.1). Even when 
phagocytosed by macrophages, Y. pestis can survive and reproduce inside the cells. After 
adaptation to the microenvironments in flea bite sites, the bacteria can enter the lymphatic 
system until they reach a lymph node, where they stimulate severe haemorrhagic 
inflammation that causes the lymph nodes to expand. The expansion of lymph nodes is 
the cause of the characteristic "bubo" associated with the disease (251). 
The bacteria rapidly enter into the bloodstream via the lymphatics so that they can 
travel to anywhere in the body. At this stage, bubonic plague progresses to septicemic 
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plague (142, 245). In septicemic plague, bacterial endotoxins can induce disseminated 
intravascular coagulation (DIC). Some of these clots can clog the vessels and cut off 
blood supply to various organs such as the liver, brain, or kidney. These organs will then 
stop functioning. Over time, the clotting proteins are consumed, and bleeding into the 
skin and other organs occurs, which manifests as a red and/or black patchy rash and 
hemoptysis (coughing up or vomiting of blood). While septicemic plague is usually 
secondary to lymphadenitis, patients with septicemic plague sometimes have no history 
of a bubo, and this clinical form has been termed primary septicemic plague. Untreated 
septicemic plague is usually fatal and the patients often die on the same day symptoms 
first appear.  
The third form is pneumonic plague that can be caused by two ways, primary and 
secondary (138, 245). Secondary pneumonic plague is the typical one and develops 
secondarily to either bubonic or septicemic plague. Primary pneumonic plague is rare and 
caused by person-to-person transmission through a bacteria-containing aerosol. The 
incubation period for pneumonic plague is usually between two and four days, but can be 
as little as a few hours. The initial symptoms are fever, weakness and headache, which 
make it indistinguishable from viral flu.  However, this disease can rapidly progress to 
pneumonia with shortness of breath, chest pain, cough and hemoptysis. Without diagnosis 
and treatment, the patient will die from respiratory failure and shock in one to six days; 
mortality in untreated cases is approximately 100%. 
 
b) Clinical diagnosis and treatment 
Because of the rapid progression of the disease, a clinical diagnosis of plague is 
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generally based on the symptoms and exposure history. For example, if a patient has a 
history of contact with rodents or other wild animals in the southwestern area of the 
United States and developed a painful, swollen lymph node and high fever, bubonic 
plague should be suspected. Septicemic plague and pneumonic plague are more difficult 
to diagnose because they display non-specific gram-negative septicemia and pneumonia 
symptoms, respectively, instead of the distinctive “bubo” in bubonic plague. As soon as 
plague is suspected, different samples, such as blood, bubo aspirates, sputum, and 
scrapings from skin lesions, should be obtained for laboratory diagnosis. However, 
treatment should start immediately while waiting for the laboratory results. 
A laboratory diagnosis of plague includes tests based on bacteriologic and serological 
evidence (245). Staining techniques such as the Gram, Giemsa, Wright, or Wayson stain 
can provide supportive but not presumptive or confirmatory evidence of a plague 
infection. A new rapid diagnostic test that uses fluorescent antibody against the fraction 1 
(F1) antigen, a pilus antigen expressed predominantly at 37ºC, has recently shown 
promise for early detection of plague. Alternative methods for diagnosing plague have 
been developed, including enzyme linked immunosorbent assays (ELISA), PCR analysis, 
and DNA hybridization. However, none of these techniques has been developed 
sufficiently and evaluated to be used routinely by clinical laboratories. To confirm a 
diagnosis of plague, it is necessary to isolate the organism from the samples collected 
from the patient. Y. pestis grows slowly and may require more than 48 hours to form 
visible colonies. The optimal growth occurs at 28°C. Blood culture results are positive in 
85-96% of patients, and bubo aspirate culture results are positive in 80-85% of patients, 
while sputum culture results are positive only if lung involvement is present. 
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All patients suspected of having bubonic plague should receive supportive care, such 
as crystalloid infusion and administration of oxygen, as well as isolation for at least 48 
hours after starting antibiotic treatment to prevent the potential spread of the disease in 
case the patient develops secondary plague pneumonia. Early administration of 
antibiotics is essential. Drugs that cover Y. pestis should be given empirically to any 
patient with predisposing risk factors and signs and symptoms of plague. The antibiotics 
usually used in anti-plague treatment include gentamicin, streptomycin sulfate, 
chloramphenicol, doxycycline, ciprofloxacin, tetracycline and co-trimoxazole. Antibiotic 
treatment duration should be 10 days. In severe cases, a 2-drug regimen should be used. 
The tetracyclines are popular antibiotics for plague prophylaxis (211, 245).  
c) Vaccines 
Although plague can be cured these days, the potential for rapid spread still raises a 
concern for public health. Meanwhile, the individuals who might be exposed to Y. pestis, 
e.g. veterinarians, scientists engaged in research with Y. pestis and individuals who are 
travelling to parts of the world where the disease is endemic, are at high risk for the 
disease and should be vaccinated. Therefore, in the long term, prophylactic vaccination 
against this disease holds the brightest prospect for its control. 
Both live and killed vaccines have been used. The live vaccine was derived from an 
attenuated strain (EV76), while a killed vaccine (named USP) used a formalin-fixed 
virulent strain of Y. pestis and relied on the Y. pestis-specific F1 fibril protein as the 
principal immunogen (212). The killed vaccine was used in people from the late 1890s 
and although evidence indicates that these formulations reduced the incidence of bubonic 
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plague (62), there is no evidence that they are effective against pneumonic plague in 
humans (67). While the live EV76 vaccine conferred greater protection against infection 
with WT Y. pestis, this vaccine caused severe adverse reactions (198, 275), not to 
mention the quick waning of the protective responses induced by this vaccine (245).  
Therefore there is need to seek new plague vaccines. The virulence factors produced 
by the plague bacterium have been studied because of their potential immunogenic and 
protective properties. Foremost amongst these have been the F1 proteins and V antigen 
plus Yops (Yersinia outer proteins), which will be described in the next section. As 
potential vaccine candidates, F1 and V antigen have been studied separately (11, 184, 227) 
and a combination of them has been formulated (126, 358). The latter candidate showed 
not only significantly greater protective efficacy than the killed vaccine, but also 
protected against pneumonic plague in a murine model (359). 
 
B. The virulence properties and transmission properties of Y. pestis 
a) The Transmission Cycle of Y. pestis 
As shown in Figure 1.2, Y. pestis is maintained in nature through transmission 
between hematophagous adult fleas and certain rodent hosts including wild and domestic 
rodents (106). Humans are dispensable in the maintenance of Y. pestis. Fleas acquire Y. 
pestis from an infected blood meal and the bacteria are restricted to the digestive tract of 
the flea. The organisms multiply in the midgut (stomach) of the flea, and the stomach 
exhibits clusters of brown specks containing Y. pestis after 2 days.  
A bacterial biofilm, which is a dense aggregate of microorganisms embedded in an 
extracellular matrix (ECM) and usually attached to a surface, is formed by Y. pestis on 
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the flea spines that line the interior surface of its proventriculus, a valve guarding the 
entrance to the midgut (149). Growth and consolidation of the biofilm interferes with the 
patency of the proventricular valve as well as the passage of blood into the midgut (22, 
245).  Between days 3 and 9 after the infected blood meal, the bacterial masses may 
completely block the duct between the stomach and the esophagus; then no further blood 
meal can access the stomach. Blocked fleas make frequent, persistent attempts to take a 
blood meal before they die from starvation. The blood sucked by the hungry flea is mixed 
with the bacteria and regurgitated as aggregates coated with polysaccharide (bacterial 
biofilm) into the mammalian host. It is worth noting that the unblocked flea also can 
transmit Y. pestis, although fleas with a completely blocked proventriculus make 
prolonged and repeated attempts to feed, which increases the opportunity for transmission 
(92).  
When the infected flea bites a human, the bacteria in the regurgitated blood are 
injected into the dermis layer of skin (289). Due to the lower temperature (<28ºC) in the 
flea gut, Y. pestis cells released from fleas are readily phagocytosed by 
polymorphonuclear leukocytes (PMNs) and monocytes, although these bacteria can 
express some antiphagocytic properties such as insecticidal-like toxins complex (343). 
Cells phagocytosed by PMNs are largely destroyed, while those engulfed by resident 
mononuclear cells such as macrophages are believed to grow intracellularly and develop 
resistance to further phagocytosis (63, 185). 
Then Y. pestis spreads from the flea bite site to the regional lymph nodes and 
multiplies there to high numbers, causing formation of a bubo. After that the infection 
spreads into the bloodstream, liver, spleen and other organs, which means that bubonic 
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plague progresses to septicemic plague (245). In 5% of human cases, Y. pestis spreads 
hematogenously to the lungs and causes pneumonic plague (289). Bubonic plague does 
not transmit directly between human patients; however, pneumonic plague is easily 
spread from one patient to another through aerosols containing Y. pestis. Meanwhile, 
since the bacterium transmitted this way comes from the mammalian hosts, the infecting 
Y. pestis is fully armed with thermally up-regulated virulence properties. The 
immunosuppressive bias of the lung and absence of acute inflammation for 36-48 h after 
infection allow rampant bacterial proliferation (173). Therefore, the incubation time is 
shorter and the mortality rate is much higher than those in bubonic plague.  
Yersinia pestis was evolved from the oral-fecal pathogen Yersinia pseudotuberculosis 
(2). At least three human pathogenic biovars of Y. pestis were identified through 
metabolic and genomic studies, based mainly on their abilities to ferment glycerol and 
reduce nitrate. These three biovars, named Antiqua, Medievalis, and Orientalis, were 
thought to be associated with the three plague pandemics (1, 2). However, there is no 
direct evidence connecting any of the biovars with historical plague. Furthermore, the 
correlations between geography and history are based exclusively on the three classical 
biovars and do not take into account isolates of “atypical” Y.  pestis that do not fit into the 
classical biovars, i.e. so-called pestoides and microtus (13, 372). It is suggested that Y. 
pestis should be subdivided into populations based on molecular groupings, rather than 
biovars. Eight populations, which do not correspond directly to classical biovars, were 
recognized (1).  
Y. pestis cycles between a mammal and a flea vector and expresses distinct subsets of 
genes in its two hosts. Products encoded by the genes specifically required to infect and 
 9 
cause disease in the mammalian host are referred to as virulence factors and the 
properties in Y. pestis that enable it to be transmitted by flea are termed transmission 
factors. Five transmission factors of Y. pestis, murine toxin (MT), F1 capsule, 
plasminogen activator (Pla), hemin storage locus (hms) encoding enzymes and 
insecticidal toxin compex that are involved specifically in flea-borne transmission have 
been identified, and their properties are listed in Table 1.1. It is worth noting that Y. pestis 
diverged from its Y. pseudotuberculosis ancestor only within the last 10,000-20,000 years 
and Y. pseudotuberculosis is transmitted through the oral-fecal route only between 
mammalian hosts. Therefore, some of these transmission factors were acquired during the 
evolution from Y. pseudotuberculosis to Y. pestis (for example, pMT and Pla (58), F1 (66) 
and biofilm (95)). Their functions favor the growth of bacteria in the internal 
environment of the flea (such as MT and biofilm), promote transmission and dispersal 
(F1), and promote the dissemination of the bacteria in the mammalian host after 
inoculation by a flea bite (such as Pla). Meanwhile, some of these factors (MT and 
biofilm) are sensitive to the culture temperature, which means that they are highly 
expressed at the temperature in the flea (26°C) and downregulated at the internal 
temperature of the mammalian host (37°C). Both transmission and virulence factors will 
be discussed below in detail. 
 
b) Major Chromosomal Virulence Factors of Y. pestis 
In humans, half of the iron is in hemoglobin and one-tenth is in cellular proteins that 
use iron for important cellular processes like storing oxygen (myoglobin) and performing 
energy-producing redox reactions (cytochromes). A small amount of iron circulates 
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through the plasma, bound in transferrin. Some iron in the body is stored. Physiologically, 
most stored iron is bound by ferritin molecules; the largest amount of ferritin-bound iron 
is found in liver hepatocytes, the bone marrow and the spleen. Macrophages of the 
reticuloendothelial system store iron as part of the process of breaking down and 
processing hemoglobin from engulfed red blood cells. The mammalian host has 
developed many mechanisms to inhibit the amplification of the invading pathogens by 
limiting the nutrients necessary to their growth. Iron sequestration by mammalian 
proteins is one of the most important ones (56). Therefore the ability of a bacterium to 
compete with the host for iron should be important to its virulence.  
Analysis of the KIM genome has identified 16 putative iron transport systems (103). 
The 16 systems can be divided into 4 categories: siderophore-dependent systems, ABC 
iron transporters, non-ABC iron transporters, and hemin transporters.  
A siderophore is a small compound that is synthesized and secreted by the bacterium 
to acquire iron from the environment. The yersiniabactin (Ybt) system is the only one 
with a clear function in this category. The Ybt system is essential for virulence of Y. 
pestis from infection by subcutaneous routes and important for iron acquisition in early 
stages of the bubonic plague in mice (29). The genes encoding the Ybt system are located 
in the pigmentation locus (pgm), which is a large unstable area of Y. pestis chromosomal 
DNA (102-kb) (99). The pgm locus is composed of a ~35 kb iron acquisition segment 
linked to a ~68 kb pigmentation segment (55). This iron acquisition segment is 
considered to be a high-pathogenicity island (HPI) (59) and contains a cluster of genes 
encoding the iron-regulated proteins (irp), yersiniabactin siderophore biosynthetic and 
transport proteins (ybt) and the pesticin/yersiniabactin outer membrane receptor (psn) 
 11 
which are involved in the iron-regulated biosynthesis and transport of the Yersiniae 
siderophore Ybt. pgm cultures are bacteria highly attenuated in mice inoculated via 
peripheral routes, while they are fully virulent by the intravenous (IV) route of infection 
because they can get iron from blood (99). 
The second category, ABC transporters, is generally composed of a solute-binding 
protein in the periplasm along with an inner membrane permease and an inner 
membrane-associated ATPase. Yfe, an ABC transporter for both manganese and iron, has 
been found to be important for full Y. pestis virulence in a bubonic plague mouse model 
(30). Other ABC transporters for iron (Yfu and Yiu) and hemin transporters (Hmu, 
encoded by hmu (hemin uptake locus)) have been functionally characterized, but were 
not found to be required for virulence in the mouse model (115, 160, 334).  
In Y. pestis, the iron acquisition and transport systems are under the regulation of a 
ferric uptake regulation (Fur) protein encoded by the fur gene located in another area of 
the chromosome outside the iron acquisition segment (312). 
The second important component of pgm is the hms locus, which is located in the 
pigmentation segment of pgm and is responsible for binding hemin and Congo red, 
causing the so-called pigmented phenotype (Pgm
+
) of colonies grown on Congo red-agar 
plates (55). The hms locus contains a 4-gene operon, hmsHFRS. There are also two 
unlinked genes not in the pgm locus, hmsT and hmsP, which are essential for the normal 
pigmentation phenotype. HmsH and HmsF were characterized as surface exposed outer 
membrane proteins, and HmsR, and HmsT contain transmembrane domains and appear 
to be inner membrane proteins. The function of the hms gene products are similar to 
glycosyl transferase and polysaccharide deacetylase enzymes in other bacteria that are 
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required to produce extracellular polysaccharides (134). Therefore, hms gene products 
mediate the production of biofilm which blocks the foreguts of vector fleas, as described 
in B a) The Transmission Cycle of Y. pestis (135). Grown at ambient temperature in the 
flea or in vitro, Y. pestis synthesizes an ECM of poly-β-1,6-linked N-acetyl-D-
glucosamine (β-1,6-GlcNAc) that is essential for biofilm formation. Biofilm formation is 
sensitive to the culture temperature and is downregulated at mammalian internal 
temperature (37°C) (95, 149).     
                                
c) Major Plasmid Virulence Factors of Y. pestis 
All of the Y. pestis strains contain three plasmids of 9.5, 70 to 75, and 100 to 110 kb. 
In strain KIM derivatives, these three plasmids are termed pPCP1 (Pesticin, Coagulase, 
Plasminogen activator), pCD1 (Calcium Dependence), and pMT1  (245), respectively.  
The multicopy pPCP1 encodes three proteins: Pla, the bacteriocin pesticin (Pst), and 
the pesticin immunity protein (Pim) (245, 303). Loss of the 9.5-kb plasmid results in 
greatly decreased ability of Y. pestis to cause its usual systemic infection following 
subcutaneous inoculation or intraperitoneal injection and attenuates Y. pestis by a 
millionfold in a subcutaneous infection model (51, 303, 304). Pst is a muramidase that 
can slowly hydrolyze murein in the bacterial wall and convert bacterial cells into stable 
spheroplasts (350). Whereas Pim is located in the periplasma and inactivates the Pst 
before it degrades murein of the Pst producing bacterium (248). Studies on rats infected 
through flea transmission or intradermal (ID) injection showed that the pla gene is not 
only one of the most highly expressed genes in the bubo but also indispensable for the 
establishment of bubonic plague (289, 290). However, primary septicemic plague does 
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not depend on Pla (289), and Pla is not required for virulence (lethality) of Y. pestis in 
pneumonic plague but it is required for the bacterial colonization of the lung (174).  
Pla is a highly abundant integral outer membrane protein expressed more strongly at 
37°C than 26°C. As a proteinase, the main virulence function of Pla is to convert 
plasminogen (Plg) to plasmin (Pln) through cleavage. It also increases the activities of 
plamin by inactivating the main Pln control protein α2-antiplasmin (164). The major 
function of plasmin is fibrinolysis which may support bacterial dissemination and evasion 
of innate immune surveillance systems (80). Meanwhile, Pla is also thought to promote 
bacterial spread by digesting laminin of basement membranes and activating collagenases 
and gelatinases, which further damage the tissue barriers (169). Pla has nonproteolytic 
functions in adhesion of Y. pestis to extracellular matrix components such as laminin, the 
major glycoprotein in basement membranes, and it can promote invasion of Y. pestis into 
epithelial cells in vitro (75, 170, 322). These effects could underlie its colonization role in 
the lung in pneumonic plague. Further, Pla promotes invasion of alveolar macrophages 
by binding to c-type lectin receptor, DEC-205 (CD205), and this interaction promotes 
bacterial dissemination from lung to spleen in pneumonic plague (371). Thus, Pla is 
multifunctional but its predominant role in bubonic plague is thought to be to promote 
hemorrhagic dissemination of the bacteria from the primary site of infection. Meanwhile, 
it is believed that the major late pathologic manifestation of untreated human plague is 
related to the plasmid-encoded plasminogen activator activities (303).  
The 70-kb plasmid pCD1 encodes the Yop virulon, which is comprised of three 
components: the Yop effector virulence proteins, the Ysc (Yop secretion) system， i.e. 
Yop translocon and injectisome for secreting Yops out of the bacterial cell, and the 
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injectisome tip complex of so-called translocator Yops which is necessary for injecting 
the effector Yops into host cells (73, 245) (Figure 1.3).  
Before contact with eukaryotic target cells, Yersinia bacteria incubated at the 
temperature of their mammalian host (37
o
C) build several syringe-like Ysc injectisomes 
at their surface (74). These are protein pumps spanning the peptidoglycan layer and the 
two bacterial membranes and topped by a stiff needle-like structure protruding outside 
the bacterium. The whole organelle is comprised of 27 proteins. The internal part 
contains 10 proteins, which include an essential part of the pump, the ATPase (YscN). 
The part of the injectisome that spans the bacterial outer membrane is a homomultimeric 
ring-shaped structure. The Ysc injectisome ends with a needle formed by the 
polymerization of monomers of the YscF protein (Figure 1.3). Through the Ysc 
injectisome effector Yops can be efficiently targeted into the host cytosol without 
“leaking” into the extracellular space. The six injected effector Yops favor the growth of 
invading bacteria in mammalian hosts through several mechanisms, such as disrupting 
phagocytosis, blocking the production of proinflammatory cytokines and perturbing the 
dynamics of the cytoskeleton (337) (Figure 1.4, see further discussion below). 
The largest plasmid pMT contains the gene encoding the so-called murine toxin (Ymt) 
and the structural gene for the F1 protein fibrillar capsule (245). Murine toxin refers to 
two forms of a protein (native polymers of 240 and 120 kDa) toxic only for mice and rats 
but not to other animals (136, 283). Murine toxin was shown in early studies to have β-
adrenergic blocking ability (48) and its toxic function was manifested by hypotension and 
vascular collapse when it was released from lysing bacteria at the terminal stage of 
septicemic plague (283). However, this toxin later was found to be a phopholipase D and 
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to be more important for the growth of  the bacteria in the flea gut (136) instead of in 
mice, since deletion this ymt gene does not significantly increase the lethal dose in mouse 
infection (137).  
The caf1M1A1 operon in pMT encodes a pilus called F1 and referred to in the plague 
literature by the misnomer “capsule”. The production of F1 is strongly dependent on the 
temperature, which must be at least 35°C (89). Therefore, no F1 capsule is detected in the 
flea gut, whereas caf1 is one of the most highly expressed genes during infection of the 
mammal. A coating of F1 fibrils encapsulates Y. pestis in vivo and causes interactions 
with host cells to be inefficient, thereby protecting the bacteria from phagocytosis and 
contributing to virulence in systemic plague (49, 89). The F1 fibrils are highly 
immunogenic (65, 290), which makes F1 antigen a promising candidate for plague 
vaccine development (11). Interestingly, the virulence of Y. pestis is not affected by the 
deletion of the caf1 gene in ID or IV infected mice. However, F1 capsule is indispensable 
for full virulence in the flea-transmitted bubonic plague model (288), indicating the 
importance of F1 in the natural transmission of Y. pestis. 
 
C. Delivery of Yops by Type III Secretion System (T3SS) 
a) T3SS 
The T3SS is an export machine used by pathogenic Gram-negative bacteria to deliver 
proteins straight into the eukaryotic cytosol with the aim to subvert the host cell defense 
(41, 107). Made up of more than 20 proteins, the T3SS is among the most complex 
protein secretion systems known in Gram-negative bacteria. Its structure shares many 
similarities with bacterial flagella (long, rigid, extracellular structures used for motility) 
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and some of the proteins participating in the T3SS share amino-acid sequence homology 
with flagellar proteins. The basic structure of the T3SS consists of the membrane-
embedded basal body, the needle and the tip structure, except the flagellar translocon (the 
ancestral T3SS) that does not have a needle or function for injecting into eukaryotic cells. 
As the central component of the typical T3SS, the needle complex is a supramolecular 
structure that mediates the passage of the secreted proteins through the multi-membrane 
bacterial envelope. There are two hallmarks of the T3SS: the protein substrates are 
selected by the system through recognition of an N-terminal recognition sequence of 
amino acid and/or mRNA codons without cleavage; then these proteins pass through two 
bacterial membranes without a periplasmic intermediate (bypassing Sec system). The 
T3SS is used by Gram-negative bacteria to secrete proteins that help the bacteria infect 
multicellular, eukaryotic organisms. The proteins are secreted directly from the bacterial 
cell into the cells of the organism to be infected (the host) using a needle-like structure 
which is the hallmark of the T3SS. 
The T3SS proteins can be grouped into three categories: (1) structural proteins 
building the base, the inner rod and the needle (2) effector proteins secreted into the host 
cell to promote infection (3) chaperones binding effectors in the bacterial cytoplasm and 
protecting them from aggregation and degradation and directing them towards the needle 
complex. Secretion by the T3SS is triggered by contact of the needle with a host cell. 
T3SS effectors manipulate host cells in several ways, such as antiphagocytosis and 
induction of apoptosis (74, 132).  
 
b) The signals for secretion of effector Yops 
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The internal diameter of the needle-like injectisome is not large enough for the fully 
folded effector Yops to pass through (73); thus the Yops must transit in a partially 
unfolded state and there must be some signals mediating the translocation of Yops, 
although no classical signal sequence has been found in the amino acid sequence in those 
Yops (214). Fifteen codons at the N-terminus have been confirmed necessary for Yop 
secretion (307); however, changes in the amino acid sequence by point or frameshift 
mutations could not block the secretion of YopE, YopN and YopQ (8, 9) and led to the 
idea that the 5’ end of the mRNA is the true signal for secretion; thus secretion was 
hypothesized to occur concomitantly with Yop mRNA translation.  
This hypothesis could be true for the late phase of interaction of a yersinia with a host 
cell but is problematic in the early phase, in which antiphagocytic responses mediated by 
Yops happen very fast and cannot be explained by this co-translational translocation 
model. Meanwhile, export and translocation of some antiphagocytic Yops, such as YopE 
and YopH, have been proven to be controlled at the posttranslational level (39, 114); and 
the mutation of the first 11 codons without alteration of the amino acid sequence does not 
block the secretion of YopE (188). Therefore, the signal for the initial secretion is likely 
to be in the amino acid sequence, instead of in the Yop mRNA. 
Another group of proteins named Syc (Specific Yop Chaperone) are also necessary 
for the secretion of some (but not all) Yops by keeping these Yops in a “secretion 
competent” state (unfolded or partially folded conformation which is easy to pass through 
the injectisome) (36, 314, 356, 357). Each Syc protein binds only to a specific partner 
Yop, for example, SycE specifically binds YopE (Figure 1.4), and in general, the gene 
encoding each Syc protein is located beside the gene encoding the corresponding Yop. 
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The Syc proteins are indispensable because the secretion of each Yop is significantly 
impaired without its specific Syc.  
 
c) Contact between bacterium and eukaryotic cell 
Once the bacteria enter into the mammalian host and reach a temperature of 37
o
C, the 
injectisomes start to be assembled and the bacteria begin to synthesize Yops. However, 
before the bacterium contacts a eukaryotic host cell, Yops stay in the cytosol instead of 
being expelled into the extracellular space. Actually, to avoid the deleterious effect of 
excessive Yops on the bacterium itself, the production of Yops is also closely controlled 
before the physical contact between bacterium and host cell is established (72).  
The required contact is not accomplished by the injectisome itself but by the 
interaction between bacterial outer membrane proteins called adhesins and host 
molecules at the surface of a target cell (Figure 1.4). Potential adhesins expressed by Y. 
pestis are Pla, pH 6 antigen (Psa) and attachment-invasion locus (Ail). Pla is encoded by 
pPCP1 and its function has been described in detail in section Major Plasmid Virulence 
Factors of Y. pestis.  
A fimbrial adhesin, Y. pestis pH 6 antigen, whose encoding gene is located on 
chromosome (186), was named for its regulated expression because it is expressed only 
when the bacteria grow between pH 5 and 6.7 at temperatures of 35 to 41
 o
C. It is 
reported that Psa is involved in the binding of Y. pestis to target cells to allow effective 
intracellular delivery of Yops (316). More recent studies showed that Psa uses the 
phosphorylcholine moiety of phosphotidylcholine as a receptor to mediate bacterial 
binding to pulmonary surfactant and alveolar epithelial cells (108). Y. pestis lacking the 
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fimbrial subunit PsaA is deficient in dissemination during bubonic plague and, to a lesser 
degree, during pneumonic plague (61).  
However, a pH 6 antigen mutant only has a modest decrease in virulence via the IV, 
subcutaneous (SC), or intranasal (IN) routes of infection (61, 173, 186), and the 
expression of pH 6 antigen is greatly downregulated in a mouse model of pneumonic 
plague due to fully virulent Y. pestis (173). Thus, other adhesins may be required for Y. 
pestis Yop delivery. The Ail outer-membrane protein, which binds host fibronectin (339), 
was found to be the predominant adhesin for Yop delivery in vitro when the Y. pestis 
strain KIM5 was grown at 28
 o
C, and deletion of ail from KIM5 increased the LD50 ca. 
3000 fold in Swiss Webster mice (98). 
Yaps (Yersinia Autotransporter Proteins), another potential group of adhesins, were 
also found recently. Autotransporters are a family of proteins secreted by the type V 
secretion mechanism, in which the secreted protein contains all of the necessary 
information to mediate translocation across the bacterial outer membrane after passing 
through the inner membrane via the Sec system (129). The autotransporter YadA, which 
is indispensable in Y. pseudotuberculosis and Y. enterocolitica, does not contribute to Y. 
pestis virulence since it is only a pseudogene in Y. pestis (302). However, another 
autotransporter, YapE, has been proven to be important in efficient Y. pestis CO92 
colonization in C57B/6 mice, as well as for the binding of Y. pestis to eukaryotic cells 
(177). 
 
d) Effector Yops injected into eukaryotic cells by translocators 
The injectisome, as described here, is sufficient for bacteria to secrete Yops into their 
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surrounding environment but it is not sufficient for the injection of Yops into target 
animal cells. A group of proteins, or translocators, include YopB, YopD, and LcrV, and 
form a transient pore structure in the eukaryotic cell membrane. YopB and YopD contain 
hydrophobic regions that are predicted to function as transmembrane domains (73). 
However, only YopB is actually detected in the host cell membrane, and LcrV may act 
like a chaperone for YopB and YopD. YopD may act to facilitate insertion of YopB in 
the host cell membrane (74). 
Interestingly, LcrV (low calcium response protein V, the V antigen mentioned earlier 
in the context of plague vaccines) lacks a predicted transmembrane domain and exists as 
a soluble dimer in solution. Unlike Yops B and D, LcrV is a multifunctional protein. As a 
structural component of the translocon within the bacterial cytoplasm, LcrV permits Yops 
secretion by forming a stable complex with a negative regulatory protein, LcrG (199). 
Before the bacterium contacts a eukaryotic cell or when Y. pestis is cultured in the 
presence of millimolar calcium, the level of LcrV in the cell is low so that LcrG blocks 
the Ysc from the cytoplasmic face of the inner membrane. As soon as the physical 
contact between bacterium and host cell is established or calcium is removed from the 
medium, levels of LcrV are increased and the excess LcrV titrates LcrG away from the 
Ysc, allowing secretion of Yops to occur.  
In addition, LcrV is released in large amounts into the surrounding medium and may 
silence host immune cells which do not contact Yersinia directly (10, 227, 246). LcrV 
may bind a Toll-Like Receptor (TLR)2/6 complex and elicit production of the anti-
inflammatory cytokine interleukin (IL)-10 (50, 84). Further, unlike effector Yops, LcrV 
can enter cells by a novel T3SS-independent mechanism after in vitro infection. LcrV co-
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localizes with endosomal proteins between 10–45 min of infection, followed by 
lysosomal protein(s) between 1– 2 h. After 2.5–3 h of infection, V was observed in 
conjunction with mitochondrial proteins, and subsequently with Golgi protein(s) between 
4–6 h of infection (87, 100). However, its activity and interactions inside host cells are 
not known.  
 
e) The functions of the effector Yops 
The T3SS delivers the set of six Yop effector proteins into host cells once the bacteria 
contact host target cells at mammalian body temperature. Enzymatic and cell biological 
mechanisms of five of the Yops, YopH, YopE, YopT, YpkA/YopO and YopJ/YopP, 
have been elucidated.  
YopJ inhibits activation of MAP kinase kinases (MKKs) and nuclear factor-κB (NF-
κB) signaling through acetyltransferase or ubiquitin-like cysteine protease activities (228, 
234) (Figure 1.5) but is not required for virulence in either a mouse model of systemic 
plague (317) or mouse and rat models of bubonic plague (180, 369). Y. pestis was found 
to suppress the secretion of tumor necrosis factor-α (TNF-α) and phosphorylation of 
mitogen-activated protein kinase (MAPK) in a YopJ specific manner in in vitro infected 
macrophage cells as efficiently as enteropathogenic
 
Yersinia, but was less able to activate 
caspases, suppress NF-κB activation, and induce apoptosis in macrophages than the high-
virulence Y. enterocolitica WA O:8 strain. The lower efficiency of translocation of Y. 
pestis YopJ into the host cell than that of the corresponding Y. enterocolitica effector 
YopP was shown to be related to the above differences (367). Paradoxically, the lower 
cytotoxicity due to Y. pestis YopJ correlates with the increased virulence in bubonic 
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plague by minimally stimulating innate and adaptive immune responses (368). 
In tissue-culture infection models, YopH, YopE, YopT, and YopO have been shown 
to antagonize focal complex formation and activity of Rho family GTPases and 
synergistically inhibit phagocytosis by mammalian cells (73, 349). Phagocytosis is a 
complicated process involving many cytoskeletal molecules. Each of three major family 
members of Rho GTPases, RhoA, Rac-1, and Cdc42, control the formation of individual 
cytoskeletal elements: stress fibers by RhoA, lamellipodia by Rac-1, and filopodia by 
Cdc42. When bound to GTP, the GTPase is active and allows interaction with 
downstream effectors, while the inactive GDP-bound conformation blocks the pathway. 
Three main regulatory molecules tightly control the GTP-binding and hydrolytic cycle. 
Guanine nucleotide-Exchange Factors (GEFs) activate Rho proteins by GDP/GTP 
exchange, and GTPase-activating proteins (GAPs) inactivate them through inducing GTP 
hydrolysis. The third one is a negative regulator, GDP dissociation inhibitor (GDI), which 
binds the inactive, GDP-bound form of the Rho protein, inhibits the exchange of GDP for 
GTP (which would reactivate the Rho protein) and delivers it to its original membrane.   
YopE is important for full virulence of Yersinia pestis and deletion of yopE increases 
the LD50 at least 10
4
-fold in a systemic plague model (245). As shown in Figure 1.5, 
YopE plays a role as a GAP to inhibit Rho proteins by accelerating hydrolysis of GTP. In 
addition to anti-phagocytosis, YopE may also function to counteract proinflammatory 
cytokine production, presumably through downstream effects of inhibiting  Rho GTPases 
(349).  
It is essential for Rho proteins to attach to the inner side of the cell plasma membrane 
by the C terminus in order to gain their normal function. Therefore, when YopT, a 
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cysteine protease, cleaves RhoA, Rac, and Cdc42 near their C terminus and releases them 
from the membrane, cytoskeleton dynamics maintained by these Rho proteins are 
interrupted (296, 349).  
After a translocation channel (YopB) is inserted into the plasma membrane, a 
transient pore is formed but there is no membrane lysis. Meanwhile, pore formation in the 
membrane only can be detected when the infecting bacteria lack some Yops, indicating 
that these Yops can counteract the pore-forming function of YopB (73). It was reported 
that YopE and YopT inhibit pore formation through GAP activity and releasing the 
GTPase from the membrane, respectively (Figure 1.5) (348). 
YopO (YpkA in Y. pseudotuberculosis) is an autophosphorylating serine-threonine 
kinase that shows some sequence and structural similarity to RhoA-binding kinases (349). 
YopO binds to GDP- or GTP-bound RhoA or Rac-1 with similar affinity without 
affecting GDP/GTP exchange. YopO is activated by actin binding, and actin can also 
function as an in vitro substrate of the kinase. Although binding of YopO to actin and to 
RhoA and Rac-1 are clearly relevant to phagocytosis inhibition, the kinase target and the 
exact mode of action of YpkA/YopO are still unknown. 
YopH is a highly active protein tyrosine phosphatase (PTP) that antagonizes several 
signaling pathways associated with phagocytosis (97), as well as other immune response 
pathways in host cells, for example, the production of Monocyte Chemoattractant 
Protein-1 (MCP-1); also called CCL2 (Chemokine (C-C motif) ligand 2) in mouse 
macrophages (281). Although the studies of the YopH virulence mechanism have been 
mainly done on Y. pseudotuberculosis and Y. enterocolitica, YopH has been shown to be 
crucial for lethality in a mouse model of systemic plague (IV infection), and a yopH 
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strain is attenuated for both bubonic and pneumonic plague (54).  
The function of YopM is the focus of this dissertation and the background on research 
on its function is discussed below. 
 
D. YopM is necessary for Y. pestis growth in a systemic plague model by 
counteracting innate defenses  
The sixth effector Yop, YopM, is the only effector Yop that does not have an 
enzymatic activity. YopM is essential for virulence in the mouse model of systemic 
plague: in C57BL/6 mice, a YopM
-
 strain of Y. pestis KIM5 is reduced in lethality by at 
least 4 orders of magnitude (183). 
 
a) Structure  and intracellular trafficking of YopM 
YopM is a 46.2-kDa acidic protein that is 409 residues in length and made up almost 
entirely of fifteen repeats of a 19-residue leucine-rich repeat (LRR) motif (184). The 
YopM monomer is horseshoe-shaped and has the potential to form tetramers in which the 
monomers stack together to form a hollow cylinder with an inner diameter of 35 A˚; 
however the form that YopM assumes within the mammalian cell is not known (96) 
(Figure 1.6). 
Similarly to the other five effector Yops, YopM is injected by the T3SS into the 
eukaryotic cell (Figure 1.7). However, it is the only one proven to be transported into the 
nucleus (300). After delivery to the host cell cytoplasm, YopM localizes to the nucleus in 
a process that is facilitated by vesicular trafficking (Figure 1.7). Among the cytosolic 
proteins identified as being able to bind YopM, such as -thrombin (183), 1-antitrypsin 
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(131), and the serine/threonine kinases ribosomal S6 protein kinase 1 (RSK1) and PRK2 
(202), the two kinases have drawn more attention because they were proven to be 
activated by this interaction. 
RSK1 is a substrate of extracellular signal-related kinase (ERK) in the Ras/MAPK 
signal transduction pathway and plays an important role in cell survival and growth (105). 
However, nuclear localization of YopM is not dependent on its RSK1 interaction (201). 
PRK2 is a member of the protein kinase C family involved in cytoskeletal changes, 
receptor tyrosine kinase signaling, and activation of translation after it is activated by the 
GTPase RhoA, phospholipids and MEK kinase 2, and interacts with the tyrosine kinase 
adaptor proteins Nck and Grb2 (202).  
Two groups recently studied the interaction between YopM and RSK1 or PRK2 by 
serial deletion of YopM domains or LRRs (201, 204). They identified a C-terminal 
domain of YopM (from LRR12 to the C-terminus) and an internal portion encompassing 
LRR6-15 that are required for interaction with RSK1 and PRK2, respectively. However, 
there is no visible effect of delivery of YopM into cultured cells, and microarray analysis 
of macrophage-like cell lines infected with Y. enterocolitica having or lacking YopM also 
has not yielded any clue to YopM’s mechanism of action (139, 282).   
 
b) Mechanism of YopM’s Function in in vivo infection  
Although the precise cellular mechanism of YopM remains to be established, there is 
no doubt YopM is an important Yersinia virulence factor. A Y. enterocolitica yopM 
mutant was unable to establish a systemic infection following oral challenge of mice 
(338), and virulence of a Y. pseudotuberculosis yopM mutant was significantly 
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attenuated in mice via the IV route of infection (204). The LD50 value for a Y. pestis 
yopM mutant was at least 105-fold higher than that of the parental strain in mice 
challenged intravenously. The Y. pestis yopM mutant proliferates in spleen and liver of 
mice for several days following IV infection but is then rapidly eliminated from these 
organs, and this growth limitation of ΔyopM Y. pestis is retained in severe combined 
immunodeficiency (SCID) mice, indicating that YopM is important for resistance to 
innate immunity (159). 
YopM was shown to promote virulence of Y. pseudotuberculosis by altering the 
balance of key cytokines in serum on d 4 post infection (p.i.), for example, decreased 
production of IFN-γ and increased levels of IL-18 and IL-10, and the PRK2 and RSK1 
interaction domains of YopM were both required for IL-10 induction in vivo (204). 
Meanwhile, the mutation of RSK1 binding sites on YopM increased the recruitment of 
monocytes as well as inhibited colonization in spleen during septicemic Y. 
pseudotuberculosis infection, which implicates RSK1 as a potential molecular target of 
YopM in the cytosol (201).  However, the pathway from RSK1 to YopM’s effects on 
cytokine expression during infection has not yet been delineated. 
Because in vitro approaches to defining the pathogenic mechanism of YopM in Y. 
pestis infection have not been fruitful, we have begun to characterize YopM’s effects in 
vivo. Previously Kerschen et al. found that YopM was still required for lethality in IV 
infected SCID mice, showing that YopM’s virulence mechanism does not require B or T 
cells and indicating that early in systemic plague, YopM’s main function is to counteract a 
component of innate immunity (159). A striking YopM-specific effect during systemic 
plague in normal C57BL/6 mice was the depletion of natural killer (NK) cells from 
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spleen and a reduction of NK cell numbers in blood, suggesting that YopM might cause a 
loss of the NK cell compartment during systemic plague. Correlated with this effect, there 
was a YopM-associated loss of mRNA for IFN-gamma by NK cells in infected spleens 
and diminished expression of mRNAs in splenic macrophages for cytokines that are 
required for viability and activation of NK cells (IL-15, IL-18 and IL-12). These findings 
supported the hypothesis that YopM may function to inhibit IFN-mediated activation of 
macrophages through the depletion of  NK cells (159).  
 
E. Thermal regulation of major virulence factors and transmission factors 
When Y. pestis is transmitted by flea to mammals, the expression of virulence and 
transmission factors is altered due to the change of the surrounding temperature. As 
described in B a), production of biofilm and MT is downregulated once the bacteria 
move from the ambient temperature (26°C) to the internal temperature of a mammal 
(37°C). Pla synthesis is not temperature-dependent, but its plasminogen activator activity 
that leads to fibrinolysis is much greater at 37°C than at temperatures below 28°C (203).  
When the bacteria enter into a mammalian host, insecticidal toxin complex proteins 
made in the flea may provide some immediate protection to the bacteria by inhibiting 
phagocytosis (343). Meanwhile, the bacteria need to activate their T3SS through 
establishment of contact with the eukaryotic cells. As discussed in C c), several adhesion 
factors including Pla, pH 6 antigen, Ail and Yaps are involved in this process. Y. pestis 
pH 6 antigen is expressed only when the bacteria grow between pH 5 and 6.7 at 
temperatures of 35 to 41
o
C, which means it is absent in the flea and present in the 
mammal (61). Through binding to phosphotidylcholine in the host cell membrane, pH 6 
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antigen promotes bacterial dissemination in bubonic plague and pneumonic plague. Ail 
protein is expressed at both ambient temperature and 37
 o
C, and mediates two distinct 
different host-parasite interactions. By binding host fibronectin (339), Ail is the major 
adhesin to facilitate Yop delivery in vitro in bacteria grown at 28
 o
C prior to the assay 
(98), whereas it is responsible for the constitutive serum-resistance of Y. pestis in a 
mammal (37
 o
C) (28), which will be discussed further in F b). The last group of adhesins 
is the Yaps that belong to the autotransporter family. One member of the Yap family, 
YapE, has been proven to mediate the binding of Y. pestis to eukaryotic cells and play an 
important role in efficient Y. pestis CO92 colonization in C57B/6 mice (177). Apparently 
YapE functions at 37
 o
C, but it is not known whether its expression is temperature-
dependent.  
Once shifted to 37°C, the expression of the T3SS and Yops is upregulated. The 
injectisomes start to be assembled and the synthesis of Yops is upregulated (226), which 
have been discussed in C d) and e). The production of F1 fibrils, which contribute to the 
antiphgocytosis activity of Y. pestis in concert with the T3SS, is also induced by the shift 
of temperature; however its anti-phagocytosis function needs 4-5 hours to be detected 
(89).  
Another important temperature-dependent virulence factor of Y. pestis is 
lipopolysaccharide (LPS). LPS consists of three portions: O-antigen, core oligosaccharide 
and Lipid A. Y. pestis has a rough-type LPS that lacks an O-specific chain (301), which 
favors efficient plasminogen activation by Pla (165). Another important component is 
Lipid A, which interacts with the host LPS receptor complex consisting of TLR4 and its 
coreceptor MD-2 to induce cellular responses. The number and length of acyl side chains 
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of Lipid A are critical
 
for TLR4 signaling in humans. Hexa-acylated Lipid A maximally 
stimulates immunological
 
responses in humans, whereas altering the number or length of
 
the attached fatty acids reduces the magnitude of the response (215). The Lipid A 
obtained from bacteria cultivated at ambient temperature is normally a typical
 
hexa-
acylated LPS. However, after the temperature transition from
 
26°C to 37°C, Y. pestis
 
immediately begins to produce LPS with tetra-acylated Lipid A, which is not
 
only 
nonstimulatory for TLR4 but also acts as an antagonist
 
to the stimulatory hexa-acylated 
form of LPS (91, 223).  
 
F. Host responses to Y. pestis: innate and adaptive responses  
a) Innate and adaptive immune responses 
The innate immune response is the first line of host defense against pathogens in a 
non-specific manner, which means that the cells of the innate system recognize and 
respond to pathogens in a generic way. However, unlike the adaptive immune system, the 
innate immune system provides immediate but not long-lasting defense against infection. 
The innate immune system includes barrier structures, phagocytic cells including PMNs, 
macrophages and monocytes, DCs, NK cells, platelets, mast cells and molecules such as 
complement proteins, cytokines, and antimicrobial peptides. 
The adaptive immune system is composed of highly specialized systemic cells and 
processes that eliminate or prevent pathogenic challenges. The adaptive immune response 
provides organism-specific protection that frequently has a long-lasting immunological 
memory. In most cases, the bacterium will be eliminated from the host by the synergistic 
effect of both innate and adaptive immunity.   
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To survive inside of the host and maintain a persistent infection, Y. pestis uses a 
variety of mechanisms to evade or overcome the host immune system, especially the 
innate immune system (Figure 1.8) (185). 
 
b) Preparation of Y. pestis in the flea to overcome incoming mammalian host 
defenses 
The first threat from the host immune system to Y. pestis is complement attack 
because the bacteria must survive and/or grow in blood to be transmitted between its 
insect vector and mammalian hosts and in the transudate at the foci of infection which 
also contains complement proteins. The ability of Y. pestis to escape complement attack 
is termed serum resistance (245).  
The enteropathogenic yersiniae (Y. enterocolitica and Y. pseudotuberculosis) are fully 
resistant to complement when they are grown at 37°C but not when they are grown at 
26°C (12, 40, 245). In contrast, Y. pestis is resistant to complement at both 26 and 37°C 
(12), which favor its growth in both flea and mammalian host. Resistance to complement 
in Y. enterocolitica has been studied in detail and has been shown to involve YadA, Ail, 
and LPS O antigen, with YadA playing a dominant role (35).  
However, Y. pestis does not express YadA and expresses only rough LPS (245). 
Previous studies have suggested that Y. pestis LPS may mediate serum resistance (245); 
however, there is no evidence of a direct role for LPS in serum resistance. The ail Y. 
pestis strains are
 
extremely sensitive to complement. It is currently suggested
 
that Ail 
might be the sole complement resistance factor due
 
to its requirement for full protection 
of Y. pestis from complement-mediated
 
lysis in vitro (28). Alteration in the structure
 
of 
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LPS may also interfere with the expression and the surface exposure
 
of Ail. 
Another possible early host response against Y. pestis could be induced by TLR4-
mediated activation, which is inhibited when Y. pestis Lipid A changes from the hexa-
acylated form to tetra-acylated one after the temperature transition (91, 223).  
 
c) Y. pestis escapes from immune attack at an early stage of infection  
Y. pestis is believed to exist predominantly in an extracellular location in vivo, 
although initially the bacteria might invade resting tissue phagocytes such as 
macrophages and DCs, based on assays of mouse spleens in the systemic phase of 
bubonic plague (192). The intracellular vs. extracellular location of Y. pestis during the 
peripheral phases of plague in skin or lung have not yet been studied. 
Phagocytes including macrophages and PMNs are the major players in the first 
surveillance line for bacterial infection. These cells recognize invading pathogens and 
engulf and destroy them. At
 
the early stage of infection, the first immune cells 
encountered by Y. pestis in skin probably are dermal
 
macrophages and DCs at the 
infection site. To avoid clearance at this stage, Y. pestis develops several different 
mechanisms to block phagocytosis, such as insecticidal toxin complex YipA and YipB 
(expressed while the bacteria are in the flea) and F1 fibrils and effector Yops. However, 
the antiphagocytosis function of Y. pestis is not equally efficient against the various host 
cell types; and even for any one cell type it is not 100% effective. Evidence has shown 
that Y. pestis is resistant to phagocytosis by PMNs but not monocytes by 3 h of growth in 
vivo at 37°C (prior to F1 fibrils expression). After 3 to 5 h, the bacteria are resistant to 
uptake by both types of phagocytes (245). Meanwhile, histological evidence indicates 
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that Y. pestis is killed within
 
PMNs, and analyses of the cell association, intra- vs extra-
cellular localization, and viability of Y. pestis in spleen following SC infection indicate 
that at up to 2 days p.i. host PMNs
 
are able to control Y. pestis growth (192). 
Unlike PMNs, macrophages provide a protected environment for Y. pestis to survive 
and proliferate, as well as avoid contact with other components of the host
 
immune 
system. Y. pestis proliferates in the phagolysosome of macrophages,
 
acquires the ability to 
evade phagocytosis and expresses various virulence determinants (253, 319), which are 
essential for pathogenesis. Further, the bacteria within macrophages
 
can be trafficked to 
the local draining lymph node (254).
 
Between 4 and 5 days p.i., the numbers of Y. pestis
 
increase rapidly in vivo, and the bacteria can escape from macrophages
 
into the 
extracellular compartment.
 
The two-component system PhoP/PhoQ may regulate one or 
more
 
genes important for the intracellular survival of Y. pestis
 
in macrophages (237). 
These include ones for synthesis of 4-aminoarabinose and its addition to lipid A, a 
modification that confers resistance to cationic antimicrobial peptides (261, 360). 
 
d) Y. pestis modulates innate immune responses  
After Y. pestis accommodates to conditions within the mammalian host, the 
environmental factors that are different from those in the flea, such as high temperature 
(37°C) and physical contact with host cells, stimulate the expression of Y. pestis virulence 
factors including the T3SS and Yops, F1 pilus, Psa and high activity of pla. They no 
longer express polysaccharide biofilm (95) and their lipid A is tetra-acylated. Hence the 
bacteria surface is radically different from that initially present upon injection by flea bite. 
At 1 to 2 days p.i.,
 
disturbance of the host immune responses by the virulence factors 
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become detectable (245). 
Phagocyosis at this stage is inhibited by three mechanisms. While within 
macrophages, Y. pestis plasmid pMT starts to encode F1 protein which forms a gel-like 
fibrillar coating around the bacterium.
 
This capsule increases bacterial resistance to 
engulfment by
 
both macrophages and PMNs, probably through masking the bacterial 
ligands from the receptors on phagocytic cells (89). In an acidic environment like the 
phagolysosome of macrophages and necrotic lesions, expression of pH6 antigen will be 
induced, which has a fimbrial structure and acts as adhesin to establish the contact 
between bacterium and host cells without triggering engulfment (316). Meanwhile, 
purified
 
pH6 antigen has been found to selectively bind to apolipoprotein B (apoB)-
containing
 
lipoproteins in human plasma, mainly LDL. This interaction could prevent
 
recognition of the pathogen by the host defense systems (195). The third mechanism is 
the effector Yops. As described in Section C. e) The functions of the effector Yops, 
YopH, YopE, YopT, and YopO synergistically inhibit phagocytosis by mammalian cells 
through inhibiting multiple pathways that govern actin mobilization.   
In addition to antiphagocytosis, effector Yops also modulate innate immune responses 
through other mechanisms. For instance, YopH can suppress the production of reactive
 
oxygen intermediates by macrophages and PMNs (116) and YopM depletes NK cells 
from spleen in the systemic plague model (159), which will be discussed in detail in this 
work. 
Cytokines and chemokines are the bridge connecting the innate and adaptive immune 
systems. Through negative regulation of major signal pathways in the infected cells, 
effector Yops inhibit the production of many cytokines. YopJ/YopP has been shown to
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inhibit TNF-α release by macrophages and IL-8 release by epithelial and endothelial cells 
(44). YopM causes decreased expression of TNF-α, IL-1β, IL-12, IL-18, IL-15, and IFNγ, 
which are cytokines that activate innate immune cells including macrophages, DCs, NK 
cells, and PMNs (159, 276). Another component of the T3SS, LcrV, is also found to 
trigger the release of the suppressive cytokine IL-10 (349).  
Besides cytokines, effector Yops also inhibit the expression of some important 
chemokines or adhesion molecules and in turn block the recruitment of key immune cells. 
Examples include the inhibition of the expression of MCP-1 by YopH (281) and reduced 
production of adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) 
and E-selectin, by YopJ/YopP (43). 
 
e) Y. pestis paralyzes DCs without affecting their maturation  
DCs are key players at the interface of innate and adaptive
 
immunity. Circulating 
precursor DCs enter tissues as immature DCs, where they can directly encounter 
pathogens that induce secretion of cytokines (e.g. IFN-α), which in turn can activate 
eosinophils, macrophages, and NK cells. Contact with the microorganisms also triggers a 
series
 
of programmed events that include migration of immature DCs to lymphoid organs 
and conversion of immature DCs into mature ones,
 
together with the degradation of 
pathogens within
 
the phagosome and the presentation of microbial antigens by
 
the major 
histocompatibility complex (MHC) molecules. This in
 
turn causes DCs to activate T cells 
by an MHC-specific manner, and activated T cells promote terminal maturation of the 
DCs (23, 24). In addition to the control of the costimulatory pathway,
 
DCs seem to 
contribute to T-cell activation by overcoming suppression
 
mediated by CD4 and CD8 
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regulatory T cells by secretion of IL-6 (178).
 
Activated T lymphocytes migrate to the 
injured tissue. Helper T cells (CD4
+
) secrete cytokines, which permit activation of 
macrophages, NK cells, and eosinophils. Cytotoxic T cells (CD8
+
) eventually lyse the 
infected cells. B cells become activated after contact with T cells and DCs and then 
migrate into tissues where they mature into plasma cells and produce antibodies that 
neutralize the initial pathogen (23, 24).  
Many pathogens have developed a variety of mechanisms to disarm
 
host defenses, 
such as impairing DC maturation, promoting
 
apoptosis of DCs, and inhibiting cytokine 
secretion. Y. enterocolitica was found to induce apoptosis of murine DCs as well as 
inhibit the expression of MHC-II; major adhesion molecules such as CD54 (ICAM-1), 
CD 80, and CD86; and cytokines including KC, TNF-α, IL-10 and IL-12 by DCs (94). 
During infection by Y. pestis, DCs are one
 
of the early targets of Y. pestis (197, 370). 
However, instead of a negative effect on DC viability and maturation, the most 
pronounced
 
effect of Y. pestis on DCs appears to be the paralysis of DC
 
movement by 
impairing cytoskeletal rearrangement, and this effect seems to be mediated by the 
products encoded by pCD1 (347). Paralysis of DCs also results from the compromised 
TLR4-dependent induction of IL-12(p40)2 by DCs in Y. pestis infection (268) 
 
f) Y. pestis reduces host adaptive immunity by both
 
influencing the induction of 
cytokine expression and acting directly on
 
immune cells 
The adaptive immune response is characterized by selective and clonal expansion
 
of 
immune cells (T and B cells) to recognize antigens from
 
a pathogen, providing specificity 
and long-lasting immunological
 
memory. Given the very short incubation time of plague, 
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the protection an infected person receives during the primary infection from the adaptive 
immune system may be limited. However, studies about the modulation of adaptive 
responses by this bacterium will facilitate vaccine development and understanding that 
may apply to the pathogenesis of other facultative intracellular bacteria. 
Yersinia has the ability to influence adaptive immunity by directly
 
suppressing T cell 
activation as well as inducing the mitochodrially regulated apoptosis of T cells. One of 
the effector Yops, YopH with tyrosine phosphatase activity, exerts both of these effects in 
a cell culture model (6, 52). For example, YopH was found to block in vitro T cell antigen 
receptor (TCR) signaling at its very first step by dephosphorylating LcK (leukocyte-
specific protein tyrosine kinase), which associates with the cytoplasmic tails of the CD4 
and CD8 co-receptors on T helper cells and cytotoxic T cells, respectively, and then 
transmits signaling from the TCR complex (6). A recent study also reported that that 
primary human cytolytic T cells respond to Y. pestis pCD1-encoded virulence proteins 
that are presented by infected monocytes and dendritic cells, and T cell responses to non-
Yersinia antigen are maintained (278).  
So far I have not found any study showing a direct inhibitory effect of Y. pestis on T 
cells in vivo. However, some in vivo studies of the cellular immune responses to Y. pestis 
showed the possible importance of T cells in the defense against Y. pestis. Parent et al. 
vaccinated B-cell-deficient
 
µMT mice intranasally with live replicating Y. pestis and 
found that vaccination dramatically increased survival of µMT mice that were 
subsequently IN challenged
 
with a lethal Y. pestis dose(239). The vaccine significantly
 
reduced bacterial growth in lung, spleen and liver and elevated the number of pulmonary 
T cells.
 
T cell ablation abolished this vaccine-mediated protection, and the transfer of Y. 
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pestis-primed T cells to naive
 
µMT mice protected against lethal intranasal challenge. 
Meanwhile, IFN-γ, TNF-α and inducible NO synthase (iNOS), key products of cellular 
immunity,
 
perform critical protective functions during humoral defense
 
against lethal 
pulmonary Y. pestis challenge (240). And a more recent paper reported that mice 
vaccinated with live attenuated
 
Y. pestis (KIM5 Δpgm) are synergistically protected by 
primed CD4 and
 
CD8 T cells from lethal pulmonary
 
Y. pestis infection (247). 
Serum samples collected from mice infected IP with Y. pestis
 
can transfer passive 
protection to IN infected C57BL/6 mice (240), indicating that
 
humoral immunity plays an 
important role against Y. pestis challenge.
 
Two major immunogenic proteins, F1 and LcrV 
(V antigen), provide a high degree of protection,
 
and subunit vaccines based on these 
proteins have demonstrated
 
efficacy in small animal models (11, 184, 227). Classical 
humoral immune mechanisms could directly combat extracellular
 
Y. pestis organisms and 
simultaneously aid cell-mediated immunity
 
by neutralizing surface-exposed Y. pestis 
virulence factors that dampen cellular
 
responses, thereby promoting T-cell activation.
 
At 
the same time, classical cell-mediated immune mechanisms
 
may aid humoral defense by 
eradicating intracellular Y. pestis
 
reservoirs.
 
Thus, the two major components of the 
adaptive immune system could act synergistically to protect the host against Y. pestis. 
 
G. Current animal model for Y. pestis study 
Corresponding to each of the three natural forms of plague, there is usually more than 
one animal model used to study plague. Here I focus on the mouse models related to the Y. 
pestis strains used in this study, which are Δpgm strain KIM5 and the fully virulent strain 
CO92.  
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To establish bubonic plague, the best and most natural way is to infect the mice with a 
Y. pestis infected flea, X. cheopis (150, 289). X. cheopis fleas are infected by feeding 
them with blood containing Y. pestis. Then a mesh-covered capsule containing infected X. 
cheopis is applied to a shaved area on the dorsolateral surface of restrained mice for a 
certain time. However, since the Y. pestis used in this model is usually the fully virulent 
strain, this infection model needs several specially designed instruments, such as the 
artificial feeding system with strict temperature and humidity as well as a mouse 
restrainer in a biosafety level 3 (BSL3) Lab.  
The convenient way to mimic the natural bubonic plague is to inject Y. pestis into the 
skin of mice. Traditionally this was done by injecting the bacteria SC. However, Sebbane 
et al. showed that fleas initially deposit Y. pestis into dermal tissue, and not SC, because 
the infection that develops at the bite site is ID and the flea mouthparts are not long 
enough to penetrate through the dermis (289). Therefore, in our study Y. pestis CO92 was 
injected ID into the shaved skin on the back at the base of the tail to set up a bubonic 
plague model in BSL3 containment. Histopathological analysis showed that inflammation 
was limited to the dermis and epidermis at the early stage of infection (Figure 3.3, panel 
C and D). 
There are two ways to set up a pneumonic plague model, IN inoculation of Y. pestis 
or exposure of the mouse to aerosol containing Y. pestis. The lungs from mice infected by 
both methods developed acute inflammation and contained a large amount of bacteria in 
the histopathological analysis (3, 173). Since the aerosol-mediated infection model needs 
a special mouse restrainer and nebulizer in a BSL3 lab, we chose the simpler method, 
which is IN inoculation in BSL3 containment.  
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Systemic plague can be caused by infecting mice in BSL2 containment with the 
attenuated pgm strain KIM5, since the pgm Y. pestis is fully virulent for the IV route 
of infection through which they can get iron from blood (99). Bacteria can be injected 
into the vein of mice through the tail vein or retro-orbital plexus which was chosen in this 
study. And in IV-infected C57BL/6 mice, yopM Y. pestis KIM5 show growth limitation 
in liver and spleen, which is a strong YopM-specific virulence phenotype that greatly 
facilitates sorting out the key players in YopM’s pathogenic effects.   
Since the goal of this study was to identify the immune responses compromised by 
YopM, parent strains (KIM5 or CO92) containing YopM and yopM mutant strains were 
used to develop the systemic, bubonic and pneumonic plague models. The infection doses 
were chosen between the LD50 of the parent and mutant strains in order to display the 
possible effects of YopM on the host immune system.   
 
H. Hypothesis and rationale for the overall experimental approach in these 
studies 
To characterize YopM’s effects in vivo, we sought to determine how YopM modulates 
the function of immune cells to favor Y. pestis growth in the host. There was no 
information yet on the target cells or relative importance of Yops other than YopH in 
pneumonic or bubonic plague. Since we already knew that the growth limitation of 
yopM mutant Y. pestis was maintained in SCID mice (159), which lacked normal T and 
B cell function, we focused our work on the innate immune system. The hypothesis was 
that YopM undermines a function of at least one innate immune cell.  
The YopM-dependent NK cell depletion in spleen and blood during infection made 
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NK cells the first candidate to study (159). mRNA analysis by RT-PCR had shown 
YopM-associated loss of mRNA for IFN-γ by NK cells in infected spleens and 
diminished expression of mRNAs in splenic macrophages for cytokines that are required 
for viability and activation of NK cells (IL-15, IL-18 and IL-12). These findings 
supported the hypothesis that YopM may function to inhibit IFN-γ-mediated activation of 
macrophages through the depletion of  NK cells. To test this hypothesis, C57BL/6 mice 
with depletion of NK cells from spleen and liver were used. If NK cells are critical for 
controlling yopM Y. pestis, the absence of this cell population in mice should relieve the 
growth defect of the yopM strain. Meanwhile since the growth defect of yopM Y. pestis 
also exists in liver, the dynamics of NK cells in liver during the infection with both parent 
and mutant strains should be examined. 
It is believed that tissue macrophages, DCs and PMNs are early target cells for Yops 
delivery in vivo, because these cells are present before or soon after infection begins and 
function to initiate the innate defenses that are undermined by Yops. Consistent with this 
hypothesis, Y. pestis has been found in association with alveolar macrophages early 
during lung infection of mice (46) and likewise in association with macrophages, DCs, 
and PMNs in spleens of mice infected IV, and YopM can be injected into these cells 
(197).  
We characterized the dynamics of macrophage, DC, and PMN populations in both 
liver and spleen during systemic plague in mice and identified any YopM-associated 
recruitment of these immune cells into both organs. We hypothesized that the recruitment 
of these cells into organs may be inhibited by YopM because the growth limitation of the 
yopM Y. pestis could be explained if these bactericidal cells were present in the yopM  
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Y. pestis-infected organs but not the parent strain infected ones. 
To test whether the above immune cell populations are responsible for the growth 
limitation of yopM Y. pestis in spleen and liver, mice ablated for different immune cells 
were used. For ablation of both PMNs and monocytes, anti-Gr1 antibody was injected IP 
into the mice; and liposome-clodronate was used to remove the resident macrophages and 
DCs as well as the inflammatory monocytes in the circulation and tissue. To specifically 
deplete PMNs, anti-Ly6G was injected IP into the mice. Finally mouse strains lacking the 
major chemokine CCL2/MCP-1 or its receptor Chemokine (C-C motif) Receptor 2 
(CCR2) were used to study the inflammatory monocytes and a newly discovered class of 
DCs, Tip DCs. The rationale was that if any of these cell types played a critical role in 
YopM’s virulence mechanism, the absence of this cell population should relieve the 
growth defect of the yopM mutant. Since spleen and liver contain different 
microenvironments and responses to infection; the infection dynamics and distribution of 
leukocytes in both of the organs were studied and compared in every ablation model. 
If there was any cell type identified as a key player responsible for the growth defect 
of yopM Y. pestis mutant, the effects of YopM on functions of this cell type should be 
studied.  
The major animal model used in this study was the systemic model with IV injection 
of the pgm Y. pestis KIM5, because we already knew the growth defect of the yopM 
strain in this model. However, systemic or septicemic plague is almost always secondary 
to bubonic or pneumonic plague. And it is becoming clear that spleen and lung present 
distinctly different inflammatory environments when infected by Y. pestis, with PMNs 
migrating rapidly into spleens infected by the IV route but not appearing in lungs until 36 
 42 
h after IN infection (173, 318). Accordingly, some virulence properties required for 
lethality of systemic plague are not required in pneumonic plague. Examples are the 
capsular fibril F1 and the antiphagocytic adhesin PsaA (49, 61, 79). Therefore, to 
understand how YopM modulates the host immune responses in natural plague, it was 
worth checking the role of YopM in both bubonic and pneumonic plague, in which the 
pgm
+
 strain must be used. 
The bacteria used in the systemic model were cultured at 26°C overnight before the 
infection to identify host responses and the role of YopM in an infectious process like the 
one that occurs after flea bite. However, natural systemic plague usually occurs 
secondarily to bubonic plague, which means the bacteria have already adapted to the 
internal environment in the mammalian host before they seed in spleen and liver. At the 
body temperature of the mammalian host (37°C), the T3SS of Y. pestis is activated so the 
Yops can be injected into the host cells, whereas the infecting bacteria grown at 26°C 
have to hide in the resident macrophages or DCs for a while to activate this system. To 
mimic the natural systemic plague model, we used pre-induced bacteria, which grew at 
26°C overnight and were transferred to 37°C three hours before infection. We 
hypothesized that the growth defect of the yopM strain would be maintained after that 
pre-induction. The infection dynamics and distributions of leukocytes during systemic 
plague in wild-type (WT) C57BL/6 mice, anti-Ly6G treated mice and CCR2 knock-out 
(KO) mice were tested and compared between infection by non-induced Y. pestis grown 
at 26°C and by pre-induced bacteria which received 3 hours stimulation at 37°C before 
the infection. 
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Table 1.1. Y.  pestis transmission Factors  
  
 
Summarized and modified from reference (133, 134, 288, 343) 
 
 
 
 
 
 
Factors Gene Location  
of Gene 
Expressing Specie(s) 
of Yersinia 
Function and 
Role in 
Transmission 
Murine Toxin 
(Phospholipase D)  
ymt pMT 
(plasmid) 
Y. pestis Bacterial survival 
in flea midgut 
F1 capsule caf1M1A1 pMT 
(plasmid) 
Y. pestis Prevents 
autoaggregation 
Pla pla pPCP1 
(plasmid) 
Y. pestis Cleavage and 
activation of 
plasminogen to 
promote 
dissemination of 
bacteria from 
fleabite site 
 
Enzymes 
(e.g., 
Polysaccharide 
deacetylase and  
glycosyl 
transferase) 
hmsHFRS 
operon 
hms locus in 
pgm locus 
(chromosome) 
 
Y. pestis 
Y. pseudotuberculosis 
biofilm 
formation to  
block the 
proventriculus 
Insecticidal toxin 
complex 
yitRABC 
operon, 
yipAB 
operon 
chromsome Y. pestis 
Y. pseudotuberculosis, 
Some 
Y. enterocalitica 
Phagocytosis 
resistance 
immediately after 
transmission 
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Figure 1.1 World Distribution of Plague and the bubonic plague vector Xenopsylla 
cheopis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the Centers for Disease Control and Prevention (CDC) website 
 
 
 
 
 
 
 
Male Xenopsylla cheopis engorged 
with blood. Both male and female 
fleas can transmit the infection.  
Countries that reported plague, 1970-1998 
Regions where plague occurs in animals 
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Figure 1.2 The Transmission Cycle of Y. pestis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Simplified from Dr. Neal R. Chamberlain’s figure. 
(http://www.unbc.ca/nlui/wildlife_diseases_bc/plague_cycles.gif)  
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Figure 1.3 The Ysc Injectisome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ysc injectisome spanning the outer membrane (OM), the peptidoglycan layer (PG) and 
the cytoplasmic membrane (CM) of the bacterium. The ring in the OM is made of the 
secretin YscC, assisted by the lipoprotein YscW. YscF, YscO, YscP and YscX are 
external parts of the injectisome. YscF is the main constituent of the needle structure. 
YscV, YscU, YscR, YscT and YscS are proteins of the basal body that are in contact with 
the CM. YscN is the ATPase of the translocon. Not shown is the tip complex that creates 
a pore in the host cell plasma membrane. (74) 
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Figure 1.4 Secretion of Yops by the Ysc injectisome and translocation across the target 
cell membrane 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At 37°C, Yersinia assembles its Ysc injectisome. The secretion channel opens and Yops 
are exported after a stable contact is established between a eukaryotic target cell and the 
bacterium through the interaction of the bacterial adhesins YadA or Inv in 
enteropathogenic Yersiniae with integrins; and pH 6 antigen, Pla and Ail in Y. pestis with 
Phosphatidylcholine (108), CD205 (371) and Fibronectin (339) on the eukaryotic cell 
surface. YopB with the aid of YopD forms a pore in the target cell plasma membrane, and 
the effector Yops are translocated across this membrane into the eukaryotic cell cytosol. 
YopM is the only Yop migrating to the nucleus. EM, outer membrane; P, peptidoglycan; 
IM, plasma membrane. (73) 
 
 48 
Figure 1.5 Modulation of host signaling pathways by Yops 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YopH, YopE, YopT, and YopO antagonize focal complex formation and activity of Rho 
family GTPases, whose activation triggers phagocytosis in the case of the β1 integrin 
signaling pathway, or pore formation (leakiness after insertion of the Ysc tip complex) in 
the case of the translocator pathway. YopE and YopT inhibit phagocytosis by acting as a 
GAP (YopE) and cleaving the C-terminal isoprenyl cysteine from RhoA, which releases 
the GTPase from the membrane (YopT). YopO binds to the active or inactive Rho 
GTPase and counteracts signaling and phagocytosis by an unknown mechanism. The PTP 
activity of YopH inhibits early steps in the β1 integrin signaling pathway to counteract 
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phagocytosis. Rho GTPase activation also stimulates gene transcription via the MKK and 
NF-κB pathways, leading to the production of cytokines and survival factors. YopJ 
acetylates serine and/or threonine residues in the activation loops of MKK and inhibitor-
κB kinase (IKK). YopM enters into the nucleus by unknown mechanism, as well as forms 
a complex with two serine/threonine kinases, protein kinase C-related kinase 2 (PRK2) 
and ribosomal S6 protein kinase 1 (RSK1) in the cytosol. (349) 
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Figure 1.6  Schematic representation of the YopM structure 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel A, YopM monomer. The N and C-terminal residues that were observed in the 
crystal structure are labeled. Panel B, Two views of the YopM tetramer. (96) 
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Figure 1.7 Model for YopM’s cellular trafficking 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YopM (M) is injected by the T3SS into the eukaryotic cell through the pore in the plasma 
membrane (PM) formed by translocator YopB and binds to the surface of a vesicle, which 
then carries YopM to the endosomal compartment (EC). YopM’s endosomal trafficking is 
microtubule dependent. At some point, YopM is released from the surface of the vesicle 
and interacts with the hypothetical component X, which chaperones YopM through the 
nuclear pore. Microtubules are shown schematically as a dotted line. GC, Golgi 
compartment; ER, endoplasmic reticulum; NM, nuclear membrane. (300) 
 
 
 
 
 
 
 
 52 
Figure 1.8 Y. pestis modulates host immune responses to survive 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Y. pestis defense mechanisms against host innate immunity. (a) Defense mechanisms at 
the early stage of infection. (b) Defense mechanisms after the release of Y. pestis from 
macrophages. The figure was modified from the reference (185). 
Copyright © Zhan Ye 2010 
Delivery of Yersinia pestis by Flea Bite 
Adaptive Immunity 
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Chapter Two: Methods and Materials 
 
A. Bacterial strains and in vitro cultivation 
Bacterial strains and plasmids used in this study are listed in Table 2.1. This study 
employed strains from the two most recently evolved groups of Y. pestis populations (1), 
Y. pestis KIM5 (Kurdistan Iran Man, molecular grouping 2.MED), an isolate from Iran, 
and Y. pestis CO92 (1.ORI), isolated in the USA. The genomes of both strains have been 
sequenced (82, 241). Y. pestis KIM5 and its derivatives lack the chromosomal pgm locus 
and are conditionally virulent: they are attenuated from peripheral routes of infection but 
are virulent by the IV route of infection, which bypasses the requirement for the Ybt 
siderophore-based iron-acquisition mechanism encoded in this locus (159, 341). KIM5-
3002, the yopM-1 derivative of KIM5, was created by deletion of the entire yopM gene, 
from −2 bp before the initiating Met codon through the stop codon by an allelic exchange 
method (159).  The lacZ Y. pestis KIM5-3003 was created in the Y. pestis KIM5 
background by allelic exchange followed by sucrose selection to cure the suicide plasmid 
pLacZ as described previously (42). Y. pestis CO92.S6 and CO92.S19 were created by 
Christine Wulff in our lab (104, 363). Y. pestis CO92.S6 is fully virulent and Y. pestis 
CO92.S19 is the yopM-2 derivative of strain CO92.S6. CO92.S19 and CO92.S6 were 
handled only in BSL3 containment with select agent security.  
Y. pestis KIM5-derived strains were routinely grown at 26ºC or 26ºC plus 3 hours pre-
induction at 37ºC (26/37ºC) for pre-induction in Heart Infusion Broth (HIB,  Difco 
Laboratories) without calcium and harvested in exponential phase at A620 = 0.8 to 1.2. 
Cells were centrifuged at 23,281 x g and 4°C for 5 min, washed and diluted in PBS. 
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Samples from the dilutions were plated on tryptose blood agar (TBA, Difco Laboratories) 
(241) and incubated at 30°C for 2 d to determine the actual dose. To distinguish KIM5-
3003 from the mixture of KIM5 and KIM5-3003, bacterial mixtures were plated on TBA 
plus 40 g/ml X-Gal (Research Organics) and incubated at 30°C for 2 d. Y. pestis CO92-
derived strains were grown at 28
o
C or 37
o
C as indicated in HIB supplemented with 2.5 
mM CaCl2 and 0.2% xylose; when the CO92 Lcr plasmid pCD2 was present, 50 g/ml 
carbenicillin (Cb) also was present. Prior to infecting mice, the cultures were diluted in 
PBS. Samples of the doses and appropriate serial dilutions were plated on supplemented 
HIB + Cb and the number of colony forming units (CFUs) was determined after 
incubation for 2 d at 28
o
C. The presence of the pigmentation locus (245) in all Pgm
+
 
strains was confirmed by the formation of red colonies on Congo red agar (323) at 28°C. 
The presence of a functional Lcr virulence plasmid was confirmed by absence of growth 
at 37
o
C on supplemented HIB agar containing 0.2 M MgCl2 and 0.2 M sodium oxalate 
(MgOx plates) and by the low calcium response growth and Yop secretion phenotypes 
(245) in the defined medium TMH (317).  
pCD2Ap yopM-2 was created by Christine Wulff in our lab. The yopM ORF and 
197 upstream bases containing the yopM promoter (265) were deleted from pCD2Ap of 
the Y. pestis CO92 derivative Y. pestis CO99-3015.S6. Briefly, primers LF up 5’ 
ACATTAGAGCTCTGCCTGTCTCCGTTGTTG 3’ and LF down 5’ 
TACTATCTGCAGTGTATGGCCGCAGAGT 3’ were used to copy 1180 bp of DNA 
upstream of the deleted locus by PCR, and primers RF up 5’ TGCTGCAGACGCA-
AGAGCGTTCAT 3’ and RF down 5’ ATCTCTCGAGACGCCACCGTTGATTA 3’ were 
used to copy 1230 bp of downstream DNA. The upstream and downstream DNAs were 
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cloned into pLD55 as respective SacI/Pst1 and PstI/XhoI PCR products to create the 
allelic exchange plasmid pyopM-2 in Escherichia coli DH5pir. The deletion was 
moved into pCD2Ap by allelic exchange as previously described (210, 233). The deletion 
did not remove any ORFs other than yopM, and its upstream boundary was 196 bp 
downstream from the stop codon of the nearest potential ORF (265). The deletion 
extended 1 bp downstream of the yopM stop codon (similarly to the yopM-1 mutation in 
Y. pestis KIM, which deletes the stop codon but no downstream bases). The resulting 
yopM deletion was confirmed by PCR. The absence of YopM expression in the yopM-2 
strain but normal expression and secretion of YopH and LcrV with appropriate regulation 
by calcium in the medium was confirmed by immunoblot analysis of whole cells and 
culture supernatants. The two mutations, yopM-1 in the KIM5 background and yopM-
2 in the CO92 background, are believed to have the same phenotypes because they are 
both well separated from upstream and downstream ORFs; but because they are not 
identical, we have given them different allelic designations.   
 
B. Infection of mice and measurement of bacterial viable numbers in tissues 
All animal experiments in this work were reviewed and approved by the University of 
Kentucky Institutional Animal Care and Use Committee. For studies with Y. pestis KIM5, 
KIM5-3002 and KIM-3003, 6 to 8 week old female C57BL/6N.HSD mice (Harlan 
Sprague Dawley, Inc) or female CCR2
-/-
 and CCL2
-/-
 C57BL/6J mice (obtained from 
Jayakrishna Ambati M.D., Department of Ophthalmology and Visual Sciences, 
University of Kentucky and bred by Annette Uittenbogaard in our lab (7)) ranging from 6 
to 15 weeks of age were anesthetized with an isoflurane-oxygen mixture by a rodent 
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anesthesia machine. 100 μL (400 CFU) of bacterial suspension was injected into each 
mouse IV via the retro-orbital plexus. This was above the LD50 for the parent strain and 
below that for the yopM-1 mutant. At designated times after infection, groups of three or 
four mice per strain per time point were humanely killed by CO2 inhalation followed by 
cervical dislocation, and their spleens and livers were weighed, transferred to a sterile bag 
containing 5 ml of PBS, and placed on ice. The tissues were homogenized in a Stomacher 
80 lab blender (Tekmar Co.) for 60 s with high speed. The liver and spleen homogenates 
were diluted in PBS and plated to measure the bacterial burden in the organs. When 
studying the distribution of bacteria in mice, bone marrow from femurs was flushed by 1 
ml sterile PBS, and the intestine was harvested and minced finely before homogenization. 
In most of the experiments, TBA plates were used, whereas Yersinia selective agar (YSA; 
Difco Laboratories) was used to recover Yersinia pestis from the intestine.  
To study the function of peritoneal cells, C57B/L6 mice were IP injected with the 
designated dose in 100 l sterile PBS. At harvest timepoints, 5 ml ice-cold PBS was 
injected into the peritoneal cavity of each mouse immediately after it was killed by CO2 
inhalation. The peritoneal lavage fluid was harvested by using a 10 ml syringe with an 18 
gauge needle after thorough massage of the abdomen.   
For infection with Y. pestis CO92 strains, the mice were anesthetized with ketamine 
(100mg/kg, IVX Animal Health) and xylazine (10mg/kg, Butler Co.) given IP. Bacterial 
doses were made in 100 l of PBS for ID infection and administered with a 1-ml 
tuberculin syringe fitted with a retractable 26 gauge needle (Becton, Dickinson and 
Company). For IN infection a 20 l volume of bacteria in PBS was instilled into the nares 
from a plastic micropipette tip. The effect of xylazine was then reversed by subcutaneous 
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injection of yohimbine (2mg/kg, Ben Venue Laboratories), at a different site than used for 
infection) and the mice were treated with an optical lubricant before being returned to 
their cages. At designated times after infection, the mice were humanely killed by IP 
injection of 100 l of Beuthanasia-D (minimum of 150 mg/kg) followed by thoracic 
puncture, and the spleen and a patch of skin surrounding the infection site were recovered.  
Spleens were minced, and taken into a 3-ml syringe along with 1 ml of sterile distilled 
water (dH2O). A second syringe equipped with a 20-gauge emulsifying needle was 
attached, and the sample was passed back and forth 20 times to further disrupt the tissue 
and release the bacteria. The piece of skin was minced and transferred to a 50-ml conical 
tube containing 2 ml sterile PBS, collagenase (40,000 U/ml), dispase protease (224 U/ml), 
and DNase (16,000 U/ml). The tubes were then agitated for 30 min in an upright position 
at 250 rpm on a gyrotory platform at 37
o
C.  The resulting digest was taken into a 5-ml 
syringe and emulsified as above through an 18-gauge emusifying needle.  The resulting 
spleen and skin suspensions were then serially diluted in PBS and plated in duplicate to 
determine CFUs.   
 
C. Tests of virulence in mice 
To determine LD50 values, groups of 8 mice were infected IV, IN, ID or IP with 10-
fold or 3-fold increasing doses of YopM
+
 parent or yopM strains as indicated. The mice 
were monitored daily for 14 d for signs of illness and mortality. Mice were humanely 
killed if deemed unlikely to survive to the next observation and counted as though they 
were dead at the next observation. Criteria for humane killing were loss of the righting 
reflex or immobility accompanied by hunched posture, ruffled fur, and heavy breathing. 
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D. Innate immune cell ablation 
NK cell ablation was mediated by anti-NK1.1 mAb PK136 that had previously been 
prepared by injecting the B cell hybridoma PK136 clone (American Type Culture 
Collection) IP into pristane-primed BALB/c mice and was a gift from Donald A. Cohen, 
Ph.D. in our Department. Ascites was clarified by centrifugation and stored at -20
 o
C. 
Before use in mice, antibodies were again centrifuged and then filtered through a 0.22 
μM pore-size low-protein-binding membrane (Millipore). Anti-NK1.1 mAb or rat IgG 
(Sigma-Aldrich Chemical Co.) was injected IP at 1 mg/mouse on d –1, 1 and 3 of Y. 
pestis infection. 
Ablation of Gr1
+
 cells was done as described previously (272). Briefly, anti-Gr1 mAb 
had been prepared from B cell hybridoma line R6-8C5
 
(DNAX Research Institute) and 
partially
 
purified using ammonium sulfate precipitation. It was provided for this work by 
Donald A. Cohen Ph.D. in our Department. Anti-Gr1 mAb or rat IgG was injected IP at 
100 µg/mouse on d –1 and 1 of Y. pestis infection.  
Systemic ablation of macrophages/DCs was mediated by liposome-encapsulated 
clodronate (Cl2MDP). The liposomes were prepared as previously described 
(346).  Liposomes containing clodronate (clodronate liposome) or PBS (PBS liposome) 
were purchased from Nico van Rooijen Ph.D., Department of Molecular Biology, Vrije 
Universiteit Medical Center. Mice in ablation groups or control groups were injected IV 
via the retro-orbital
 
plexus with 200 µL
 
clodronate liposomes or PBS liposomes 18 h 
prior to Y. pestis infection and on d 1 p.i..   
PMNs were ablated with the PMN-specific anti-Ly6G mAb (mAb 1A8; Bio X Cell) 
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or rat IgG (Sigma) injected IP at 200 µg/mouse on d –1 and 1 of Y. pestis infection.  The 
extent of ablation in these and in mock-treated mice was assessed by flow cytometry with 
detection via fluorochrome-tagged anti-Ly6G and anti-CD11b antibodies.   
To test the importance of recruitment of inflammatory monocytes into foci of 
infection, two KO mice strains were used. CCR2
–/–
 and CCL2
–/–
 strains were generated as 
described previously (168, 191). To create the CCR2 KO strain, the entire CCR2 coding 
region was replaced by insertion of a neomycin-resistance expression cassette, while 
CCL2/MCP-1 KO mice were created through targeted disruption of CCL2/MCP-1 gene. 
Although the original KO strains were generated on a mixed C57BL/6 × 129/Ola genetic 
background, the mice used in this study represent the progeny of the eighth generation 
backcross of the KO mutations to inbred C57BL/6 animals. Therefore C57BL/6 mice 
were used as control to the ablated mice. 
Two tests employed transgenic Macrophage Fas-induced apoptosis (MaFIA) mice on 
a C57BL/6 background (57). These mice were bred and confirmed by PCR to be 
homozygous for the inducible suicide transgene before use in experiments. Mice were 
between 5 and 8 weeks old, and both sexes were used, distributed equally among 
treatment groups. These mice can be ablated for cells of the macrophages/DCs lineage by 
treatment with the dimerizer drug AP20187 (gift of Ariad Pharmaceuticals, Inc. to Donald 
A. Cohen Ph.D.). Seven days prior to infection, the ablation regimen was initiated by IV 
injection of 10 mg/kg of dimerizer drug or mock injection solution (water containing 4% 
[vol/vol] ethanol, 10% [wt/vol] PEG-400, and 1.7% [vol/vol] Tween-20). Injection was 
done within 30 min of dilution of dimerizer into the injection solution, and the volume, 
adjusted by body weight, averaged 100 l per mouse. The mice received daily injections 
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of drug or mock solution for 5 days and then were allowed to rest two days before being 
infected with Y. pestis KIM5. 
 
E. Flow cytometry 
Cells isolated from livers and spleens were analyzed in a FACSCalibur flow 
cytometer (Becton Dickinson FACS Systems). Briefly, spleens were placed in sterile 
bags containing 5 ml PBS and then processed with the Stomacher 80 lab blender for 60 s 
at high speed. The homogenate was centrifuged (913 x g and 10 min) and resuspended in 
2 ml RBC lysis buffer (150 mM NH4Cl, pH 7.2). After 2 min, the reaction was 
terminated by addition of 8 ml of PBS. The cell suspensions were filtered through a 
40μm-pore-size cell strainer (Becton, Dickinson and Company) to remove connective 
tissue, centrifuged (913 x g for 10 min), and resuspended in PBS containing 1% (wt/vol) 
BSA and 0.1% (wt/vol) sodium azide (PBS-BSA-azide).  
To process livers, finely minced livers were placed into sterile bags containing 10 ml 
RPMI 1640 (Life Technologies Inc.) with 10% FBS (ATCC) and processed with the 
Stomacher 80 lab blender for 60 s at high speed. The homogenates were incubated with 
DNase I (160 U/ml, Sigma-Aldrich) and collagenase (400 U/ml, Invitrogen) for 30 min in 
a 37°C water bath with shaking at 125 rpm. After filtration through a 40 μm-pore-size 
cell strainer, cell suspensions were washed once with ice-cold PBS-BSA-Azide and 
resuspended with 5 ml 33.8% Percoll (Amersham Bioscience, GE Healthcare) followed 
by a 12-min centrifugation at 693 x g. The cells in the bottom layer were collected, 
washed with PBS and treated with RBC lysis buffer. Nonlysed cells were resuspended in 
PBS-BSA-azide. 
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In some experiments, blood was obtained by cardiac puncture using a syringe 
containing 30 l of 1000 units/ml heparin (Elkins-sinn, Inc). Approximately 200 l of 
blood was harvested from each mouse and then mixed with 5 ml of PBS. The mixture 
was carefully overlaid on 5 ml Lympholyte-Mammal (Cedarlane Labs), and then 
centrifuged at 600 x g for 20 min at room temperature. The leukocytes were obtained 
from the interface and washed twice in PBS-BSA-Azide. When harvesting the leukocytes 
from bone marrow, two femurs were isolated from each mouse. Bone marrow from every 
femur was flushed by 1 ml sterile PBS and the leukocytes were obtained after washed 
twice with PBS-BSA-Azide.  
The antibodies and compounds used in flow cytometry staining are listed in table 2.2. 
The following antibodies were purchased from BD Pharmingen, Inc.: allophycocyanin 
(APC)-conjugated anti-CD11c, APC-conjugated anti-NK1.1, APC-conjugated anti-
CD62L, Fluorescein isothiocyanate (FITC)-conjugated anti-CD3, FITC-conjugated anti-
CD11b, FITC-conjugated DX5 (anti-CD49b), Phycoerythrin (PE)-conjugated anti-B220, 
PE-conjugated anti-CD8, PE-conjugated DX5, PE-conjugated anti-Ly6G, PE-conjugated 
anti-NK1.1, PE-conjugated anti-CD86 and PE-conjugated anti-IA
b
. To gate out apoptotic 
or dead cells, ethidium monoazide (EMA, Sigma) was used for viability staining. To 
evaluate NKT cells, mCD1d/PBS57 (APC conjugated) was used (provided by the NIH 
Tetramer Core Facility). 
Prior to staining, the cells were counted, and samples were adjusted to 5 x 10
5
 cells 
per 100 l and treated with Fc Block™ for 15 min. All samples were stained with EMA 
to identify dead cells. In the presence of the appropriate combinations of antibodies and 
EMA, the cells were incubated on ice for 30 min, with the last 10 min being in the light. 
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After being washed in PBS, the cells were resuspended in ice-cold PBS containing 4% 
(wt/vol) paraformaldehyde, pH 7.4 and treated at least 30 min before flow cytometric 
analysis.  
To detect intracellular iNOS and TNF in particular cell types, cells were processed 
with BD Cytofix/Cytoperm™ Plus Fixation/Permeabilization Kit (BD Biosciences). 
Briefly, cells were treated with GolgiPlug™ (1 μl per ml of cell suspension) for 4 hours at 
37
o
C followed by surface marker staining described above. Then the cells were incubated 
with Fixation/Permeabilization solution for 20 min at 4
 o
C. After being washed with 
Perm/Wash™ buffer, the cells were stained with appropriate antibodies at 4°C for 1 hour 
in the dark. Then they were sent for flow cytometric analysis after washes and 
resuspended in PBS-BSA-Azide. 
Flow cytometric processing was performed by the Flow Cytometry Core Facility at 
the University of Kentucky. Software WinMDI (Version 2.7; Joseph Trotter, Salk 
Institute for Biological Studies, La Jolla, CA [available at 
http://facs.Scripps.edu/software.html]) was used to analyze the data. To measure the 
expression level of each cellular surface marker, mean fluorescence intensity (MFI) of the 
fluorochrome conjugated to this marker’s monoclonal antibody was used. Typical 
leukocyte populations obtained by these methods from non-infected mice are given in 
Table 2.3. The numbers of total leukocytes harvested from spleen and liver did not 
change significantly after infection (data not shown). Therefore, the percentages, not the 
absolute numbers, of individual immune cell type in the total live leukocytes were 
reported in this dissertation excepte in Figure 8.4. 
 63 
F. Giemsa Staining to test the cellular contents of the peritoneal lavage in IP 
infection  
Peritoneal cells harvested from the IP infected mice were pelleted (913 x g for 10 
min), resuspended with ice-cold PBS and counted. 200 uL cell suspensions (4x10
5
 cells/ 
mL) was loaded into the assembled cytospin cartridge (Shandon) and centrifuged at 700 
rpm for 7 min. Slides then were collected and air-dried for 10 min at room temperature. 
The cells then underwent 2 min fixation with LeukoStat Fixative Solution (Fischer 
Diagnostics), 25 sec of staining with Diff Quick Solution 1 (Baxter) and 1 min of staining 
with Diff Quick Solution 2 (Baxter). After 2x washes with double-distilled water, the 
slides were air-dried and sealed by Permount (Fischer Diagnostics) and coverslips, and 
then were ready for reading under the microscope. 
 
G. Measurement of Reactive Oxygen Species (ROS) and nitric oxide (NO) 
production in leukocytes from infected spleen or peritoneal lavage 
To study the splenic leukocytes, spleens were homogenized with the Stomacher 80 
lab blender for 60 seconds at high speed and treated with 300U/ml collagenase 
(Invitrogen) at 37°C for 30 minutes. To study their stimulability, those cells were treated 
with 200 nM Phorbol Myristate Acetate (PMA, Cell Signaling Technology) or PBS as 
control at 37°C for 1 hour after RBC lysis. Then the cells were stained with 2',7'-
dichlorodihydrofluorescein diacetate (DCFDA) and 4-amino-5-methylamino-2',7'-
difluorofluorescein (DAF) (Invitrogen) (5 M in 1x Hanks salt solution (GIBCO))  at 
37°C for 30 minutes. DCFDA and DAF powder was dissolved by pure (H2O free) 
dimethyl sulfoxide (DMSO) to make 5 mM stock solution and kept in lightproof 
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container at -20°C as 10 uL aliquot. As soon as DCFDA or DAF was added, the cells 
were incubated or transported in lightproof container.  
Finally those splenic leukocytes were stained with antibodies against appropriate 
surface markers and EMA for 30 minutes. After two washes, the samples were analyzed 
by the Flow Cytometry Core Facility at the University of Kentucky immediately. 
Peritoneal cells were harvested by peritoneal lavage as described in Section 2.F. The 
cells were washed with ice-cold PBS twice, resuspended with 1x Hanks salt solution, and 
counted.  1x10
5 
cells were loaded into each well of 96-well plate. After treatment with 
200 nM PMA or PBS for 1 hour at 37°C, the cells were incubated with DCFDA or DAF 
(5 M in 1x Hanks salt solution) for 30 minutes. The relative fluorescence units (RFUs) 
were read by microplate reader (Molecular Devices Corporation).  
 
H. Histopathology 
Lobes of liver were harvested from C57BL/6 mice infected IV with either Y. pestis 
KIM5 or Y. pestis KIM5-3002. In the BL3 facility, skin patches at the infection sites were 
excised from C57BL/6 or CCR2
-/-
 mice ID infected with either Y. pestis CO92.S6 or Y. 
pestis CO92.S19. In the pneumonic plague model, portions of lung were harvested from 
C57BL/6 mice IN infected with either Y. pestis CO92.S6 or Y. pestis CO92.S19. All of the 
above tissues were fixed for 24 h at room temperature in 10% buffered formalin and 
processed through graded alcohol and xylene, followed by embedment in paraffin 
(performed in the Histology Laboratory in Department of Pathology and Laboratory 
Medicine at the University of Kentucky). Sections stained with hematoxylin and eosin 
were examined and photographed with an Axiophot microscope (Carl Zeiss, Inc.).  
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I. Statistical analysis 
With few exceptions (note in the text), all experiments were conducted at least twice 
with at least 3 replicate mice per group. Then the data from the replicate experiments 
were pooled for analysis of significance. Significance of differences among groups was 
assessed by the Student’s unpaired 2-tailed t test. Values for P < 0.05 were considered 
significant. Data are presented as the mean
 
value ± standard deviation and the numbers of 
mice used for each datum point are given in the figure legends. Virulence tests measuring 
lethality were conducted at least twice with four to eight mice per group and three or four 
dosage groups. Probit analysis was applied to log-transformed pooled data (17; 
implemented through BioStat 2008 5.1.1.0 [by A. Simachov at AnalystSoft]). Pairwise 
comparison of data groups with nonparametric distributions was made with the Wilcoxon 
two sample test. Four frequently used notations for significance in this dissertation are 
listed in Table 2.4. The less-used notations are described in individual figures. 
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Table 2.1 Bacterial strains and plasmids used in this study                     
Strain Relevant properties Source or 
Reference 
Y. pestis   
KIM5 Pgm
-
 Lcr
+
; pCD1 pMT1 pPCP1; conditionally 
virulent pgm 2.MED strain; also called KIM 
D27 
R. R. Brubaker 
KIM5-3002 yopM-1 derivative of KIM5; yopM coding 
sequence deleted from 2 bp upstream of Met 
through the translational stop codon. 
(159) 
KIM5-3003 lacZ derivative of KIM5; created by allelic 
exchange followed by sucrose selection to cure 
the suicide plasmid pLacZ 
(42) 
CO99-3015.S6 CO92 Ap
r
 pgm Lcr+ pFra, pPCP1; contains 
pCD2Ap   
Spencer Leigh; 
(104) 
CO92.S6 CO92 Ap
r
 Pgm
+
 Lcr
+
 pFra, pPCP1; 
reconstituted virulent strain made by 
introduction of pCD2Ap into CO92.S1. 
(104) 
CO92.S19 Reconstituted Lcr
+
 yopM-2 strain made by 
introducing pCD2Ap yopM-2 from CO99-
3015.S11 into CO92.S1. 
(363) 
E. coli   
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DH5pir recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 deR Δ(lacZYA-argF)U169 λpir+ 
Lab stock 
Plasmids   
pLD55 Suicide vector with oriR6K and fusaric acid 
selection; Ap
r
Tc
r
 
(210) 
pyopM-2 pLD55 containing the 1180 bp left flank DNA 
upstream of the yopM-2 locus fused to the 
1230 bp right flank DNA downstream of 
yopM-2                   
This Study 
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Table 2.2 Antibodies and compounds used in flow cytometry staining 
Fluorochrome  Antibodies or Compounds Sources 
FITC CD3 
DX5 
CD11b 
iNOS 
Gr1 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
PE Ly6G 
TNF-alpha 
CD19 
Mac3 
CD8 
B220 
NK1.1 
DX5 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
APC CD11c 
NK1.1 
Gr1 
mCD1d/PBS57 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
BD Pharmingen, Inc. 
NIH Tetramer Core Facility 
Compound EMA Sigma 
Compound 
Compound 
DCFDA 
DAF 
Invitrogen 
Invitrogen 
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Table 2.3 Average populations of total leukocytes, PMNs, MDMs, NK cells, DCs and 
iDCs obtained from the spleens and livers of uninfected mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Total Number per Organ (10
6
) 
Cells Spleen Liver 
Total leukocytes 110.7 ± 9.5 8.9 ± 0.3 
PMNs (Ly6G
+
 CD11b
+
) 9.3 ± 0.5 0.29 ± 0.03 
MDMs (Ly6G
-
 CD11b
+
) 5.5 ± 2.9 0.79 ± 0.05 
NK cells (NK1.1
+
 DX5
+
 CD3
-
) 7.4 ± 1.5 0.73 ± 0.08 
DCs (CD11c
+
) 
iDCs (CD11b
+
CD11c
int
) 
4.5 ± 0.9 
2.1±0.2 
1.2 ± 0.25 
0.21±0.007 
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Table 2.4 Notations for the significance 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
Infecting Strains  Comparison Between 
Different Groups of Mice 
Notation 
yopM strain 
(KIM5-3002) 
NK-ablated and mock-
ablated mice 
 
Gr1+ cell ablated and mock-
ablated mice  
 
PMN ablated and mock-
ablated mice 
 
MDM-ablated and mock-
ablated mice 
 
CCR2 KO and WT mice 
 
CCL2 KO and WT mice 
 
 
 
 
†, P<0.05; ††, P<0.01 
 
 
 
 
 
Parent strain 
(KIM5) 
NK-ablated and mock-
ablated mice 
 
Gr1+ cell ablated and mock-
ablated mice  
 
PMN ablated and mock-
ablated mice 
 
MDM-ablated and mock-
ablated mice 
 
CCR2 KO and WT mice 
 
CCL2 KO and WT mice 
 
 
 
 
#, P<0.05; # #, P<0.01 
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B. 
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Mice  Comparison Between 
Y. pestis strains 
Notation 
Immune cell mock-ablated 
mice 
 
 
 
WT mice 
 
 
 
 
yopM strain 
(KIM5-3002) and 
parent strain (KIM5) 
 
 
 
 
*, P < 0.05; **, P < 0.01 
 
 
NK-ablated mice 
 
Gr1+ cell ablated mice  
 
PMN ablated mice 
 
MDM-ablated mice 
 
CCR2 KO mice 
 
CCL2 KO mice 
 
 
 
yopM strain 
(KIM5-3002) and 
parent strain (KIM5) 
 
 
 
 
, P < 0.05; , P < 0.01 
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RESULTS 
Chapter Three: Characterizing Different Plague Models 
 
In most experiments of this study, we used a systemic plague model, which means 
direct injection of bacteria into the retro-orbital plexus of mice to infect the spleen and 
liver. The bacteria used in this model were Δpgm Y. pestis KIM5 so they were virulent 
from the IV route but not the ID route. The bacteria were inoculated and cultured in HIB 
medium at 26ºC or 26/37ºC, then diluted to the target concentration before infection. The 
bacteria seed spleen and liver within 30 min of infection (57). Therefore this model 
offered the strong advantage of a synchronous infection that can be readily quantified 
under BSL2 conditions to provide insight on host responses to simulated  flea-grown 
(26ºC)  or  mammal adapted (26/37ºC) Y. pestis.  
Other models in this study were ID and IN infections. Fully virulent Y. pestis CO92 
was used. In the BSL3 lab, CO92 was cultured at 28ºC and diluted before infection. 
These bacteria have the pgm locus so they are not iron-dependent and can multiply in 
skin and lung tissue, where the Ybt iron acquisition system is important to obtain iron for 
bacterial growth. These ID and IN routes of infection mimic the real diseases, bubonic 
and pneumonic plague, respectively.  
To check the role of YopM in the virulence, the first step was to measure the effect of 
this protein on lethality (LD50) of Y. pestis. Based on the LD50, bacterial doses were 
chosen and the growth patterns of the bacteria with or without YopM were plotted.   
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A. Y. pestis mainly disseminates into spleen and liver in the  systemic model 
It is important to know where the injected bacteria seed because the seeding sites, 
especially early seeding sites, are the microenvironment in which bacteria contact the 
host immune system. As shown in Figure 3.1A, a high dose of Y. pestis KIM5 (5000 
CFU/mouse) was injected retro-orbitally and different organs, including spleen, liver, 
intestine, gallbladder, lung, kidney, cervical lymph nodes and bone marrow, were 
harvested after 6, 24 and 48 hours. The homogenate was plated onto TBA or YSA plates, 
and CFUs were counted after 2 days incubation at 30 ºC. The percentages of recovered 
CFU in each organ with respect to the infecting dose were calculated and plotted.  
Surprisingly, only less than 30% bacteria could be recovered after 6 hours, mainly in 
spleen and liver (Figure 3.1B), and no bacteria were detected from other organs except a 
few from intestine. Thus, over 70% of the infecting bacteria were cleared and the actual 
percentage could be even higher, since the bacteria kept multiplying in that 6 hours. The 
viable numbers of bacteria recovered from spleen and liver at 24 and 48 hours p.i. were 
much higher than those at 6 hours p.i., and bacteria were recovered from all of the other 
organs, although the number was much lower than in the spleen and liver (Figure 3.1 C 
and D). This finding helped us to focus our work on spleen and liver as the major target 
organs.     
 
B. YopM is required for the virulence of Y. pestis in this systemic plague model 
and compromises the proinflammatory response in liver 
First, we measured the LD50 of yopM-1 Y. pestis. A serial dilution of yopM-1 Y. 
pestis was injected IV into C57BL/6 mice and those mice were observed closely for 2 
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weeks. The actual doses were obtained by plating dilutions of the infecting suspension 
and the death of mice was recorded. Through the software Biostat, we derived the LD50 
of the yopM-1 mutant (26ºC, table 3.1). Compared to the known LD50 of the parent 
strain KIM5 (Table 3.1) (159), we found the LD50 of the yopM-1
 
Y. pestis KIM5-3002 to 
be 4000-fold higher. This showed that YopM is indispensable for the full virulence of Y. 
pestis in this systemic model.   
Next we compared the growth pattern of the parent and yopM-1 strains. The design 
of this experiment is shown in Figure 3.2A. Groups of 3 or 4 mice were infected with 400 
CFU of the parent strain KIM5 or the yopM-1 strain KIM5-3002. A group of mice 
infected with each strain was euthanized daily from d 1 to d 5 p.i. and bacteria were 
recovered from spleens and livers. The growth curves (Figure 3.2B) displayed the pattern 
of both strains in spleen and liver. In spleen, the parent strain showed an early rapid 
growth before d 2 p.i. and a subsequent brief plateau. A second growth spurt occurred 
between d 3 and d 4 p.i., followed by the second plateau and death of the mice. The 
yopM-1 strain grew in spleen similarly to the parent strain until d 2 p.i. and remained at 
the same level until d 4 p.i., followed by clearance. The parent strain showed a similar 
growth pattern in liver to that in spleen, whereas the plateau of the yopM-1 growth 
curve in liver only lasted until d 3 p.i. and was followed by clearance. The difference 
between two strains became significant in both spleen and liver after d 2 p.i.. 
Together with the LD50 data, this finding showed that the absence of YopM not only 
increases the lethal dose but also inhibits the multiplication of Y. pestis in the host at an 
early stage of the infection. 
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To check YopM’s effect on the inflammatory response at the early stage of plague, we 
did histopathological analysis of the livers from the mice infected with these two strains. 
The lesions in the mice infected with parent Y. pestis were found to be dominated by 
resolving acute inflammation on d 3 p.i., whereas those from mice infected with the 
yopM-1 mutant contained large numbers of PMNs and macrophages (Figure 3.2C). We 
hypothesized that the difference in the acute inflammatory response between the parent 
and mutant strains may be responsible to their different growth characters in this model. 
 
C. YopM is necessary for the pathogensis of bubonic plagues, but not for 
pneumonic plague and probably functions to counteract inflammation 
To mimic the natural infection, we used other two models: a bubonic plague model 
and a pneumonic plague model. Fully virulent Pgm
+
 Y. pestis CO92.S6 and its yopM-2 
mutant CO92.S19, in which YopM and its promoter were deleted from the CO92.S6 
background, were given to mice. In the bubonic model, fully virulent Y. pestis grown at 
28ºC were injected ID at the site just above the base of the tail to mimic flea bites (289). 
In the pneumonic plague model, the mice were infected with the 37ºC-grown bacteria 
through the nasal cavity. As in the systemic model, we also checked the role YopM by 
measuring the LD50 and by histopathological analysis.   
The LD50 of the yopM-2 mutant CO92.S19 by the IN route was similar to that for 
CO92.S6 (Table 3.1), indicating that YopM is not a virulence factor for pneumonic 
plague. However, by the ID route, the yopM-2 strain was reduced in lethality by 25-fold 
compared to Y. pestis CO92.S6 (Table 3.1). These results showed that YopM is required 
for full virulence in bubonic plague but not pneumonic plague.   
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Influx of inflammatory cells does not occur into lungs before 36 to 48 h p.i. in 
pneumonic plague (173), but it was not known whether there is a rapid inflammatory 
response in bubonic plague. We addressed this question in the experiments of Figure 3.3. 
We harvested the skin surrounding the infection site at 8, 24 48 and 72 h p.i. for 
histopathological analysis. For comparison, lungs of mice infected IN were also 
evaluated. There was no inflammation present in the lungs after 24 h p.i. (Figure 3.3C 
and 3.3D, lower panels). Marked hemorrhage as well as numerous inflammatory cells 
appeared by 48 h p.i. in the IN infection of either strain (Figure 3.3E). In contrast, a 
robust influx of inflammatory cells was underway as early as 8 h p.i. in the skin of mice 
infected ID with either Y. pestis strain but limited in epidermis by 24 h p.i. (Figure 3.3C 
and 3.3D, upper panels), while the inflammatory response expanded into the dermis at 48 
h p.i. (Figure 3E, upper panel). Although there was no difference between the parent and 
the yopM-2 strains seen in the pathological appearance of the cutaneous infection sites, 
these strains differed in their virulence (LD50, Table 3.1) in this bubonic model. These 
findings are consistent with an indispensable role of YopM in Y. pestis virulence being its 
function in modulation of the early inflammatory responses. Because there is no early 
inflammatory response in pneumonic plague, YopM is not needed for full virulence in 
that disease, whereas YopM is required for bubonic plague, to overcome the rapid 
inflammatory response.  
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Table 3.1 Virulence in 6 to 8-week female C57BL/6 mice of Y. pestis strains used in this 
study. 
Y. pestis Strain Key Properties Culture 
Temperature 
Route LD50 (Reference) 
KIM5 (D27) pgm 26 ºC IV 
IP 
<50 (159) 
6 x 10
4
 (this study) 
KIM5-3002 yopM-1 pgm 26ºC IV 
IP 
2.08 x 10
5
 (this study) 
> 10
7 
(this study) 
KIM5-3002 yopM-1 pgm 26/37ºC
a
 IV 5.4 x 10
4
 (this study) 
CO92.S6 Pgm
+
  28 ºC IN 14  (363) 
 ID 17  (this study) 
CO92.S19 
 
yopM-2 Pgm+  
 
28 ºC IN 39  (363) 
 ID 409  (this study) 
a. 26/37ºC means the bacteria were cultured at 26 ºC overnight and transferred to 37 ºC 
for 3 hours before processed for infection. 
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Figure 3.1 Distribution of KIM5 Y. pestis in mice at early stage of the infection 
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C57BL/6 mice were infected IV with 5000 CFU Y. pestis KIM5 (the parent strain) that 
had been grown at 26
o
C. At the indicated times, groups of mice were analyzed for 
bacterial viable numbers (CFU) in different organs.  Panel A, experimental design. Panel 
B, the ratio of recovered CFU in spleens, livers and intestine to the infecting dose 
(expressed as percentage). Each datum point represents the average of values from 6 mice. 
S, Spleen; L, liver; I, intestine; G, gallbladder; Lu, lung; K, kidney; B, bone marrow; LN, 
cervical lymph node. 
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Figure 3.2 Comparisons of bacterial CFUs and histopathological responses in C57BL/6 
mice infected with yopM-1 Y. pestis KIM5-3002 or the parent strain KIM5 Y. pestis 
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Mice were infected IV with 400 CFU of KIM5-3002 or KIM5 Y. pestis. At the indicated 
times p.i., spleens and livers of mice were analyzed for bacterial viable numbers (CFU) 
and histopathology. Panel A, experimental design. Panel B, CFUs of KIM5-3002 (open 
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circles) or KIM5 (closed circles) Y. pestis from spleens and livers. The data represent the 
average plus SDs (error bars) for 29 mice (pooled from groups of 3 or 4 mice) per datum 
point. The day 0 points give the total bacterial doses as determined by plating the inocula. 
Values that are significantly different between KIM5-3002 and KIM5 infected groups are 
indicated (**, P < 0.01). Panel C, histopathology on d 3 p.i. in liver of mice infected with 
KIM5-3002 (left) or KIM5 (right) (Bars: 20 m) (H&E staining).  
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Figure 3.3 Histology in skin after ID infection and in lung after IN infection with 
yopM-2 Y. pestis CO92.S19 or the parent strain CO92.S6 
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8
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Tissue samples were harvested from uninfected mice and the mice infected by the fully 
virulent Y. pestis CO92.S6  (the parent strain) or the yopM-2 derivative at 8, 24 and 48 h 
post ID infection with ca. 200 CFU (actual doses: CO92.S6 = 216 and CO92.S19 = 163 
CFU) or post IN infection with 5100 CFU of CO92.S6 and 4000 CFU of CO92.S19. 
2
4
 h
4
8
 h
 84 
Panel A, experimental design. Panel B, skin and lung from uninfected mouse. Panel C, D 
and E skin near the infection sites and lungs harvested from the mice 8, 24 and 48 h post 
infection, respectively. Bars in the panels of skin: 50 m in panel B, C and D; 100m in 
panel E. Bars in the panels of lung: 100 m. 
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RESULTS 
Chapter Four: NK cells are not a key target of YopM 
 
The time course for the growth of the parent Y. pestis KIM5 is similar in liver and 
spleen of mice with systemic plague; and the timing of the growth and clearance of the 
yopM-1 mutant KIM5-3002 are also similar for the two organs although clearance 
begins earlier in liver (Figure 3.2B). It was hypothesized that the host mechanisms that 
control the growth patterns are similar in the two organs. In previous work (159), several 
leukocyte populations had been characterized in spleens and blood of mice with systemic 
plague, and NK cells showed a YopM-dependent pattern of influx into spleen. However, 
none of these cell types had been tested in liver and their roles in limiting the growth of 
the yopM-1 mutant also needed to be clarified. In this work we checked the recruitment 
of NK cells into liver and their requirement for controlling growth of yopM-1 Y. pestis 
in liver as well as in spleen. 
 
A. YopM-containing Y. pestis depleted the NK1.1
+
CD3
-
 NK subgroup in spleen, 
whereas the splenic NK1.1
+
CD3
+
 (NKT) subgroup was intact 
There are two major surface markers on NK cells in C57BL/6 mice: NK1.1 (clone: 
PK136) and CD49b (clone: DX5). NK1.1 is unique to NK cells, whereas CD49b is 
expressed by NK cells and some T cells (224). Meanwhile, some NK1.1
+
 cells also 
express TCR and CD3, which are usually on the T cell surface. These cells are called 
NKT cells and are a potent source of immunoregulatory cytokines, including IL-4, IFN-γ 
and TNF. A specific stain to detect NKT cells is mCD1d/PBS-57 (113). PBS57 is a 
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fluorescent analogue of α-galactosylceramide, which is loaded onto a MHC-like molecule 
mCD1d, which is the ligand for the specific double-negative - TCR on NKT cells. 
There are two main subsets of mCD1d-dependent NKT cells: NK1.1
+
 and NK1.1
-
 NKT 
cells. The majority of NKT cells express NK1.1 on their surface and these cells produce 
higher levels of IFN- and lower levels of IL-4 than their NK1.1- counterparts. Therefore, 
the relevant NKT cells in our study should be the NK1.1
+
 NKT cells (34, 113). 
Meanwhile, almost all the mCD1d/PBS-57
+
 cells in our experiments were positive for 
CD3 and NK1.1 simultaneously (Figure 4.1B). 
According to above surface markers, classical NK cells were defined as 
NK1.1
+
DX5
+
CD3
-
 and NK1.1
+
DX5
-
CD3
-
, while NKT cells were simply defined as CD3
+
 
NK1.1
+
. In order to cover all possible NK-like cells, a subset of DX5
+
 cells, DX5
+
NK1.1
-
CD3
-
, with unknown function was also checked (Table 4.1). Representative flow-
cytometric scatter plots of the different cell types considered in this dissertation are 
shown in Figure 4.2.  
Groups of 3 or 4 C57BL/6 mice were infected IV with 400 CFU of Y. pestis KIM5 or 
KIM5-3002. Spleens were harvested for flow cytometric analysis on d 2, 4 and 5 p.i.. The 
design of this experiment is shown in Figure 4.1A. YopM-dependent loss of splenic 
NK1.1
+ 
(DX5
+
 or DX5
-
) CD3
-
 NK subgroups was observed during infection as 
previously reported (159) (Figure 4.1C). Neither NK1.1
+
CD3
+ 
NKT cells nor 
DX5
+
NK1.1
-
CD3
-
 cells showed any YopM-dependent changes, although the percentages 
of these latter cells dropped by ca. 2-fold between d 2 and d 4 p.i. in mice infected by 
either Y. pestis strain (Figure 4.1D).  
 
 87 
B. There was no YopM-associated depletion of either classic NK cells or NKT 
cells in liver 
We then tested whether the YopM-specific NK cell depletion seen previously in 
spleen was truly a global effect, which means that ablation occurred in the two major 
organs (liver and spleen, Figure 3.1B) colonized by Y. pestis early in systemic plague. 
Groups of 3 or 4 C57BL/6 mice were infected IV with 400 CFU/mouse of Y. pestis KIM5 
or KIM5-3002. Livers were harvested for flow cytometric analysis on d 2, 4 and 5 p.i..  
The staining of splenic leukocytes by all of three antibodies (anti-NK1.1 and 
DX5/anti-CD49b) was consistent and reproducible. However, the staining with DX5 was 
not consistent in liver so only anti-NK1.1 was used. As with spleen, representative flow-
cytometric scatter plots of different cell types in liver are shown in Figure 4.2.  
Figure 4.1E shows the dynamics of the influx of major NK populations (NK1.1
+
CD3
- 
NK cells and NK1.1
+
CD3
+
 NKT cells) into infected livers. In contrast to the results in 
spleen, there was no YopM-related depletion of any NK cell population in liver. These 
data indicated that YopM-specific depletion of NK cells is not systemic, and contrary to 
our hypothesis, YopM modulates immune responses through different mechanisms in 
spleen and liver.    
 
C. Ablation of NK cells by anti-NK1.1 (PK136) did not relieve the growth defect 
of the yopM-1 mutant in spleen and liver 
Although we confirmed that YopM in the parent strain cannot deplete NK cells from 
livers, it did not mean that NK cells were not key cells to control growth of the yopM-1 
mutant, because splenic NK cells still showed YopM-dependent depletion. The best way 
 88 
to test the role of NK cells in the YopM virulence mechanism is to compare the infection 
in mice lacking NK cells to that in mice with an intact NK cell population. If NK cells are 
responsible for growth restriction of the yopM-1 mutant Y. pestis, this growth limitation 
should be relieved in mice lacking NK cells.  
As shown in Figure 4.3A, we tested this hypothesis by comparing the growth of 
parent and yopM-1 mutant Y. pestis in mice ablated for NK cells by antibody anti-
NK1.1. On d 1 prior to infection and d 1 and 3 p.i. we injected PK136 mAb (anti-NK1.1) 
or rat-IgG to each mouse IP in the ablation groups or mock groups, respectively. Mice 
were then infected IV with 400 CFU and killed humanely on d 2, 4 and 5 p.i. for analysis 
of CFU, leukocyte populations, and histopathology in spleen and liver.  
Since DX5
+
 cells include some T cells, DX5 was not the best antibody to test the 
efficiency of PK136 treatment. We decided to use anti-NK1.1 to detect the residual NK 
cells. To avoid false ablation, i.e., a situation in which some NK cells were bound by the 
PK136 used for ablation and hence masked for detection with PK136 but were not 
actually ablated, we used the isotype control antibody anti-IgG2a to detect any PK136 
bound live NK cells. The result showed that very few IgG2a
+
 cells were present after 
PK136 treatment (Figure 4.3B).  
About 90% of NK1.1
+
CD3
-
 cells were ablated from both spleen and liver by the 
initial antibody treatment and the subsequent treatments maintained very low levels of 
NK cells during the experiment (Figure 4.3D, dashed and dotted lines). However, 
successful NK cell ablation failed to relieve the restricted growth of yopM-1 Y. pestis 
KIM5-3002 in either organ (Figure 4.3E, dashed lines).  
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D. NK ablation did not convert the pathological appearance of the yopM-1 
mutant-infected livers to that of parent strain-infected ones 
Histopathological analysis of the livers (d 4 p.i.) in both the KIM5-3002-infected 
mock-treated or NK cell-ablated mice showed lesions that were similar in character and 
number (Figure 4.3C). The histopathological appearance was typical of the 
proinflammatory response that precedes micro-granuloma formation in C57BL/6 mice 
that are curbing net growth of the yopM-1 mutant (Figure 3.2C).  
Although it is possible that the less than 10% of NK1.1
+
 cells remaining in the anti-
NK1.1 mAb-treated mice could be sufficient to exert full growth-limitation of the 
yopM-1 mutant, we consider it more likely that YopM-dependent NK cell depletion 
may be a side effect caused by the compromised function of other cell types such as 
PMNs, macrophages and DCs in spleen.   
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Table 4.1 Surface markers on different leukocytes in flow cytometric analysis  
 
 
 
 
Cell Type Markers Staining combinations 
NK cells 
 
 
 
NKT cells 
DX5, NK1.1 and CD3 
 
 
 
mCD1d/PBS57, DX5, NK1.1 
and CD3 
NK1.1
+
DX5
+
CD3
- 
(Spleen) 
NK1.1
+
DX5
-
CD3
-  
(Spleen) 
NK1.1
+
CD3
-
 (Liver) 
 
mCD1d/PBS57
+
 CD3
+
 
NK1.1
+
CD3
+ 
 
PMNs Ly6G, CD11b and Gr1 Ly6G
+
CD11b
+ 
Ly6G
+
Gr1
+ 
 
MDMs Ly6G, CD11b Ly6G
-
CD11b
+ 
 
iDC CD11b, CD11c CD11b
+
CD11c
int 
 
DCs  CD11c, CD11b, CD8 and B22 CD11b
+
CD11c
+
 
CD8
+
CD11C
+
  
B220
+
CD11c
Low
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Figure 4.1 Comparisons of bacterial CFUs and NK cell percentages of live leukocytes in 
spleens and livers after infection of C57BL/6 mice with yopM-1 Y. pestis KIM5-3002 or 
the parent Y. pestis KIM5 
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D 
 
 
 
 
 
 
 
E 
 
 
 
 
 
 
 
 
Mice were infected IV with 400 CFU of KIM5-3002 (open circles) or KIM5 (closed 
circles) Y. pestis. Panel A, experimental design. Panel B, flow cytometric scatter plots 
defining a population of mCD1d/PBS57
+
CD3
+
 cells recruited to spleen infected by 
yopM-1  Y. pestis (left panel) and determining where those cells mapped in an analysis 
of  NK1.1
+
 CD3
+
 cells in that sample (right panel). At the indicated times p.i., the 
percentages of different subgroups of NK1.1
+
 cells in leukocytes from spleen (panel C 
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and D) or liver (panel E) were determined. The data represent the average plus SDs for 12 
mice per datum point for spleen and 14 mice per point for liver, pooled from replicate 
experiments. Differences between KIM5-3002 and KIM5 infected groups (*, P < 0.05; **, 
P < 0.01) are indicated. 
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Figure 4.2 Representative Flow-cytometric Scatter Plots  
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Figure 4.3 Anti-NK1.1 mAb-mediated NK cell ablation failed to relieve the growth 
defect due to the yopM-1 mutation 
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Mice were given anti-NK1.1 mAb (NK cell-ablated groups, dashed and dotted lines) or 
rat IgG (mock ablation groups, solid lines) IP one day before IV infection with 400 CFU 
of yopM-1 Y. pestis KIM5-3002 (open triangles and dashed lines for NK cell ablation 
groups and open circles for mock-treated groups) or the parent strain KIM5 (solid 
triangles and dotted lines for ablation groups and solid circles for mock-treated groups). 
Panel A, experimental design. Panel B, flow cytometric scatter plots detecting IgG2a
+
 
cells present after PK136 (lower panel) or mock treatment (upper panel). Panel C, 
histopathology on d 4 p.i. liver of NK cell-ablated and mock-treated mice infected with 
KIM5-3002. The lower panels (Bars: 20 m) and the upper panels (Bars: 100 m) show 
typical lesions caused by KIM5-3002. The percentages of CD3
-
 NK cells (panel D) and 
numbers of CFUs (panel E) in spleens and livers on d 2, 4, and 5 p.i. were determined. 
The data represent the average plus SDs (error bars) for 6 mice per datum point, pooled 
from replicate experiments. Values that are significantly different in the NK cell-ablated 
and mock ablation groups of mice infected with KIM5-3002 are indicated as follows: †, 
P<0.05; ††, P<0.01. Values that are significantly different in the NK cell-ablated and 
mock ablation groups of mice infected with KIM5 are indicated as follows: #, P<0.05; # 
#, P<0.01.  
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RESULTS 
Chapter Five: With the exception of CD8
+
 DCs, the numbers of classic DCs are not 
altered in a YopM-related way before day 4 p.i. 
 
Since NK cells did not prove to be a target of YopM that was critical for virulence, we 
evaluated other leukocyte population dynamics for clues that would point toward cells 
that are responsible for the in vivo growth defect of yopM-1 mutant Y. pestis. From 
previous studies done by our lab with SCID mice, we already knew that adaptive 
immunity, which involves classic T and B cells, is not responsible for controlling the 
growth of yopM-1 mutant Y. pestis in the systemic plague model (159). Here we focused 
on innate immune cell types, such as DCs, PMNs and monocytes. DCs were the first cell 
type to be studied because they are present at portals of microbial infection and in 
reticuloendothelial organs colonized by Y. pestis, and their potent antigen-presentation 
and surveillance functions are important for both innate and adaptive defenses against 
invading microorganisms. Further, because of the large YopM-associated effect on NK 
cells in spleen, we performed this analysis in mice ablated for NK cells as well as in 
mock-treated mice to learn if the absence of this important but apparently non-critical cell 
would unmask an effect of YopM on other cell types. 
 
A. In spleen, only the influx of CD8
+
DCs was inhibited by YopM before day 4 p.i. 
There are three major DC subgroups: myeloid DCs (CD11b
+
CD11c
+
), lymphoid DCs 
(CD8
+
 CD11c
+
) and plasmacytoid (CD11c
Low
 B220
+
) (16, 187). According to their 
surface markers (Table 4.1), we used anti-CD11c to detect all DCs and anti-CD11b, anti-
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CD8 and anti-B220 to distinguish different subgroups. Representative flow-cytometric 
scatter plots of the different cell types are shown in Figure 4.2.  
As described in Figure 5.1A, groups of C57BL/6 mice were infected IV with 400 
CFU/mouse the parent Y. pestis KIM5 or the yopM-1 mutant KIM5-3002. On d 2, 4 and 
5 p.i., spleens were harvested for flow cytometric analysis. Figure 5.1B shows that in 
spleens (left panels) only CD8
+
 DCs displayed a reproducible YopM-associated pattern 
of change in which the numbers of these DCs declined significantly by d 4 p.i. of 
infection by the parent Y. pestis strain but were maintained in the yopM-1 mutant. Other 
subgroups, CD11b
+
 and B220
+
 DCs, did not show any YopM-dependent change even on 
d 5 p.i.. Staining for surface activation markers of DCs, such as CD86 and IA
b
 (295), 
from infected spleens on d 1, 2 and 3 p.i. did not reveal any significant difference 
between yopM-1 mutant and parent Y. pestis infections as indicated by MFI (Figure 
5.1C). 
 
B. The three classical DC subgroups in liver showed YopM-associated influx on 
or after day 4 p.i., which was later than the appearance of the yopM-1 mutant 
growth limitation 
Depletion of NK cells by YopM had been confirmed to occur in spleen but not in 
liver. This result indicated that the immune response to YopM is organ-specific, which 
makes sense because spleen and liver have different surveillance mechanisms for 
pathogens. Therefore, we also tested DC subgroups in liver of mice infected as described 
in Figure 5.1A. In contrast to spleen, in liver all of the three DC subgroups showed 
moderate YopM-related changes, which were significant on d 4 and 5 p.i. for CD8
+ 
DCs 
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and d 5 p.i. for CD11b
+
 and B220
+
 DCs (Figure 5.1B, right panels).  
Considering the growth pattern of these two Y. pestis strains (Figure 3.2B), the 
growth curves of parent KIM5 and yopM-1 mutant always diverge by d 3 p.i. in liver 
and the net growth of the yopM-1 mutant is controlled thereafter. That indicates that the 
immune responses which are compromised by YopM must occur before d 3 p.i.. 
Therefore, at least based on their numbers, both CD11b
+
DCs and B220
+
 DCs did not as 
appear to be the key cells controlling the growth of the yopM-1 mutant in liver. 
 
C. NK cell ablation did not affect the distribution of DCs in spleen and liver 
There is extensive cross-talk between DCs and NK cells, for example, DCs could 
have a role in NK cell survival through cell-to-cell contact and production of cytokines 
including IL-15 (353). To test whether NK cell depletion in spleen affected DC 
recruitment, we compared all three DC subgroups in mock-treated mice to those in NK 
cell-ablated mice infected with the parent Y. pestis KIM5 or the yopM-1 mutant 
(experimental design described in Figure 4.3A). As shown in Figure 5.2, NK cell ablation 
did not affect the distribution of any of the DC subgroups in spleen and liver.  
Although CD8
+
 DCs showed a relatively early YopM-related change, the difference 
in cell number of these DCs was not significant at d 2 p.i., when the growth limitation of 
the yopM-1 strain was already apparent, and it was hard to believe that they were the 
major cell type controlling the yopM-1 mutant. Therefore, we extended our study to 
larger innate immune cell populations, such as PMNs and monocytes.  
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Figure 5.1 Comparison of 3 DC subgroups in liver and spleen between mice infected 
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DCs were analyzed from the viable leukocyte populations obtained from Y. pestis KIM5 
or KIM5-3002 infected spleens and livers. Panel A, experimental design. Panels B 
showes CD11b
+
 DCs, CD8
+
 DCs and B220
+
 DCs (15 and 13 mice per datum point for 
spleen and liver, respectively) in spleen and liver. Panel C, MFI (mean fluorescence 
intensity) of the staining of surface activation markers, CD86 and Ia
b
, on DCs from Y. 
pestis KIM5 or KIM5-3002 infected spleens. Values that are significantly different 
between Y. pestis KIM5-3002 and KIM5 infected groups are indicated (**, P < 0.01). 
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Figure 5.2 Effects of NK cell ablation on the distribution of three DC subgroups in liver 
and spleen between mice infected with yopM-1 Y. pestis KIM5-3002 or the parent Y. 
pestis KIM5  
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DCs were analyzed from the viable leukocyte populations obtained in the experiments of 
Figure 4.3; symbols and lines are the same as in Figure 4.3. Panels A, B and C show 
CD11b
+
 DCs, CD8
+
 DCs and B220
+
 DCs (6 mice per datum point), respectively, in 
spleen and liver. The notations for statistical significance are the same as in Figure 4.3, 
with the addition of comparisons between groups of mock treated mice infected with Y. 
pestis KIM5 and KIM5-3002, where *, P < 0.05; **, P < 0.01. 
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RESULTS 
Chapter Six: Gr1
+
 cells are responsible for controlling the yopM-1 mutant in both 
spleen and liver 
 
To evaluate the importance of PMNs and inflammatory monocytes in the pathogenic 
mechanism of YopM, we ablated these cells in vivo with anti-Gr1 (Ly6G/Ly6C) mAb 
given on d 1 prior to, and d 1 post, infection of C57BL/6 mice with the yopM-1 mutant 
or the parent Y. pestis strain and harvested organs in an early stage of disease, i.e., before 
d 3 p.i.. The design is shown in Figure 6.1A.  
Gr-1 is expressed on mature granulocytes in bone marrow and peripheral tissues. It is 
also expressed transiently during monocyte differentiation in bone marrow and at low 
levels on plasmacytoid dendritic cells in lymphoid tissues. Anti-Gr1 reacts with Ly-6G, a 
21–25 kDa GPI anchored specific cell surface protein on PMNs and less strongly with 
Ly-6C
high
 cells, which include inflammatory monocytes (130). Therefore, anti-Gr1 
treatment actually ablated both PMNs and inflammatory monocytes.  
 
A. Anti-Gr1 antibody successfully depleted most PMNs from spleen and liver, 
and the influx of inflammatory monocytes into spleen was also abolished 
To measure the efficacy of anti-Gr1, spleens and livers were harvested for flow 
cytometric analysis. To detect PMNs, the staining combination of Ly6G and CD11b was 
used. CD11b, a 165-170 kDa integrin αM, non-covalently associates with CD18 to form 
αMβ2 integrin (Mac-1) and binds to CD54 (ICAM-1), C3bi, and fibrinogen (33, 309, 311). 
CD11b is expressed on monocytes, macrophages, some DCs, and PMNs and functions in 
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various adhesive interactions as well as in mediating the uptake of complement coated 
particles (310). In flow cytomeric analysis, PMNs were defined as being Ly6G
+
CD11b
+
. 
Ly6G
-
CD11b
+
 cells were a mixture of inflammatory monocytes, macrophages and some 
DCs, termed MDMs (inflammatory monocytes/DCs, macrophages and myeloid DCs) in 
this study (Table 4.1). Representative flow-cytometric scatter plots of these different cell 
types are shown in Figure 4.2.  
Figure 6.1B (dashed and dotted lines) shows that the ablation protocol removed over 
90% of the PMNs from both liver and spleen. As shown in mock-treated groups (Figure 
6.1C, solid lines), MDMs had a YopM-related pattern in spleen, which should be 
described as failure to be recruited by parent strain instead of depletion. However, the 
increase in MDMs in both organs was also abolished or delayed by anti-Gr1 treatment 
(Figure 6.1C, dashed and dotted lines). This phenomenon could result indirectly from the 
absence of PMNs caused by the anti-Gr1, or directly from depletion of MDMs by this 
antibody. 
 
B. The yopM-1 mutant grew uncontrolled in spleen and liver from Gr1+ cell 
depleted mice compared to mock-treated mice 
In mock-treated mice, the YopM-associated growth defect was exhibited as expected 
at days 2 and 3 p.i. (Figure 6.1D. solid lines). Strikingly, the growth defect of the yopM-
1 mutant strain in both spleen and liver disappeared in the mice treated with anti-Gr1 
antibody, and growth of the parent strain was slightly enhanced (Figure 6.1D, dashed 
lines). This result indicated that Gr1
+
 cells, including PMNs and some MDMs, are the 
major cells to clear the yopM-1 mutant in systemic plague. 
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C. The lesions in livers from anti-Gr1 treated mice morphologically mimicked 
those in the livers from the mock-treated mice 
The lesions in livers of mock-treated mice infected with parent Y. pestis were 
dominated by dissipating acute inflammation on d 3 p.i., whereas those from mice 
infected with the yopM-1 mutant contained large numbers of PMNs and macrophages, 
as described previously (Figure 6.1E, upper panels; (231, 318)). However, this 
histological picture appeared to be in conflict with whole-organ flow cytometry which 
showed no significant difference in the percentage of intact PMNs and MDMs (“intact” 
means EMA
-
) in livers infected with the two strains of Y. pestis (Figure 6.1B and C, right 
panels). To address this issue, we visually scored all the lesions in the d 3 p.i. 
histopathological slides for number, size, and character. We found that infection by the 
yopM-1 strain caused fewer but larger foci than those by Y. pestis KIM5. The foci in 
livers of mice infected by the yopM-1 mutant always contained morphologically intact 
PMNs and MDMs, whereas livers from mice infected by the parent strain typically 
contained a mixture of morphologically intact cells and cellular debris (Figure 6.1F, 
bottom panels; illustrated in higher magnification by the upper panels in Figure 6.1E). 
The difference in the foci between the two strains was clear by d 2 p.i. (Figure 6.1F, 
upper panels), indicating that there was a YopM-associated difference in PMN and MDM 
integrity or function that correlated with the difference in growth for the parent and 
yopM-1 mutant strains.    
After treatment with anti-Gr1, lesions in mice infected by the yopM-1 Y. pestis 
morphologically mimicked those in mice infected with the parent strain (Figure 6.1E, 
lower panels), which had advanced to the bland necrosis typical of d 4 p.i. and later (159). 
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In general, ablation of Gr1
+
 cells made the infection by the yopM-1 mutant resemble 
that by the parent strain and implicated these cells as cellular targets of YopM during its 
modulation of the host immune response.  
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Figure 6.1 Ablation of Gr1
+
 cells relieved the growth defect of the yopM-1 Y. pestis 
KIM5-3002     
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Mice were given anti-Gr1 (Ly6G/Ly6C) mAb IP (Gr1
+
-cell ablated groups, dashed and 
dotted lines) or rat IgG (mock ablation groups, solid lines) one d before and one d after 
infection IV with 400 CFU of KIM5-3002 (open triangles and dashed lines for Gr1
+
-cell 
ablation groups and open circles for mock-treated groups) or the parent strain KIM5 
(solid triangles and dotted lines for ablation groups and solid circles for mock-treated 
groups). Panel A, experimental design. On d 1, 2, and 3 p.i., the percentage of PMNs 
(panel B) and MDMs (panel C) in viable leukocytes from spleens and livers and numbers 
of CFUs (panel D) in spleens and livers were determined. The data represent the average 
plus SD (error bar) for 6 mice per datum point for panels B and C and 9 mice per point 
for panel D, pooled from replicate experiments. Values that are significantly different for 
the Gr1
+
- cell-ablated and mock ablation groups of mice infected with KIM5-3002 are 
indicated as follows: †, P < 0.05; ††, P < 0.01. Values that are significantly different for 
the Gr1
+
-cell-ablated and mock ablation groups of mice infected with Y. pestis KIM5 are 
indicated as follows: #, P < 0.05; # #, P < 0.01. Values that are significantly different for 
mock-treated groups of mice infected with Y. pestis KIM5 and KIM5-3002 are indicated 
as follows: *, P < 0.05; **, P < 0.01.Values that are significantly different for Gr1
+
_ cell-
ablated groups of mice infected with Y. pestis KIM5 and KIM5-3002 are indicated as 
follows: , P < 0.05; , P < 0.01. Panel E and F: Histopathology in livers from mice that 
were ablated for Gr1
+
 cells or mock-treated and infected with Y. pestis KIM5 or KIM5-
3002. Panel E (Bars: 20 m), shows lesions from d 3 p.i.. In panel F (Bars: 100 m), 
differences in numbers and sizes of lesions caused by the two Y. pestis strains are 
illustrated for both d 2 and d 3 p.i.. 
Copyright © Zhan Ye 2010 
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RESULTS 
Chapter Seven: The roles of PMNs in the controlling yopM-1 Y. pestis growth in 
spleen and liver 
 
As mentioned above, Gr1+ cells include PMNs and some MDMs, both are major 
immune cell populations during inflammation and among the first cell types encountering 
bacteria in Y. pestis infection. Since these cells have many distinct functions in the innate 
immune response and there is extensive cross-talk between them, it is necessary to 
identify their individual roles in YopM’s immune-modulating mechanism. We firstly 
studied PMNs in their recruitment into organs and their activation in two different animal 
models. Further, anti-Ly6G, an antibody specific for PMNs, was used to ablate this cell 
type in the systemic plague model to distinguish its role from that of MDMs.     
 
A. YopM-containing Y. pestis showed the same ability to recruit PMNs into 
spleen and liver as the yopM-1  mutant when the mice were infected by IV route 
In this experiment, mice were IV-infected with the parent strain or the yopM-1 
mutant, and spleens and livers were harvested on d 1, 2 and 3 p.i., as described in Figure 
7.1A. Figure 7.1B shows that the percentage of PMNs (Ly6G
+
CD11b
+
) in the total live 
splenic or hepatic leukocytes increased during infection by both Y. pestis strains, peaking 
on d 2 p.i.. However, no YopM-associated difference between the two strains was found. 
Thus, there was no significant difference in the influx of PMNs from blood into both 
spleen and liver regardless of the presence of YopM in the infecting strain.  
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B. PMNs from the spleens of IV-infected mice did not display any YopM-
dependent difference in ROS and NO production or altered ability to be stimulated 
ex vivo at 8, 16 and 45 hours p.i. 
Since the recruitment of PMNs was not YopM related in systemic plague, we then 
tested the activation of these cells by measuring ROS and NO production. When bacteria 
are ingested or detected by phagocytic cells, such as PMNs and macrophages, serial 
defense mechanisms are activated in the cells to kill these pathogens. One of the most 
important ones is the generation of microbicidal oxidants from the activation of an 
NADPH oxidase–mediated oxidative burst (64). Another activation marker is NO, which 
is derived from the oxidation of the terminal guanidine nitrogen atom of L-arginine by 
iNOS (221).   
The cell-permeant DCFDA is commonly used to detect the generation of reactive 
oxygen intermediates in PMNs and macrophages. Upon cleavage of the acetate groups by 
intracellular esterases and oxidation, the nonfluorescent DCFDA is converted to the 
highly fluorescent 2',7'-dichlorofluorescein (DCF) (148). DAF is commonly used to 
detect intracellular nitric oxide. Extracellularly applied DAF diacetate spontaneously 
crosses the plasma membrane and is cleaved by esterases to generate intracellular DAF, 
which is then oxidized by NO to a triazole product accompanied by increased 
fluorescence (163) .  
To qualify the ROS and NO production in splenic PMNs, groups of mice were 
infected IV with high dose (10
6
 CFU/mouse) of pre-induced (26/37°C) parent or yopM-
1 mutant Y. pestis. Pre-induction was done by transferring the 26°C cultured bacteria to 
37°C for 3 hours before infection. Pre-induction made the T3SS ready so that the bacteria 
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would inject their Yops into the host cells as soon as they contacted those cells. As 
showed in Figure 7.2A, spleens were harvested at 8, 16 and 45 h p.i.. With or without 
pre-treatment with PMA, an activator of protein kinase C to stimulate Ms and PMNs in 
vitro, the splenic leukocytes were stained with antibodies against surface markers and 
DCFDA or DAF.  
Activated PMNs were defined as Ly6G
+
Gr1
+
DCFDA
+
 or Ly6G
+
Gr1
+
DAF
+
. Since 
almost all of the Ly6G
+
Gr1
+
 cells are DCFDA
+
 or DAF
+
, we therefore used the MFI as a 
measure of the level of ROS or NO in PMNs. At 8 or 16 h p.i., in the absence of PMA, no 
differences were found in the percentages of Ly6G
+
Gr1
+
DCFDA
+
 or Ly6G
+
Gr1
+
DAF
+
 
cells, as well as the MFIs of DCFDA or DAF between mice infected with the parent and 
mutant strains (Figure 7.2B and C). After PMA pre-treatment, although the MFI of 
DCFDA or DAF showed a slightly higher level than those without PMA treatment, no 
YopM-dependent ROS or NO production was found (Figure 7.2B and C). At 45 h p.i., 
both strains caused significantly less recruitment of PMNs into the spleens compared to 
those harvested at 8 or 16 h p.i. (Figure 7.2B, C and D, left panels). Meanwhile, those 
PMNs failed to be activated or stimulated by PMA (Figure 7.2D, right panels). This 
phenomenon could be related to the very high infection dose (10
6
 CFU/mouse, compared 
to the much lower dose of 400 CFU/mouse used in most of our experiments), under 
which condition the cells from those spleens may be very vulnerable and undergoing 
apoptosis after 45 hour of infection. In summary, in either early or late stage infection, no 
YopM-dependent activation or stimulation in PMN were found in spleens from mice 
infected IV. 
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Only splenic PMNs were analyzed in the above experiments because the procedure to 
separate leukocytes from hepatocytes was long and contained some mechanical processes 
which may activate ROS and NO production by leukocytes. 
 
C. Differential count of the peritoneal PMNs harvested from mice infected IP 
showed the same recruitment pattern regardless of the presence of YopM 
Although spleen contains a large number of leukocytes, the MDMs and PMNs that 
are affected by YopM constitute less than 10% of them. Further, the long procedure to 
process spleen also raised a concern that transient changes in ROS and NO production in 
PMNs may have already disappeared when the cells were eventually ready to be stained. 
Therefore, we used another animal model to avoid the above problems. As described in 
Figure 7.3A, a range of doses (5x10
4
, 10
6
 or 5x10
7
 CFU/mouse) of Y. pestis was injected 
into the peritoneal cavity. Relatively high doses were used to ensure a large fraction of 
infected peritoneal cells. As in the previous set of experiments, 26/37ºC bacteria were 
used to ensure prompt delivery of Yops and detection of an effect of YopM after a short 
infection period. After 4, 6, 8 and 24 hours peritoneal lavage fluid was collected, and the 
cells were stained by Diff-Quick for differential count.  
Before we measured the influx of PMNs into the peritoneal cavity, we tested the 
virulence of the two Y. pestis strains in this model. As shown in Table 3.1, the LD50 of the 
yopM-1 mutant is 200 fold higher than that of parent strain. That indicated that YopM 
modulated the immune responses to favor the lethality of the parent strain, as in the IV 
model.  
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Diff-Quick (Giemsa staining) was used to stain the peritoneal cells, and differential 
counting was done with the slides under the microscope according to the morphology of 
those cells. As shown in Figure 7.3B and C, before infection the majority of the 
peritoneal cells (PCs) was macrophages (ca. 80%), and lymphocytes counted for ca. 20% 
of total PCs (data not shown). Less than 1% PCs were PMNs before infection. However, 
PMNs became dominant (ca. 60% of total PCs) after infection and the percentage of 
macrophages decreased to ca. 30-40% (Figure 7.3C). 
In order to find any possible difference in the influx of PMNs into peritoneal cavity, 
we tested different bacterial doses (5x10
4
, 10
6
 and 5x10
7 
CFU/mouse) and different time 
points (4, 6, 8 and 24 h p.i.). However, no significant YopM-dependent PMN recruitment 
to the peritoneal cavity was found from any of these experiments. Representative plots 
(10
6 
CFU/mouse, 6 hours p.i.) of PMNs and macrophages are shown in Figure 7.3C. 
Consistent with the impression in Figure 7.3B, there was a change in the dominant cell 
type from macrophage to PMNs. Interestingly, the total numbers of the recovered PCs 
were similar between uninfected and infected mice (ca. 10
7 
cells/mouse), which indicated 
that more than half of the macrophages had either left the peritoneal cavity or adhered to 
the peritoneum tightly after infection. This phenomenon is called the macrophage 
disappearance reaction (MDR) and will be discussed in the chapter 10. F b).  
 
 D. Peritoneal cells from mice infected IP by the yopM-1 mutant or the parent Y. 
pestis showed the same activation characteristics 
The experiments to detect ROS and NO production in peritoneal cells were designed 
as shown in Figure 7.4A. Groups of mice were infected IP with a high dose (5x10
4
, 10
6
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and 5x10
7 
CFU/mouse) of 26/37°C parent Y. pestis or yopM-1 mutant and PCs were 
harvested at 4, 6, 8 and 24 hours p.i.. Then the PCs were stained with DCFDA or DAF 
and the relative fluorescence units (RFUs) were read by microplate reader. Representative 
plots (10
6 
CFU/mouse, 6 hours p.i.) of RFUs of DCFDA and DAF are shown in Figure 
7.4B. As with MFI of DCFDA and DAF in splenic PMNs, no difference was found in the 
RFUs of DCFDA or DAF between parent and mutant strains at any dose or at any harvest 
time point, indicating that YopM produced by the infecting parent stain does not affect 
the activation of these PCs (mainly PMNs).   
Figure 7.4B also showed that the RFUs of DCFDA and DAF staining were low and 
demonstrated no significant difference between the uninfected and infected mice. These 
results could result from the failure of those PCs (the mixture of PMNs, macrophages and 
some lymphocytes) from the infected mice to be activated by Y. pestis because these PCs 
could be stimulated by PMA (data not shown). However, some drawbacks of this IP 
infection model made the interpretation of these data more difficult. First, more than half 
of the peritoneal macrophages failed to be harvested, and those missing cells may contain 
intracellular bacteria and produce ROS and NO although most of these cells may not be 
fully activated. Second, the components of PCs from uninfected and infected mice are 
greatly different (Figure 7.3C). Therefore, the PCs from uninfected mice may not be the 
right control for those from infected ones (Figure 7.4B). The PCs from mice injected IP 
with casein could be used as alternative control. However, 90% of PCs from those mice 
were PMNs (data not shown) (considering that 50% of PCs from the infected mice were 
PMNs), raising the similar concerns to that from the uninfected mice.  
 120 
E. Specific ablation of PMNs did not eliminate the difference in growth between 
the yopM-1 mutant and parent strain in spleen but did reduce this difference in 
liver 
Although we confirmed that YopM in the parent strain did not affect PMN influx into 
spleen, liver and peritoneal cavity, as well as the activation of splenic PMN or peritoneal 
cells, we still could not exclude PMNs as key cells in controlling the yopM-1 mutant, 
especially in liver. Anti-Gr1 treatment had revealed a critical role of Gr1
+
 cells, including 
PMNs and some MDMs, in the YopM virulence mechanism. Therefore, specific ablation 
of PMNs would test the hypothesis that PMNs do not mediate growth limitation of 
yopM-1 Y. pestis in liver or spleen. A commercial anti-Ly6G made these experiments 
possible. If PMNs are responsible for growth restriction of the yopM-1 mutant Y. pestis, 
this growth limitation should be relieved in mice lacking PMNs.  
As shown in Figure 7.5A, we compared the growth of parent and yopM-1 mutant Y. 
pestis in mice ablated for PMNs by antibody IA8 (anti-Ly6G). On d 1 prior to infection 
and d 1 p.i., IA8 mAb or rat-IgG was injected IP into each mouse in the ablation groups 
or mock-treatment groups, respectively. Mice were then infected IV with 400 CFU, and 
killed humanely on d 2 and 3 p.i. for analysis of CFU and leukocyte populations in spleen 
and liver.  
More than 90% of Ly6G
+
CD11b
+
 PMNs were ablated from both spleen and liver by 
the initial antibody treatment, and the subsequent treatments maintained very low levels 
of PMNs during the experiment (Figure 7.5B). Consistent with data on PMN recruitment 
and PMN activation in spleen, successful PMN ablation failed to relieve the restricted 
growth of yopM-1 Y. pestis KIM5-3002 in spleen (Figure 7.5D). However, the growth 
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defect of the yopM-1 mutant strain in liver disappeared in the mice treated with anti-
Ly6G antibody, and growth of the parent strain was slightly but not significantly 
enhanced in those mice (Figure 7.5D). This result indicated that PMNs could be one of 
the major cells to clear yopM-1 mutant in liver but not in spleen during systemic plague. 
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Figure 7.1 Comparisons of PMN percentages in spleens and livers after infection of 
C57BL/6 mice with yopM-1 Y. pestis KIM5-3002 or the parent Y. pestis KIM5 
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Mice were infected IV with 400 CFU of KIM5-3002 (open circles) or KIM5 (closed 
circles) Y. pestis. Panel A, experimental design. At the indicated times p.i., the 
percentages of Ly6G
+
CD11b
+
 PMNs in leukocytes from spleen or liver (panel B) were 
determined. The data represent the average plus SD for 19 mice per datum point for 
spleen and 15 mice per point for liver, pooled from replicate experiments.  
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Time 0 
Infect the C57BL/6 mice 
with IV pre-induced 
yopM-1 mutant KIM5-
3002 or KIM5 Y. pestis 
(10
6
CFU/mouse ) 
8, 16 and 45 hours p.i. 
Kill the mice 
humanely and 
harvest splenic 
leukocytes 
Pre-induced 
yopM-1 mutant 
KIM5-3002 and 
KIM5 Y. pestis: 
transfered the 
culture from 26°C 
to 37°C 
3 hours before infection 
Treat the splenic 
leukocytes with or 
without PMA (200 
nM) for 1 hour 
Stain the cells with 
DCFDA or DAF, 
then the antibodies 
against surface 
markers  
Figure 7.2 Comparisons of ROS and NO production by the splenic PMNs from mice 
infected with yopM-1 Y. pestis KIM5-3002 or the parent Y. pestis KIM5 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
e
rc
e
n
ta
g
e
0
4
8
12
16
20
24
Ly6G+Gr1+DCFDA+ Cells 8 h p.i.
P MU
P
e
rc
e
n
ta
g
e
0
4
8
12
16
20
24
P M
Ly6G+Gr1+DAF+ Cells 8 h p.i.
U
M
F
I
0
200
400
600
800
1000
1200
PU U P
Ly6G+Gr1+DAF+ Cells 8 h p.i.

M M
PMA

PU U PM M
PMA
M
F
I
0
500
1000
1500
2000
2500
Ly6G+Gr1+DCFDA+ Cells 8 h p.i.



 124 
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 
 
 
 
 
 
 
 
 
 
 

P
e
rc
e
n
ta
g
e
0
4
8
12
16
20
24
P M
Ly6G+Gr1+DAF+ Cells 45 h p.i.
U
P MU
P
e
rc
e
n
ta
g
e
0
4
8
12
16
20
24
Ly6G+Gr1+DCFDA+ Cells 45 h p.i.
M
F
I
0
100
200
300
400
500
600
Ly6G+Gr1+DAF+ Cells 45 h p.i.

PU U PM M
PMA
PU U PM M
PMA
M
F
I
0
500
1000
1500
2000
2500
3000
3500
4000
Ly6G+Gr1+DCFDA+ Cells 45 h p.i.

P MU
P
e
rc
e
n
ta
g
e
0
4
8
12
16
20
24
Ly6G+Gr1+DCFDA+ Cells 16 h p.i.
P MU
P
e
rc
e
n
ta
g
e
0
4
8
12
16
20
24
Ly6G+Gr1+DAF+ Cells 16 h p.i.
PU U PM M
PMA
M
F
I
0
500
1000
1500
2000
2500
3000
3500
Ly6G+Gr1+DCFDA+ Cells 16 h p.i.



PU U PM M
PMA
M
F
I
0
300
600
900
1200
1500
1800
Ly6G+Gr1+DAF+ Cells 16 h p.i.



 125 
Mice were infected IV with 400 CFU of pre-induced KIM5-3002 or KIM5 Y. pestis. 
Panel A, experimental design. At 8, 16 and 45 h p.i., the percentages of 
Ly6G
+
Gr1
+
DCFDA
+
 or Ly6G
+
Gr1
+
DAF
+
 PMNs in the live leukocytes harvested from 
spleen, as well as MFI of DCFDA and DAF staining of those cells are shown in panels B, 
C and D, respectively. Horizontal-hatched bars, uninfected mice (U); filled bars, mice 
infected with parent Y. pestis KIM5 (P); open bars, mice infected with the yopM-1 
mutant KIM5-3002 (M). PMA in the horizontal axis of the right panels of B, C and D 
indicates that the cells were stained by DCFDA and DAF after 1 hour incubation with 
PMA. Each datum point represents the average of values from 6 mice.  The error bars 
indicate the standard deviations. To compare PMA treated and mock treated PMNs from 
uninfected mice, α, P < 0.05; αα, P < 0.01; from mice infected with Y. pestis KIM5, , P < 
0.05; , P < 0.01; from mice infected with Y. pestis KIM5-3002, , P < 0.05; , P < 0.01.  
In comparisons between mock-treated PMNs from mice infected with Y. pestis KIM5 and 
KIM5-3002, *, P < 0.05; **, P < 0.01; and #, P < 0.05; # #, P < 0.01 for PMA treated 
PMNs. 
 
 
 
 
 
 
 
 
 126 
Time 0 
Infect the C57 BL/6 
mice IP with pre-
induced yopM-1 
mutant KIM5-3002 or 
KIM5 (5x104, 106 or 
5x107 CFU/mouse) 
4, 6, 8 and 24 hours p.i. 
Kill the mice 
humanely and 
harvest the peritoneal 
cells for Giemsa 
Staining 
pre-induced 
yopM-1 mutant 
KIM5-3002 and 
KIM5: transfer the 
culture from 26°C 
to 37°C 
3 hours before infection 
Count different cell 
populations according to 
their morphology (at least 
300 cells/slide counted) 
P
e
rc
e
n
ta
g
e
 o
f 
T
o
ta
l 
P
C
s
0
20
40
60
80
Total PMNs
P MU
0
20
40
60
80
Macrophages
U P M
Figure 7.3 Influx of PMNs and macrophages into peritoneal cavity after IP infection of 
C57BL/6 mice with yopM-1 Y. pestis KIM5-3002 or the parent Y. pestis KIM5 
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Mice were infected IP with 5x10
4
, 10
6
 or 5x10
7
 CFU of 26/37°C KIM5-3002 or KIM5 Y. 
pestis. At 4, 6, 8 and 24 h p.i., peritoneal cells (PCs) were harvested by peritoneal lavage. 
Panel A, experimental design. The PCs were spun down by Cytospin and stained by Diff-
Quick. Panel B, representative pictures of stained PCs (dose: 5x10
7
, harvest time: 8 h p.i. 
in this particular experiment). The percentages of PMNs and macrophages in the total 
PCs are shown in Panel C for two experiments with a dose of 10
6
 CFU and harvest time 
of 6 h p.i.. Horizontal-hatched bars, uninfected mice (U); filled bars, mice infected with 
parent Y. pestis KIM5 (P); open bars, mice infected with the yopM-1 mutant KIM5-3002 
(M). Each datum point represents the average of values from 8 mice.  The error bars 
indicate the standard deviations.  
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Time 0 
Infect the C57BL/6 mice 
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yopM-1 mutant KIM5-
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Figure 7.4 Comparisons of ROS and NO production by the peritoneal cells harvested 
from mice IP-infected with yopM-1 Y. pestis KIM5-3002 or the parent Y. pestis KIM5 
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Mice were infected IP with 5x10
4
, 10
6
 or 5x10
7
 CFU of 26/37°C KIM5-3002 or KIM5 Y. 
pestis. At 4, 6, 8 and 24 h p.i., the peritoneal cells (PCs) were harvested by peritoneal 
lavage. The PCs were stained with DCFDA or DAF for 30 min. Panel A, experimental 
design. RFUs of DCFDA and DAF staining of the PCs (dose: 10
6 
CFU/mouse, harvested 
at 6 hours p.i.) are shown in panel B. Horizontal-hatched bars, uninfected mice (U); filled 
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bars, mice infected with parent Y. pestis KIM5 (P); open bars, mice infected with the 
yopM-1 mutant KIM5-3002 (M). Note that in uninfected mice, the PCs were 80% of 
macrophages and lymphocytes and less than 1% PMNs, whereas in infected mice, the 
PCs were 40% macrophages and lymphocytes and 60% PMNs. Each datum point 
represents the average of values from 8 mice.  The error bars indicate the standard 
deviations.  
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Day 0 
Infect C57BL/6 
mice IV with 400 
CFU/mouse: 
yopM-1 mutant 
KIM-3002 or KIM5 
 
Day 2 and 3 p.i. 
Kill the mice 
humanely and 
process the 
spleens and livers 
for CFU (plating) 
and immune cells 
(flow cytometry)  
Inject the antibody 
(IP) 200μg/mouse: 
 
Ablation: IA8 (anti-
Ly6G) 
Mock: Rat-IgG 
 
Repeat the injection 
(100μg/mouse) on Day 
1 p.i. 
Day -1 
Figure 7.5 Effect of PMN ablation on infection dynamics for of yopM-1 and parent Y. 
pestis KIM5. 
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Mice treated with anti-Ly6G antibody to ablate PMNs or mock-treated with nonspecific 
rat IgG were infected and analyzed for bacterial burdens and inflammatory leukocyte 
populations in livers and spleens on days 2 and 3 p.i.. Horizontal-hatched bars, uninfected 
mice (U); filled bars, mock-treated mice infected with parent Y. pestis KIM5 (MP); open 
bars, mock-treated mice infected with the yopM-1 mutant KIM5-3002 (MM); cross-
hatched bars, PMN-ablated mice infected with Y. pestis KIM5 (AP); diagonally-hatched 
bars, PMN-ablated mice infected with the yopM-1 strain KIM5-3002 (AM).  Panel A, 
experimental design. Panels B and C, Ly6G
+
CD11b
+
 PMNs and Ly6G
-
CD11b
+
 MDMs, 
respectively, expressed as percent of total live leukocytes from spleen and liver. Panel D, 
CFU. Each datum point represents the average of values from 6 mice. The error bars 
indicate the standard deviations. To compare PMN-ablated and mock ablation groups for 
mice infected with the yopM-1 strain KIM5-3002, †, P < 0.05; ††, P < 0.01; for mice 
infected with the parent strain KIM5, #, P < 0.05; ##, P < 0.01. In comparisons between 
groups of mice infected with KIM5 and KIM5-3002, *, P < 0.05; **, P < 0.01 for mock-
treated mice; δ, P < 0.05; δδ, P < 0.01 for PMN-ablated mice. 
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RESULTS 
Chapter Eight: Distinct subsets of MDMs play different roles in controlling Y. pestis 
in spleen, and iDCs may be responsible for the growth limitation of yopM-1 mutant  
 
Since Gr1
+
 cells are the innate immune cells controlling the yopM-1 mutant in 
spleen and ablation of one of the major components in this population, PMNs, failed to 
relieve the growth defect of the yopM-1 mutant in spleen, we changed our focus to Gr1+ 
MDMs, defined as Gr1
+
Ly6G
-
CD11b
+
. Ly6G
-
CD11b
+
 MDMs include several 
subpopulations, such as resident Ms/DCs, inflammatory monocytes and a newly 
discovered DC with pro-inflammatory function. Here we studied the recruitment of 
MDMs into spleens and livers and used KO mice and conditional ablation to test their 
role in the growth of infecting Y. pestis in systemic plague. 
 
A. The accumulation of MDMs in spleens was compromised when YopM was 
present in the infecting strain 
Through experiments designed as in Figure 7.1A, the recruitment of MDMs into 
spleens and livers was studied. In contrast to PMNs (Figure 7.1B), which were recruited 
similarly by parent and yopM-1 mutant, significantly greater numbers of MDMs were 
stably recruited to spleens when YopM was absent in the infecting strain. This effect was 
not observed in livers, which showed identical accumulations of these cells during 
infection by both Y. pestis strains (Figure 8.1A). 
The cells in the peak population had high expression levels of CD11b, when analyzed 
as MFI, and thus likely were predominantly newly arrived monocytes (Figure 8.1B). 
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Accordingly, the increase in MDMs in mice infected with the yopM-1 mutant but not 
the parent Y. pestis may reflect an effect of YopM on monocyte influx into spleen but 
does not obviously explain the virulence effect of YopM in liver. 
In contrast to Gr1
+
 cell ablation, which abolished the influx of MDMs into infected 
spleens and delayed influx until d 3 p.i. in livers (Figure 6.1C), ablation only of PMNs 
did not abolish or even decrease influx of MDMs in either organ (Fig. 7.5C). This finding 
shows that PMNs are not essential for recruiting these cells from the bone marrow and 
peripheral circulation into infected organs. Further, either non-PMN Gr1
+
 cells are 
responsible for recruiting MDMs in response to infection by yopM-1 Y. pestis or the 
recruited MDMs themselves are Gr1
+
. 
 
B. Clodronate-mediated depletion inhibited the growth of both yopM-1 mutant 
and parent strains, indicating that an MDM subset may serve as the initial niche for 
Y. pestis 
Resident macrophages and DCs are believed to provide an early intracellular niche 
for Y. pestis in spleen (192). Moreover, the presence of YopM in the infecting Y. pestis 
had previously been shown to be associated with decreased expression of 
proinflammatory cytokines like TNF, IL-1, IL-12, IL-15, and IL-18 in F4/80+ cells 
(macrophages and monocytes) by d 2 p.i. (159). Accordingly, it is possible that these 
resident cells are the initial target of YopM and those PMNs and inflammatory monocytes 
are affected secondarily. To test this hypothesis, as described in Figure 8.2A, we treated 
mice IV with 200 μL of clodronate-containing mannosylated liposomes 18 h prior to, and 
one day after, infection to specifically deplete MDMs, especially macrophages/DCs. The 
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mock-treated mice received 200 μL of liposome-encapsulated PBS. Organs were 
harvested on d 1, 2, and 3 p.i. for determination of bacterial load and flow cytometric 
analysis.  
A series of preliminary experiments was performed to test the effect of clodronate on 
MDMs in spleen and liver without infection before the real experiments with Y. pestis 
infection. The experiments were designed similarly to that described in Figure 8.2A but 
without infection. For convenience, the time points in all experiments in this section were 
named according to the infection, no matter whether there was an infection. Therefore in 
Figure 8.2B, d -1 indicates the time to inject the liposomes and d 0 was 18 hours after 
injection. From Figure 8.2B, we found that the first clodronate treatment (injected on d-1) 
removed three fourths of the MDMs (CD11b
+
Ly6G
-
) from spleen and liver on d 0. Since 
there was no infection in these experiments, those ablated MDMs were considered to be 
resident cells. The second injection of clodronate maintained the low level of MDMs in 
these organs.  
In the experiments with Y. pestis, mice were infected with 400 CFU/mouse of Y. 
pestis KIM5 or KIM5-3002 in addition to the liposome treatment. Similarly to the 
preliminary experiments, clodronate depleted ca. 80% of resident MDMs from spleen and 
prevented the net increase due to influx of inflammatory monocytes (Figure 8.2D). In 
liver, however, clodronate failed to reduce initial numbers of resident CD11b
+
Ly6G
-
 cells 
but did prevent or delay the influx of monocytes (Figure 8.2D). Flow cytometric analysis 
for total CD11c
+
 DCs showed a depletion pattern similar to that of CD11b
+
Ly6G
-
 cells 
(Figure 8.2E). Nonetheless, the clodronate treatment strikingly curtailed the number of 
viable bacteria for both Y. pestis strains in both organs (Figure 8.2G).  In liver, this effect 
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did not correlate with changes in numbers of hepatic PMNs (Figure 8.2F), indicating that 
PMNs were unlikely to be responsible for this growth pattern. However, a robust influx 
of splenic PMNs (Figure 8.2F) was found in clodronate-treated mice on d 3 p.i., 
correlating with the controlled growth of both strains in spleen (Figure 8.2G). It is 
reasonable to deduce that the bacterial growth in spleen was dampened by the increased 
number of PMNs, which resulted from clodronate treatment, as well as loss of 
amplification niches for the bacteria.  
Lesions at d 3 p.i. in the mock-treated mice were similar in appearance to those of 
other mock-treated mice at the same time p.i. (compare Figure 8.2C upper panels to 
Figure 6.1E). However, in clodronate-treated mice, regardless of the strain they were 
infected with, only a few small lesions were found, and there was little or no necrosis 
present. These histopathological findings were consistent with a lower inflammatory 
status in the clodronate liposome-treated vs. PBS liposome-treated mice (Figure 8.2D). 
These data showed that clodronate-sensitive cells function to amplify bacterial numbers 
for Y. pestis with or without YopM, consistent with a previous study which suggested that 
macrophages serve as an intracellular reservoir during plague (192).  
The liposomes per se are not completely benign, and the total numbers of MDMs 
were reduced on d 3 p.i. in spleens and livers and increased on d 0 in livers of mice that 
were mock-treated with PBS-liposomes (Figure 8.2B). A different method for ablation of 
MDMs was tested by two colleagues for its effect on infection by the parent Y. pestis 
KIM5 strain. MDMs can be conditionally depleted by treating transgenic MaFIA mice 
with a dimerizer drug that initiates Fas-induced apoptosis in these cell types without 
affecting mature PMNs (57). Groups of these mice were given dimerizer or were mock-
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treated with injection solution, infected IV with 200 CFU of the parent Y. pestis, and 
analyzed for viable numbers of bacteria in liver and spleen on d 4 p.i.. The depletion of 
MDMs in dimerizer-treated MaFIA mice was about 95%, and PMNs were not depleted 
(data not shown). Figure 8.3 shows that ablation of MDMs by this alternative procedure 
again resulted in significantly lower bacterial burdens in organs.   
Interestingly, in mice treated with clodronate-liposomes the yopM-1 mutant still 
showed restricted growth compared to the parent strain, most prominently in spleen ( in 
Figure 8.2G). Because a portion of splenic MDMs always resisted the clodronate 
treatment and had a non-negligible number (ca. 4% of total live splenic leukocytes) 
(Figure 8.2D), it was hypothesized that these low numbers MDMs were responsible for 
the maintenance of growth limitation of the yopM-1 mutant bacteria after clodronate 
treatment. 
 
C. The yopM-1 mutant and parent strain showed the same ability to elicit the 
efflux of MDMs from bone marrow into circulation only at a very early stage of the 
infection  
The difference in recruitment of MDMs into spleen by parent and yopM-1 mutant 
raised a question: where was the recruitment of MDMs inhibited by YopM, efflux from 
bone marrow into blood or influx from circulation into spleen? Described in Figure 8.4A, 
mice were infected IV with the parent strain or yopM-1 mutant and bone marrow, 
spleens and blood were harvested on d 2 and 3 p.i. for flow cytometric analysis. In order 
to compare the numbers of cells from different organs, absolute numbers, instead of 
percentage per organ, are shown in the panels in Figure 8.4B and C.  
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As expected, we did not find any YopM-associated difference in the absolute number 
of PMNs in bone marrow, blood or spleen on both d 2 and 3 p.i. (Figure 8.4C). However, 
although the numbers of bone marrow MDMs in the mice infected with either strain were 
the same on d 2 p.i. (Figure 8.4B, left panel), the parent strain-infected mice contained ca. 
2x10
6
/mouse more MDMs in the circulation than the yopM-1 mutant-infected ones 
(Figure 8.4B, middle panel), given that the total volume of blood in a mouse weighing 18 
g, which is the average weight of the mice in our experiment, is ca. 1 mL (266). 
Meanwhile there were ca. 2x10
6
/mouse fewer MDMs recovered from parent strain-
infected spleens than yopM-1 mutant-infected ones (Figure 8.4B, right panel) on d 2 p.i.. 
Therefore YopM produced by the parent strain did not affect the efflux of MDMs from 
bone marrow into blood, but it did inhibit the infiltration of those cells into spleen on d 2 
p.i.  
However, the above difference for MDMs in circulation disappeared on d 3 p.i. 
(Figure 8.4B, middle panel), while the difference in the accumulation of MDMs in spleen 
became greater than on d 2 p.i. (Figure 8.4B, right panel). Although on d 3 p.i. the 
yopM-1 Y. pestis infection stimulated more bone marrow cells to differentiate into 
MDMs than did the parent strain infection (Figure 8.4B, left panel), that difference in 
absolute number was not large enough to result in the accumulation of MDMs in yopM-
1 mutant-infected spleen. Thus, the compromised recruitment of MDMs into parent strain 
infected spleen on d 3 p.i. should be explained by YopM’s negative effect on both the 
efflux of MDMs from bone marrow into blood and the influx of circulating MDMs into 
spleen.   
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D. CCR2 KO prevented the influx of MDMs into spleen and liver and 
specifically favored the growth of the yopM-1 mutant 
As mentioned earlier, in the clodronate-mediated ablation model, the liposomes 
themselves are toxic to MDMs. A more important disadvantage is that clodronate 
removes resident macrophages and DCs as well as infiltrated inflammatory monocytes, 
and these cell types have distinct functions at different stage of infection. Thus, an animal 
model that only ablated infiltrating monocytes became necessary to further study the role 
of those cells in the YopM mechanism.  
CCL2/MCP-1 is a member of the C-C chemokine family and a potent chemotactic 
factor recognized by CCR2 on the surface of inflammatory monocytes. Therefore, mice 
lacking the ccr2 gene are susceptible to infectious pathogens because their monocytes fail 
to migrate to the infection sites. Although lacking CCR2 on the surface of their 
monocytes, NK cells, memory T cells, and PMNs (85, 144, 193), CCR2
-/-
 mice are not 
significantly different from WT mice under pathogen-free conditions, which indicates 
that those mice are not severely immunocompromised. Furthermore, since the CCL2-
CCR2 chemokine pair functions mainly in the recruitment of monocytes, NK cells, and 
memory T cells, resident MDMs are not affected in CCR2
-/-
 mice, and NK cells and 
memory T cells are not Gr1
+
 and are not required for YopM to have its pathogenic effect. 
Meanwhile, PMNs would not be affected in recruitment because the CCR2 does not 
function in recruitment of that cell type (168). Therefore, all of these advantages make 
CCR2 KO mice a better model to study the role of inflammatory monocytes than 
clodronate-mediated ablation. 
As described in Figure 8.5A, CCR2
-/-
 mice and C57BL/6 mice were infected IV with 
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the parent strain and the yopM-1 mutant. On d 3 p.i., spleens and livers were harvested 
to study leukocytes and bacterial burden. In CCR2
-/-
 mice, significantly fewer Ly6G
-
CD11b
+
 MDMs were recruited to spleen and liver by the infection with both of the 
strains than in WT mice (Figure 8.5B). As expected, the MDMs were not completely 
abolished, because resident macrophages and DCs also are Ly6G
-
CD11b
+
 cells and their 
presence in organs is independent of the CCR2 signaling pathway (293). Further, the 
difference between parent and mutant strains in the residual MDMs in CCR2
-/-
 mice was 
still significant in spleen (Figure 8.5B, left panel). This indicates that there are some 
CCR2
-
 MDMs recruited into spleen with the YopM-associated pattern. The relief of 
growth limitation of the yopM-1 mutant strain in the spleens of CCR2-/- mice (Figure 
8.5D, left panel) was not complete (although the difference from the parent strains 
growth was not significant statistically); the residual growth control might be mediated 
by these splenic CCR2
-
 MDMs that were recruited through the signaling pathway of 
other chemokines and their receptors, such as CCL5/RANTES (regulated on activation, 
normal T cell expressed and secreted) and its receptor CCR3 (47, 123). Interestingly, 
infection by the yopM-1 mutant strain recruited significantly more Ly6G+CD11b+ 
PMNs into spleen than did the parent strain in CCR2
-/-
 mice (Figure 8.5C, left panel), and 
those newly recruited PMNs apparently could not clear the yopM-1 strain, because the 
bacterial burden in spleen was significantly increased in yopM-1 strain-infected CCR2-/- 
mice (Figure 8.5D, left panel). 
The accumulation of MDMs in liver showed no YopM-associated pattern in CCR2
-/-
 
mice (Figure 8.5B, right panel). In contrast, more PMNs were recruited in the livers of 
the yopM-1 strain-infected CCR2-/- mice than those of parent strain-infected ones 
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(Figure 8.5C, right panel), correlating with maintenance of the growth limitation of the 
yopM-1 strain. However, the yopM-1 KIM5-3002 actually grew much better in CCR2-
/-
 mice than in WT mice in liver (Figure 8.5D, right panel). These data supported the 
importance of PMNs in liver, whose function in clearance of the yopM-1 mutant was 
likely compromised by CCR2 KO. 
 
E.  Absence of CCR2 favored the growth of yopM-2 mutant strain in skin 
YopM was proven to be necessary for full lethality in the bubonic plague model by 
LD50 measurement and histopathological analysis (Table 3.1) (363). However, the 
immune cells in skin controlling the yopM-2 mutant strain had not been characterized. 
Since the CCR2 KO favors the growth of the yopM-1 strain in the systemic plague 
model, it is reasonable to hypothesize that CCR2
+
 cells mediate the decreased virulence 
of yopM-2 Y. pestis in the bubonic plague model, in which a strong inflammatory 
response also occurs. To test this hypothesis, CCR2
-/-
 mice and C57BL/6 mice were ID-
infected with 200 CFU of Y. pestis CO92.S6 and yopM-2 mutant CO92.S19. On d 4 and 
d 5 p.i., spleens and the skin surrounding the infection sites were harvested to study 
bacterial growth in skin and dissemination to spleen (Figure 8.6).  
In WT mice, the yopM-2 mutant Y. pestis showed a delayed growth compared to the 
parent strain.  However, in the CCR2
-/-
 mice the growth defect of the yopM-1 mutant 
strain in skin disappeared and the yopM-1 strain grew even better than the parent strain 
on d 5 p.i., while growth of the parent strain was not affected by CCR2 KO (Figure 8.6B, 
left panels). These findings suggest that CCR2
+
 cells play a critical role in controlling 
yopM-2 Y. pestis numbers in skin and YopM targets the protective function of CCR2+ 
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cells. 
As shown in the right panels of Figure 8.6B, dissemination of parent Y. pestis to 
spleen showed no significant difference between WT and KO mice on d 4 p.i., but by d 5 
p.i., 5 of the mice infected with the parent Y. pestis had died. In contrast to d 4 p.i., when 
CCR2 KO did not affect the colonization of yopM-2 Y. pestis in spleen, a higher number 
of bacteria was recovered from the spleen of CCR2
-/-
 mice on d 5 p.i., although this 
difference was not statistically significant (P = 0.09). This finding suggested that CCR2
+
 
cells may be one of the cell types inhibiting the dissemination of yopM-2 Y. pestis, but 
their importance in this process still needs further investigation. 
 
F. CCL2/MCP-1 KO favored both of the strains, consistent with the diversity of 
CCL2 functions in addition to recruiting MDMs 
Although the major chemokine recognized by CCR2 is CCL2/MCP-1, CCR2 also 
interacts with other chemokines for macrophages, such as CCL8/MCP-2 and 
CCL7/MCP-3 (85). The growth of the yopM Y. pestis in CCR2 KO mice could be 
enhanced by the absence of the CCL2-CCR2 interaction or of the CCL2-independent 
CCR2 signaling pathway.   
Therefore, in addition to CCR2
-/-
 mice, we also tested the growth of parent and 
yopM-1 strains in CCL2-/- mice. As described in Figure 8.7A, CCL2-/- mice and 
C57BL/6 mice were IV-infected with the parent strain and the yopM-1 mutant. On d 3 
p.i., spleens and livers were harvested to study bacterial burden. Unlike the enhanced 
growth of the yopM-1 mutant strain in the spleens of CCR2-/- mice, there was no change 
in the relative growth yields between these two Y. pestis strains due to CCL2/MCP-1 KO, 
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although both of them grew much better in the spleens and livers from CCL2
-/-
 mice than 
in those organs from WT ones (Figure 8.7B). 
In addition to CCR2, CCL2/MCP-1 is also recognized by CCR4 (76). Meanwhile, in 
contrast to CCR2, which is restricted in expression to a few cell types, CCL2/MCP-1 is a 
potent chemoattractant for many cell types, such as monocytes, langerhan cells, memory 
T cells and NK cells (85, 209). Further, along with IL-8, MCP-1 has been shown to 
trigger the firm adhesion of monocytes to vascular endothelium under flow conditions 
(111). CCL2/MCP-1 also can induce the degranulation of basophils and mast cells as 
well as cell aggregation in rat peritoneal mast cells (37, 70). Therefore the KO of 
CCL2/MCP-1 compromises the immune system broadly and favors the growth of both 
strains whether they express YopM or not. 
 
G. iDCs, one of the major subsets of MDMs, may be the key cells clearing the 
yopM-1 mutant in spleen 
In Chapter 8D and 8E, we concluded that the CCR2
+
 cells were the key cells to 
control the growth of the yopM Y. pestis in spleen, liver and skin. Meanwhile, ablation 
of Gr1
+
 cells from the infected mice made the yopM Y. pestis grow like the parent strain 
in both spleen and liver, pointing towards Gr1
+
 cells as the critical cellular component in 
the YopM virulence mechanism (Figure 6.1). Taken together, CCR2
+
Gr1
+
 cells were 
found to be responsible for the growth limitation of the yopM Y. pestis. It was true for 
liver, in which PMNs controlled the growth of the yopM mutant. PMNs express both 
Gr1 and CCR2 on their surface (144). Therefore, a subset of the CCR2
+
Gr1
+
 cells other 
than PMNs may be the critical cell for the yopM Y. pestis phenotype in spleen.  
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Inflammatory monocytes no doubt are one of the major cell types whose recruitment 
depends on the CCL2-CCR2 chemokine pair (85). However, another cell type, 
inflammatory DCs (iDCs) or TipDCs (TNF alpha/iNOS producing DCs), which are 
derived from monocytes and recruited like inflammatory monocytes, i.e., depending on 
CCR2 signaling, into spleen (109, 294), was also studied. These TipDCs express both 
high level Gr1 (or more specific, Ly6C) and CCR2 on their surface (293) and act as a 
critical player to control some intracellular bacteria during infection (71, 294). Therefore 
it was necessary to test the role of these cells in the infection of parent Y. pestis and 
yopM-1 mutant.  
a) Characterization of iDCs by flow cytometry and intracellular staining 
Since there are only a few studies about TipDCs, there is not a consistent way to 
define them in terms of surface and intracellular markers. Currently there are three 
surface-staining combinations for TipDCs in the literature: CD115
+
Gr1
+
(17), 
Ly6C
high
CD11b
+
(71), CD11b
int
 CD11c
int
(294). Meanwhile, combined with above surface 
marker detection, intracellular iNOS and TNF alpha staining are also important to define 
TipDCs. Since there is no literature reporting the definition of TipDCs in Y. pestis 
infection, we had to determine our own combination for these DCs. 
In order to choose the correct staining plan for our study, the cells harvested from 
spleens d 3 post infection with the parent or mutant strains were stained for intracellular 
iNOS and TNF alpaha as well as surface markers. As showed in Figure 8.8A, we decided 
to use CD11b
+
 CD11c
int
 as our definition for TipDCs (Table 4.1) because this population 
was proven to make a high level intracellular iNOS. Since iDCs express CD11b but no 
Ly6G on their surface, they must be one major component of MDMs (Ly6G
-
CD11b
+
). 
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Interestingly, we did not detect TNF alpha production in those cells, whether the 
infecting bacteria contained YopM or not. However, that experiment lacked a positive 
control showing that the assay was working, so at present we cannot conclude that these 
iDCs are TNF
-
. Therefore we decided to name those cells as iDCs (inflammatory DCs), 
instead of TipDCs. Apparently YopM from the parent strain inhibited the influx of those 
iNOS
+
CD11b
+
CD11c
int
 cells into spleens (Figure 8.8B).  
b) YopM-related difference in iDC influx into spleen was dependent on CCR2 
signaling, but not related to the presence of PMNs 
Through experiments designed as shown in Figure 8.9A, the recruitment of iDCs into 
spleens and livers was studied. Similarly to MDMs (Figure 8.1A), there was a significant 
difference in the iDCs (CD11b
+
 CD11c
int
) in spleen starting on d 2 p.i., but this was not 
observed in liver (Figure 8.9B).  
Meanwhile, CCR2
-/-
 mice were used to study the relationship between the recruitment 
of iDCs and signaling through CCR2. As described in Figure 8.10A, CCR2
-/-
 mice and 
C57BL/6 mice were IV-infected with the parent strain and the yopM-1 mutant. On d 3 
p.i., spleens and livers were harvested to study leukocytes. In WT mice, similar to the 
result in Figure 8.8B, iDCs showed a YopM-associated pattern in the recruitment into 
spleen, but not in liver (Figure 8.10B). However, in CCR2
-/-
 mice lacking CCR2-
mediated chemotactic signals, the influx of iDCs into both spleen and liver was 
compromised, whether the infecting strain contained YopM or not. Consequently, the 
difference in recruitment of iDCs into spleen between mice infected with the parent and 
mutant strains disappeared (Figure 8.10B, left panel). 
Although PMNs were confirmed not to be the major cells to clear the yopM-1 
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mutant in systemic plague in spleen, the extensive crosstalk between them and MDMs 
raised the question as to whether PMNs affect the YopM-associated recruitment pattern 
of iDCs in spleen. By using a design similar to that described in Figure 7.5A, we 
compared the influx of iDCs into spleen and liver between the parent and yopM-1 
mutant Y. pestis infection on d 2 and d 3 p.i.. As shown in Figure 8.11, absence of PMNs 
had no influence on the existing pattern of iDC influx into spleen and liver. 
The studies in this section have shown that iDCs,  a major component of MDMs, had 
exactly the same recruitment pattern as MDMs into spleen. Further, when the percentage 
of iDCs was subtracted from that of MDMs, the remaining MDMs were recruited 
similarly into spleen on d 2 p.i. (data not shown), indicating that the function of MDMs in 
the controlling the yopM-1 strain in spleen at the early stage of infection may be 
actually executed by this subset. 
c) Co-infection of parent and yopM-1 Y. pestis relieves the growth defect of the 
yopM-1 strain in spleen but not in liver  
Since it was found that YopM produced by the parent strain inhibited the influx of 
iDCs into spleen and favored the growth of these bacteria in spleen, we hypothesized that 
co-infection of the parent and yopM-1 mutant should overcome the growth limitation of 
the yopM-1 strain because YopM produced by the parent strain would inhibit the 
recruitment of iDCs, which may be critical for controlling growth of yopM-1 Y. pestis in 
spleen.  
In experiments designed as shown in Figure 8.12A, WT mice were infected with the 
parent strain lacZ Y. pestis KIM5-3003, the yopM-1 strain KIM5-3002 or a 1:1 mixture 
of the two strains. To increase the likelihood of depositing bacteria of each strain in 
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infected splenic and hepatic sinusoids, a high infectious dose (5 x 10
3
) was used in this 
experiment. The spleens and livers were harvested on d 2, 3 and 4 p.i.. To distinguish the 
two strains, we used a parent strain that lacked the lacZ gene (KIM5-3003) and used 
blue-white screening on agar medium containing X-Gal. As shown in Figure 8.12B, 
parent strain colonies were white and yopM-1 strain colony was blue.  
Figure 8.12C shows that by d 2 p.i., the two Y. pestis strains in co-infected spleens 
showed the same viable numbers, which kept increasing and became significantly higher 
than that of spleen infected only with the yopM-1 strain on d 4 p.i.. Thus the YopM-
related growth limitation in spleen was relieved by the presence of the parent strain. 
However in liver, there was little difference between the growth rates of the bacteria 
separately and together, and the YopM-associated difference between parent and mutant 
in bacterial numbers was maintained in the co-infected livers.  
These results supported our hypothesis that the effect of YopM on recruitment of 
iDCs into spleen changes the whole microenvironment in spleen and thus protects the 
YopM producing Y. pestis as well as the nearby yopM-1 strain from clearance. In liver, 
the parent strain only promoted its own growth by a mechanism which may inhibit the 
bactericidal function of PMNs and did not favor the growth of nearby yopM-1 bacteria. 
It is worth noticing that the proinflammatory effects of the yopM-1 also compromised 
the growth of the parent strain, reflected in a lower viable number of the parent strain in 
co-infected organs than in the separate infection.   
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Figure 8.1 Effect of YopM on the accumulation of MDMs in spleens and livers 
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C57BL/6 mice were infected IV with 400 CFU KIM5 (parent strain, filled circles) or 
KIM5-3002 (yopM-1 mutant, open circles) strains that had been grown at 26oC.  At the 
indicated times, groups of mice were analyzed for populations of live leukocytes in liver 
and spleen by flow cytometry. Panel A, Ly6G
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percent of total live leukocytes in spleens and livers of mice infected with KIM5 or 
KIM5-3002. Panel B, MFI of the staining of CD11b in splenic and hepatic MDMs. Points 
at time 0 indicate the values for uninfected mice. In Panels A and B, each datum point 
represents the average of values from 26 mice and 9 mice, respectively. The error bars 
indicate the standard deviations. Significant differences by the unpaired Student’s t test 
comparing data from mice infected with KIM5 and KIM5-3002 are indicated (*, P < 0.05; 
**, P < 0.01) . 
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Figure 8.2 Ablation of MDMs with clodronate-liposomes restricted growth of both Y. 
pestis strains. 
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Mice were given clodronate-liposomes (ablation groups) or PBS-liposomes (mock 
ablation groups) IV 18 h before infection with 400 CFU of yopM-1 Y. pestis (KIM5-
3002) or the parent strain (KIM5) IV. The same doses of liposomes were also given to the 
mice on day 1 p.i.. Panel A, experimental design. Panel B, the percentages of MDMs in 
spleens and livers from uninfected mice treated with clodronate-liposomes or PBS-
liposomes. Each datum point represents the average of values from 12 mice. Panel C, 
Histopathology on day 3 p.i. in the livers of the MDM-ablated and mock-treated mice 
infected with Y. pestis KIM5 or KIM5-3002. Bars, 50 m. On days 1, 2, and 3 p.i., the 
percentages of MDMs (Panel D), CD11c
+ 
DCs (Panel E), PMNs (Panel F), and numbers 
of CFU (Panel G) in spleens and livers from the mice infected with Y. pestis KIM5-3002 
or KIM5 were determined. The data in the graphs represent the averages plus SDs (error 
bars) for six mice per datum point in panels B, D, E and F; and for nine and six mice per 
datum point from the spleen and liver, respectively, in panel G, pooled from replicate 
experiments. Values that are significantly different (P < 0.01) in the MDM-ablated and 
mock-treated groups of uninfected mice are indicated (φφ). Values that are significantly 
Spleen 
Liver 
 153 
different (P < 0.01) in the MDM-ablated and mock-treated groups of mice infected with Y. 
pestis KIM5-3002 are indicated (††). Values that are significantly different in the MDM-
ablated and mock-treated groups of mice infected with Y. pestis KIM5 are indicated as 
follows: #, P < 0.05; ##, P < 0.01. Values that are significantly different (P < 0.01) in the 
mock-treated mice infected with Y. pestis KIM5 and KIM5-3002 are indicated (**). 
Values that are significantly different in the MDM-ablated mice infected with Y. pestis 
KIM5 and KIM5-3002 are indicated as follows: , P < 0.05; , P < 0.01. 
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Figure 8.3 Conditional ablation of MDMs by Fas-induced apoptosis in transgenic MaFIA 
mice also restricted growth of Y. pestis KIM5.  
 
 
 
 
 
 
 
 
 
 
MaFIA mice were given daily i.v. injections of dimerizer drug AP20187 or mock 
injection solution for 5 days and then were allowed to rest two days before being infected 
with 200 CFU of the parent Y. pestis KIM5. The numbers of CFUs in liver and spleen on 
d 4 p.i. were measured. Data (average + SD) are from 6 mice per treatment, pooled from 
replicate experiments. Differences between AP20187 and mock-treated groups (##, P < 
0.01) are indicated. (This experiment was done by E. J. Kerschen Ph.D. in S. C. Straley’s 
Lab and S. H. Burnett Ph.D. in D. A. Cohen’s Lab in our Department)  
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Day 0 
Infect the C57 BL/6 
mice IV with 400 
CFU/mouse yopM-1 
mutant KIM5-3002 or 
KIM5 
Day 2 and 3 p.i. 
Kill the mice humanely and 
harvest the bone marrow (from 2 
femurs), spleens and blood 
(heart puncture, 200 μL/mouse) 
for flow cytometric analysis of 
MDMs and PMNs 
Figure 8.4 Inhibition of MDM recruitment into spleen and into circulation by parent Y. 
pestis KIM5. 
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C57BL/6 mice were infected with the parent (KIM5) and yopM-1 (KIM5-3002) Y. 
pestis and analyzed by flow cytometry for populations of leukocytes in spleen, peripheral 
blood and bone marrow (BM) on days 2 and 3 p.i.  Filled bars, mice infected with the 
parent strain; open bars, mice infected with the YopM- mutant.  Panel A, experimental 
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design. Panel B, Ly6G
-
CD11b
+
 MDMs. Panel C, Ly6G
+
CD11b
+ 
PMNs. The number of 
MDMs and PMNs is presented as absolute numbers of the cells harvested from whole 
spleen, 1mL blood or bone marrow from 2 femurs of one mouse. Each datum point 
represents the average of values from 9 mice. The error bars indicate the standard 
deviations. Significant differences by the unpaired Student’s t test comparing data from 
mice infected with the parent and mutant strains are indicated (*, P < 0.05; **, P < 0.01). 
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Day 0 
Infect the C57 BL/6 
mice and CCR2-/- mice 
IV with 400 CFU/mouse 
yopM-1 mutant KIM5-
3002 or KIM5 
Day 3 p.i. 
Kill the mice humanely and 
harvest the spleens and livers 
for flow cytometric analysis and 
plating for CFU 
Figure 8.5 CCR2 requirement for recruitment to selectively control growth of yopM-1 Y. 
pestis KIM5-3002. 
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WT and CCR2
-/-
 C57BL/6 mice were infected and analyzed for bacterial burdens and 
inflammatory leukocyte populations in livers and spleens on d 3 p.i.. Panel A, 
experimental design. Panel B, Ly6G
-
CD11b
+
 MDMs and Panel C, PMNs (Ly6G
+
CD11b
+
 
cells), expressed as percent of total live leukocytes.  Panel D, CFU. Filled bars, WT mice 
infected with the parent Y. pestis KIM5 (P/WT); open bars, WT mice infected with the 
yopM-1 mutant KIM5-3002 (M/WT); cross-hatched bars, CCR2-/- mice infected with 
the parent strain KIM5 (P/CCR2
-/-
); diagonally-hatched bars, CCR2-/- mice infected with 
the yopM-1 strain KIM5-3002 (M/CCR2-/-). Each datum point represents the average of 
values from 9 mice.  The error bars indicate the standard deviations.  To compare WT and 
CCR2
-/-
 mice infected with strain KIM5-3002, †, P < 0.05; ††, P < 0.01; for mice infected 
with Y. pestis KIM5, #, P < 0.05; ##, P < 0.01. In comparisons between groups of mice 
infected with strains KIM5 and KIM5-3002, *, P < 0.05; **, P < 0.01 for WT mice; δ, P < 
0.05; δδ, P < 0.01 for CCR2-/- mice. 
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Day 0 
Infect the C57 BL/6 
mice and CCR2-/- mice 
ID with 200 CFU/mouse 
yopM-2 mutant 
CO92.S19 or CO92.S6 
Day 4 and 5 p.i. 
Kill the mice humanely and 
harvest the spleen and the skin 
surrounding the infection sites 
for plating 
Figure 8.6 CCR2 requirement to control local growth of yopM-2 YopM- Y. pestis CO92 
in bubonic plague. 
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Groups of C57BL/6 and CCR2-/- mice were infected ID with 100-200 CFU of the parent 
Y. pestis CO92.S6 or 200-250 CFU of yopM-2 Y. pestis CO92.S19, and skin and spleens 
were analyzed for CFU on days 4 and 5 p.i.. Because of the large number of mice 
involved, the infections for the two analysis times were done on different days. To 
improve the statistical power in the data for the yopM-2 mutant on d 4 p.i., that 
experiment was repeated and the data for the two experiments were pooled. Panel A, 
experimental design. Panel B, CFU on d 4 and d 5 p.i. Each symbol represents one mouse. 
Filled circles, parent strain and WT mice (P-WT; 8 mice in the group); filled triangles, 
yopM-2 mutant and WT mice (M-WT; 14 mice in the group on d 4 p.i. and 8 mice in the 
group on d 5 p.i.); open circles, parent strain and CCR2-/- mice (P-KO; 8 mice in the 
group); open triangles, yopM-2 mutant and CCR2-/- mice (M-KO; 14 mice in the group 
on d 4 p.i. and 8 mice in the group on d 5 p.i.); Xs, mice that died prior to analysis. Solid 
horizontal lines, median values of the data sets; dashed lines, limits of detection (a single 
colony on one of the duplicate plates); parentheses, data taken from plates with < 30 CFU. 
Significant differences of medians by the Wilcoxon two sample test are indicated: , P < 
0.01; , P < 0.001. On d 5 p.i. the number of P-KO mice that survived to be analyzed 
was too low for statistical evaluation, and the data for these mice likely underestimate 
those for the group. One sample of skin for P-WT on d 5 p.i. was lost, and one sample for 
spleen for M-KO on d 4 p.i. could not be enumerated (accounting for one less datum 
point for skin than spleen in those treatment groups). 
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Figure 8.7 Growth enhancement for both parent and YopM- mutant Y. pestis in mice 
lacking CCL2 (MCP-1). 
A 
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WT and CCL2-/- C57BL/6 mice were infected and analyzed for bacterial burdens on d 3 
p.i..  Filled bars, WT mice infected with parent Y. pestis KIM5 (P-WT); open bars, WT 
mice infected with the yopM-1 mutant KIM5-3002 (M-WT); cross-hatched bars, CCL2-
/- mice infected with the parent strain KIM5 (P-CCL2-/-); diagonally-hatched bars, 
CCL2
-/-
 mice infected with the yopM-1 strain KIM5-3002 (M-CCL2-/-).  Each datum 
point represents the average of values from 9 mice. The error bars indicate the standard 
deviations. To compare WT and CCL2-/- groups for mice infected with Y. pestis KIM5-
3002, †, P < 0.05; ††, P < 0.01; for mice infected with strain KIM5, #, P < 0.05; ##, P < 
0.01. In comparisons between groups of mice infected with Y. pestis KIM5 and KIM5-
3002, *, P < 0.05; **, P < 0.01 for WT mice; δ, P < 0.05; δδ, P < 0.01 for CCL2-/- mice. 
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Figure 8.8 TipDC markers on inflammatory DCs preferentially recruited to spleens 
infected with YopM- Y. pestis KIM5-3002. 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
C57BL/6 mice were infected as in Figure 21A and analyzed for inflammatory leukocyte 
populations in spleens d 3 p.i.. Panel A, left, flow cytometric scatter plots defining a 
population of iNOS
+
 CD11c
int
 cells recruited to spleen of a mouse infected by yopM-1 
YopM- Y. pestis (demarcated by the surround). The right panel illustrates where those 
cells mapped in an analysis of that sample for CD11b
+
 cells. Panel B compares the 
relative numbers of iNOS
+
CD11b
+
CD11c
int
 cells in spleens of mice infected with parent 
strain KIM5 (P, filled bars) and yopM-1 strain KIM5-3002 (M, open bars) Y. pestis. 
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Each datum point represents the average of values from 6 mice.  The error bars indicate 
the standard deviations. Significant differences by the unpaired Student’s t test comparing 
data from mice infected with the parent and mutant strains are indicated (*, P < 0.05; **, 
P < 0.01). 
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Day 0 
Infect the C57 BL/6 
mice IV with 400 
CFU/mouse yopM-1 
mutant KIM5-3002 or 
KIM5 
Day 2, 3, 4 and 5 p.i. 
Kill the mice humanely and 
harvest the spleens and 
livers for flow cytometric 
analysis 
Figure 8.9 iNOS-producing CD11c
int
CD11b
+
 iDCs preferentially recruited to spleens 
infected with yopM-1 Y. pestis KIM5-3002. 
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B 
 
 
 
 
 
 
 
 
 
 
  
C57BL/6 mice were infected as described in Panel A and analyzed for inflammatory 
leukocyte populations in livers and spleens. Timecourses of changes in populations of 
iDCs in spleens and livers during infection with parent (KIM5, filled circles) and yopM-
1 mutant Y. pestis (KIM5-3002, open circles). PMNs (Ly6G
+
 cells) were gated out, and 
the remaining live cells were evaluated for presence of iDCs (CD11b
+
 CD11c
low-int
).  The 
point at time 0 indicates the value for uninfected mice. Each datum point represents the 
average of values from 20 mice. The error bars indicate the standard deviations. 
Significant differences by the unpaired Student’s t test comparing data from mice infected 
with the parent and mutant strains are indicated (*, P < 0.05; **, P < 0.01). 
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Day 0 
Infect the C57 BL/6 
mice and CCR2-/- mice 
IV with 400 CFU/mouse 
yopM-1 mutant KIM5-
3002 or KIM5 
Day 3 p.i. 
Kill the mice humanely and 
harvest the spleens and 
livers for flow cytometric 
analysis  
Figure 8.10 CCR2-dependence of iDC recruitment. 
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WT and CCR2-/- C57BL/6 mice were infected with parent and yopM-1 Y. pestis and 
analyzed for iDCs in spleens and livers on d 3 p.i..  Horizontally striped bars, uninfected 
mice (U).  Filled bars, WT mice infected with parent Y. pestis KIM5 (P/WT); open bars, 
WT mice infected with the yopM-1 mutant KIM5-3002 (M/WT); cross-hatched bars, 
CCR2-/- mice infected with the parent strain KIM5 (P/CCR2
-/-
); diagonally-hatched bars, 
CCR2-/- mice infected with the yopM-1 strain KIM5-3002 (M/CCR2-/-).  Each datum 
point represents the average of values from 19 mice. The error bars indicate the standard 
deviations. To compare WT and CCR2-/- groups for mice infected with Y. pestis KIM5-
3002, †, P < 0.05; ††, P < 0.01; for mice infected with Y. pestis KIM5, #, P < 0.05; ##, P < 
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0.01. In comparisons between groups of mice infected with Y. pestis KIM5 and KIM5-
3002, *, P < 0.05; **, P < 0.01 for WT mice; δ, P < 0.05;, δδ, P < 0.01 for CCR2-/- mice, 
if there was any. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 167 
Figure 8.11 Lack of dependence on PMNs of iDC recruitment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C57BL/6 mice treated with anti-Ly6G antibody to ablate PMNs or mock-treated with 
nonspecific rat IgG were infected and analyzed as in Figure 7.5A for populations of iDCs 
in spleens and livers on days 2 and 3 p.i.. Filled bars, mock-treated mice infected with 
parent Y. pestis KIM5 (MP); open bars, mock-treated mice infected with the yopM-1 
mutant KIM5-3002 (MM); cross-hatched bars, PMN-ablated mice infected with the 
parent strain KIM5 (AP); diagonally-hatched bars, PMN-ablated mice infected with the 
yopM-1 strain KIM5-3002 (AM). Each datum point represents the average of values 
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from 6 mice. The error bars indicate the standard deviations. To compare PMN-ablated 
and mock ablation groups for mice infected with Y. pestis KIM5-3002, †, P < 0.05; ††, P 
< 0.01; for mice infected with Y. pestis KIM5, #, P < 0.05; ##, P < 0.01. In comparisons 
between groups of mice infected with strains KIM5 and KIM5-3002, *, P < 0.05; **, P < 
0.01 for mock-treated mice; δ, P < 0.05;, δδ, P < 0.01 for PMN-ablated mice. 
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Figure 8.12 Trans complementation of the yopM-1 mutant in spleen but not in liver. 
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Day 0 
Infect the C57 BL/6 mice IV with 
one of the following (5000 CFU of 
each strain/mouse): 
KIM5-3002, KIM5-3003, 1:1 
mixture 
Day 2, 3 and 4 p.i. 
Kill the mice humanely and 
harvest the spleens and livers 
for plating 
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C57BL/6 mice were infected IV with 5 x 10
3
 lacZ Y. pestis KIM5-3003 (parent strain 
with intact yopM gene) and yopM-1 mutant Y. pestis KIM5-3002 separately or as a 1:1 
mixture (Panel A, experimental design) and analyzed for CFU in spleen and liver on days 
2, 3 and 4 p.i.. Panel B, photo of representative plate of 1:1 mixture. White colonies, 
lacZ strain KIM5-3003; blue colonies, yopM-1 strain KIM5-3002. Panel C, CFUs in 
spleens and livers. Filled circles and solid lines, mice infected with the parent strain 
lacZ KIM5-3003 (P); open circles and solid lines, mice infected with the yopM-1 
strain KIM5-3002 (M); filled triangles and dotted line, parent strain KIM5-3003 CFU 
from mice infected with the mixture (Mix-P); open triangles and dashed lines, yopM-1 
mutant CFU from mice infected with the mixture (Mix-M).  The points at time 0 
represent the doses given to the mice. Each datum point represents the average of values 
from 8 mice. To compare mice infected with Mix-P and P, , P < 0.05; , P < 0.01; for 
mice infected with Mix-M and M, , P < 0.05; , P < 0.01. In comparisons between 
mice infected with M and P, *, P < 0.05; **, P < 0.01; between mice infected with Mix-M 
and Mix-P; , P < 0.05;, , P < 0.01.  
 
 
 
 
 
 
 
Copyright © Zhan Ye 2010 
 171 
RESULTS 
Chapter Nine: the growth limitation of yopM-1 strain and YopM-mediated 
modulation in host defense were maintained in the infection with pre-induced Y. 
pestis, although the loss of YopM were compensated in spleen at early stage of 
infection by a pre-induction stimulated virulence mechanism 
 
In most of the experiments described so far, we used Y. pestis cultured at 26°C to 
infect the mice. This is an appropriate choice for the bubonic plague model because Y. 
pestis in natural bubonic plague grows at ambient temperature in the flea gut.  
The systemic plague model affords the use of a wide range of well-developed 
techniques for obtaining and characterizing the host response in reticuloendothelial 
organs after infection, and we used 26°C-grown Yersinia pestis in this model to develop a 
hypothesis for the innate defense that might also operate in skin to selectively control 
growth of yopM-1 Y. pestis in bubonic plague. 
However, natural systemic plague occurs usually secondarily to bubonic plague, 
which means the bacteria infecting liver and spleen have adapted to the internal 
environment in the mammalian host. At 37°C, the body temperature of the mammalian 
host, the T3SS of Y. pestis is present on the bacterial surface and Yops are present in the 
bacterial cytoplasm so that the Yops can be delivered into the host cells immediately upon 
contact.  
It takes ca. 3-5 h at 37°C for ambient temperature-grown Y. pestis to become 
phagocytosis-resistant (63), which is equated with synthesis and assembly of the T3SS 
and Yops because this happens prior to the presence of adequate amounts of F1 fibrils, 
 172 
which can block phagocytosis (which takes 5 h at 37°C in an macrophage infection 
model) (89). Therefore, we thought that  26°C-grown Y. pestis will require 3 h within the 
mammal before it can deliver Yops into host cells, and this may be enough time for the 
bacteria to be engulfed by resident macrophages (and grow) and by early responding 
PMNs (and be killed). We wanted to compare findings from a more realistic systemic 
plague model using 26/37°C-grown bacteria to those described so far. The 26/37°C Y. 
pestis would be able to deliver Yops and would not be coated with F1, which makes 
interactions with cells less efficient. The prediction was that these bacteria would slow 
Yops-dependent effect in infection because they would by pass the initial round of 
intracellular growth. We hoped that we might even be able to identify YopM-related 
effects much earlier in infection than previously possible and characterize YopM’s initial, 
direct effects.  
 
A. Three hours pre-induction postponed the appearance of the yopM-1 mutant 
phenotype from day 2 p.i. to day 3 p.i. 
As shown in Figure 3.2B, when mice were infected with a low dose (400 CFU/mouse) 
of bacteria, the viable number of bacteria recovered from mice infected with the parent 
strain was significantly higher than that from mice infected with the yopM-1 Y. pestis by 
d 2 p.i.. To test whether this pattern began earlier with the pre-induced bacteria, mice 
were infected with 400 CFU/mouse of parent or yopM-1 mutant strains with pre-
induction or not. Spleens and livers were harvested on d 2 and d 3 p.i. for bacterial load 
measurement and flow cytometric analysis (Figure 9.1A). Although the growth limitation 
of yopM-1 Y. pestis still existed when these bacteria had been pre-induced, a significant 
 173 
difference between parent and mutant strains in bacterial burden of spleen appeared one 
day later than in the infection with non-induced bacteria, from d 2 p.i. to d 3 p.i. (Figure 
9.1B, upper panels). However, the growth dynamic of both strains in liver was not 
affected by the pre-induction (Figure 9.1B, bottom panels).  
 
B. The YopM-associated MDM and iDC influx was delayed in 26/37 Y. pestis 
infected spleen  
In chapter 8G, iDCs, one of the major subsets of MDMs, were found to be the key 
cell type to control the the growth of the yopM-1 Y. pestis in spleen. Therefore, we 
hypothesized that the virulence property of Y. pestis induced by pre-induction may 
compensate for the loss of YopM in the yopM-1 Y. pestis at the early stage of infection 
by delaying the recruitment of iDCs into spleen.  
To test this hypothesis, the leukocytes from experiments in Figure 9.1A were also 
studied by flow cytometry. We predicted that the recruitment of iDCs and MDMs into 
spleen by the yopM-1 mutant would be delayed in the mice infected with the pre-
induced Y. pestis. Indeed, we found the influx of MDMs and iDCs into the spleen of mice 
infected with pre-induced or non-induced yopM-1 Y. pestis exhibited a pattern that 
paralleled the ability of the host to control the bacterial growth (Figure 9.1C and D).  As 
shown in the bottom panels of Figure 9.1C, pre-induction may help to recruit more 
MDMs into liver. However, this effect was so small that it is hardly worth mentioning, 
and YopM still had no effect on the recruitment of these cells into liver, whether or not 
the infecting bacteria had undergone pre-induction. 
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The influx of PMNs into spleens and livers was also studied in these experiments 
because PMNs were shown to be the major cells controlling yopM-1 Y. pestis in liver. 
Here the data showed that the influx of PMNs into both organs was independent of 
YopM and pre-induction of the infecting bacteria did not change this pattern (Figure 
9.1E). These findings are consistent with the results obtained so far that YopM does not 
influence the recruitment of PMNs. 
 
C. LD50 of 26/37°C yopM-1 Y. pestis was lower than that of 26C yopM-1 
mutant 
Since pre-induction of the infecting bacteria delayed the appearance of the growth 
limitation on yopM-1 Y. pestis and of the influx of MDMs and iDCs into spleen, it could 
affect the virulence of this strain in the systemic plague model, which can be measured by 
lethality (LD50). As described previously, serial dilutions of pre-induced yopM-1 mutant 
Y. pestis were injected IV into C57BL/6 mice and those mice were observed closely for 2 
weeks. The actual doses were determined by plating dilutions of the infecting 
suspensions and the death of mice was recorded. Through the software Biostat, we 
derived the LD50 of the pre-induced yopM-1
 
mutant (26ºC, table 3.1). Compared to the 
known LD50 of the non-induced yopM-1
 
mutant strain (26/37ºC, table 3.1), we found 
that pre-induction decreased the LD50 of the yopM-1
 
mutant by 4 fold. These values 
indicate that although pre-induction does compensate for the growth defect of the 
yopM-1 mutant at the early stage of infection, the effect of this process on the lethality 
of this bacterium in mice is very limited.  
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D. Pre-induction did not change the effect of anti-Ly6G treatment on the growth 
of the yopM-1 mutant and parent strain in spleen and liver 
 In chapter 7, we concluded that PMNs were essential for controlling the yopM-1 
mutant in liver, but not in spleen, if the infecting bacteria were cultured at ambient 
temperature. However, it was possible that PMNs had an indirect effect, such as 
mediating the recruitment of bactericidal monocytes (305), in controlling the yopM-1 Y. 
pestis in spleen but this effect failed to be detected due to the YopM’s early and strong 
effect on the influx of MDMs and iDCs.  
 In the infection by ambient-temperature-grown bacteria, the YopM-associated 
difference in iDC influx appeared on d 2 p.i.. However, this difference was delayed for at 
least one day when the infecting bacteria received 3 h pre-induction. Therefore, if there 
was any indirect effect of PMNs in controlling the yopM-1 Y. pestis, it may appear in 
the infection by pre-induced bacteria. To test this hypothesis, we ablated PMNs from the 
mice infected with the pre-induced Y. pestis. 
 The experimental design (Figure 9.2A) was the same as described in Figure 7.5A 
except that the infecting bacteria were pre-induced. As shown in Figure 9.2B, anti-Ly6G 
treatment maintained Ly6G
+
CD11b
+
 PMNs at very low levels on d 2 and 3 p.i.. Similarly 
to the CFU data on spleen for non-ablated mice (Figure 9.1B), the appearance of the 
growth defect of the yopM-1 mutant in spleen was postponed to d 3 p.i. by pre-induction, 
and anti-Ly6G treatment did not change this pattern, although both of the strains grew 
better in PMN-ablated mice on d 2 p.i. than in mock-treated mice (Figure 9.2C, upper 
panels). However, PMN ablation favored the growth in liver of both of the strains, 
especially the yopM-1 mutant, and eventually relieved the growth limitation on the 
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yopM-1 mutant on d 3 p.i.. These results further supported the conclusion that PMNs are 
not the major immune cells that control the yopM-1 mutant in spleen, even if the 
infecting bacteria are able to inject YopM into the host cells when they first contact those 
cells.    
 
E. When infected with pre-induced Y. pestis, CCR2 KO still prevented the influx 
of MDMs into spleen and liver and specifically favored the growth of the yopM-1 
mutant in spleen but both strains in liver 
The yopM-1 mutant strain had been shown to grow uncontrolled in the spleen of 
CCR2
-/-
 mice (Figure 8.5D), correlating with the defective recruitment of MDMs to 
spleen (Figure 8.5B). However, the above data were gained from mice infected with non-
induced bacteria. Pre-induction of infecting bacteria stimulated some Y. pestis virulence 
property to selectively favor the growth of yopM-1 mutant in spleen (Figure 9.1B), 
accompanied with a delayed influx of CCR2
+
 iDCs into spleen (Figure 9.1D). Therefore, 
the infection of CCR2
-/-
 mice with pre-induced bacteria was studied to see whether the 
uncontrolled growth of the yopM-1 mutant in spleen and liver, which occurred on d 3 p.i. 
in the infection of non-induced bacteria, could be reproduced. 
As described in Figure 9.3A, CCR2
-/-
 mice and C57BL/6 mice were IV-infected with 
pre-induced parent strain and yopM-1 mutant Y. pestis. On d 3 p.i., spleens and livers 
were harvested to study leukocytes and bacterial burden. The influx of Ly6G
-
CD11b
+
 
MDMs into both spleen and liver was inhibited in CCR2 KO mice. This was especially 
striking in the yopM-1 mutant-infected spleen where this effect abolished the significant 
difference between two strains in CCR2
-/-
 mice (Figure 9.3B). The correlation between 
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compromised recruitment of MDMs and the uncontrolled growth of the yopM-1 mutant 
in spleen (Figure 9.3D) is similar to that in the infection with non-induced bacteria 
(Figure 8.5 B and D). Therefore, the role of CCR2
+
 MDMs in clearance of yopM-1 
mutant is independent from the pre-induction of the infecting bacteria. 
Similar to the infection with non-induced bacteria (Figure 8.5), the impact of the 
CCR2 KO on the MDM influx into liver was also not YopM-associated in the infection 
with pre-induced Y. pestis (Figure 9.3 B, right panel). The growth limitation of the 
yopM-1 mutant was kept in CCR2-/- mice whether the infecting bacteria were pre-
induced or not (Figure 9.3D and Figure 8.5D, right panels). However, only the growth of 
the yopM-1 mutant was enhanced significantly by the CCR2 KO in the infection with 
ambient-temperature-grown bacteria (Figure 8.5D, right panel), whereas both of the 
parent and mutant strains grew uncontrolled when the infecting bacteria received 3 h pre-
induction (Figure 9.3D, right panel), indicating that some property of Y. pestis induced 
by pre-induction favored their growth in a YopM-independent manner in the absence of 
CCR2 signaling pathway.  
The only YopM-associated difference in PMN influx appeared in the spleen of CCR2
-
/-
 mice; however, the growth limitation of the yopM-1 mutant was relieved in those 
spleens. This result is consistent with our data from the PMN ablation experiments and 
helped to exclude PMNs from the major cells controlling the yopM-1 mutant in spleen.  
Overall, these findings with pre-induced Y. pestis agreed qualitatively with those 
obtained with 26°C-grown bacteria. However, this infection model failed to provide the 
hoped-for insight on earlier times in infection. Apparently, a property that compensated 
for loss of YopM before d 3 of infection was induced in expression in addition to the 
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T3SS and Yops. This property influenced the infection dynamics most strongly in spleen, 
where it caused a delay in influx of MDMs and a corresponding delay in control over the 
growth of the yopM-1 mutant. 
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Figure 9.1 Effect of 3 hour pre-indcution on infection dynamics for of yopM-1 and 
parent Y. pestis KIM5. 
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E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mice were infected with pre-induced or non-induced yopM-1 (KIM5-3002) and parent Y. 
pestis (KIM5), and analyzed for bacterial burdens and inflammatory leukocyte 
populations in livers and spleens on days 2 and 3 p.i.. Panel A, experimental design. 
Panel B, CFU. Each datum point represents the average of values from 25 mice. Panels C, 
D and E, Ly6G
-
CD11b
+
 MDMs, CD11b
+
CD11c
int
 iDCs and Ly6G
+
CD11b
+
 PMNs 
expressed as percent of total live leukocytes from spleen and liver, respectively. Each 
datum point represents the average of values from 8 mice (pooled from two experiments). 
The error bars indicate the standard deviations. Filled bars, mice infected with parent Y. 
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pestis KIM5 (P); open bars, mice infected with the yopM-1 mutant KIM5-3002 (M). 
26C and 26/37 in the horizontal axis indicate the growth conditions of the infecting 
bacteria, non-induced and pre-induced, respectively. To compare mice infected with non-
induced and pre-induced yopM-1Y. pestis KIM5-3002, θ, P < 0.05; θθ, P < 0.01; for 
mice infected with non-induced and pre-induced parent strain KIM5, ω, P < 0.05; ωω, P < 
0.01. In comparisons between groups of mice infected with Y. pestis KIM5 and KIM5-
3002, *, P < 0.05; **, P < 0.01. 
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Day 0 
Infect C57BL/6 
mice IV with 400 
CFU/mouse: 
yopM-1 mutant 
KIM-3002 or KIM5 
 
Day 2 and 3 p.i. 
Kill the mice humanely 
and process the 
spleens and livers for 
CFU (plating)  and 
immune cells (flow 
cytometry)  
Inject the antibody (IP) 
200μg/mouse: 
 
Ablation: IA8 (anti-
Ly6G) 
Mock: Rat-IgG 
 
Repeat the injection 
(100μg/mouse) on Day 
1 p.i. 
Day -1 3 hours before infection 
pre-induced 
yopM-1 mutant 
KIM5-3002 and 
KIM5:  
transfer the culture 
from 26°C to 37°C 
Figure 9.2 Pre-induction of the infecting bacteria does not change the effect of PMN 
ablation on the infection dynamics for Y. pestis. 
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Mice treated with anti-Ly6G antibody to ablate PMNs or mock-treated with nonspecific 
rat IgG were infected with pre-induced Y. pestis and analyzed for bacterial burdens and 
inflammatory leukocyte populations in livers and spleens on days 2 and 3 post-infection 
(p.i.). Horizontal-hatched bars, uninfected mice (U); filled bars, mock-treated mice 
infected with the parent Y. pestis KIM5 (MP); open bars, mock-treated mice infected with 
the yopM-1 mutant KIM5-3002 (MM); cross-hatched bars, PMN-ablated mice infected 
with the parent Y. pestis KIM5 (AP); diagonally-hatched bars, PMN-ablated mice 
infected with the yopM-1 strain KIM5-3002 (AM).  Panel A, experimental design. Panel 
B, Ly6G
+
CD11b
+
 PMNs expressed as percent of total live leukocytes from spleen and 
liver. Panel C, CFU. Each datum point represents the average of values from 6 mice. The 
MMMP AP AM
C
F
U
(l
o
g
)/
S
p
le
e
n
2
3
4
5
6
7

†
MMMP AP AM
2
3
4
5
6
7 

††
C
F
U
(l
o
g
)/
L
iv
e
r
2
3
4
5
6
7
MMMP AP AM


2
3
4
5
6
7
MMMP AP AM

†
 185 
error bars indicate the standard deviations. To compare PMN-ablated and mock ablation 
groups for mice infected with the yopM-1 strain KIM5-3002, †, P < 0.05; ††, P < 0.01; 
for mice infected with the parent strain KIM5, #, P < 0.05; ##, P < 0.01. In comparisons 
between groups of mice infected with Y. pestis KIM5 and KIM5-3002, *, P < 0.05; **, P 
< 0.01 for mock-treated mice; δ, P < 0.05; δδ, P < 0.01 for PMN-ablated mice. 
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Day 0 
Infect C57BL/6 
mice and CCR2-
/- mice IV with 
400 CFU/mouse: 
yopM-1 mutant 
KIM-3002 or 
KIM5 
 
Day 3 p.i. 
Kill the mice 
humanely and 
process the 
spleens and livers 
for CFU (plating) 
and immune cells 
(flow cytometry)  
3 hours before infection 
pre-induced 
yopM-1 mutant 
KIM5-3002 and 
KIM5: transfer the 
culture from 26°C 
to 37°C 
Figure 9.3 Pre-induction of the infecting bacteria changed infection dynamics for Y. 
pestis in the liver but not in the spleen of CCR2
-/-
 mice. 
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WT and CCR2
-/-
 C57BL/6 mice were infected with pre-induced Y. pestis and analyzed for 
bacterial burdens and inflammatory leukocyte populations in livers and spleens on d 3 p.i.. 
Panel A, experimental design. Filled bars, WT mice infected with parent Y. pestis KIM5 
(P/WT); open bars, WT mice infected with the yopM-1 mutant KIM5-3002 (M/WT); 
cross-hatched bars, CCR2
-/-
 mice infected with the parent strain KIM5 (P/CCR2-/-); 
diagonally-hatched bars, CCR2
-/-
 mice infected with the yopM-1strain KIM5-3002 
(M/CCR2-/-). Panel B, Ly6G
-
CD11b
+
 MDMs and Panel C, PMNs (Ly6G
+
CD11b
+
 cells), 
expressed as percent of total live leukocytes. Panel D, CFU. Each datum point for CCR2
-
/-
 and WT represents the average of values from 6 and 12 mice, respectively. The error 
bars indicate the standard deviations.  To compare WT and CCR2
-/-
 mice infected with 
strain KIM5-3002, †, P < 0.05; ††, P < 0.01; for mice infected with Y. pestis KIM5, #, P < 
0.05; ##, P < 0.01. In comparisons between groups of mice infected with strains KIM5 
and KIM5-3002, *, P < 0.05; **, P < 0.01 for WT mice; δ, P < 0.05; δδ, P < 0.01 for 
CCR2-/- mice. 
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Chapter Ten: Discussion 
 
As one of effector Yops, the major virulence factors in Y. pestis, YopM is known to be 
delivered into the nucleus of host cells and presumed to counteract host defenses through 
regulating gene expression in major cellular components in the immune system. However, 
this protein has been refractory to in vitro attempts to identify a phenotype resulting from 
its delivery. In contrast, YopM has a strong virulence phenotype in vivo, in which parent 
Y. pestis KIM5 and the yopM-1 mutant KIM5-3002 show distinct dynamics for viable 
numbers in organs of mice infected systemically. By using the systemic plague model 
which displays the in vivo phenotype of YopM, we studied how YopM modulates the 
host immune defense by identifying the cells that are critical for imposing a growth 
limitation selectively on yopM Y. pestis. These cells would be direct or indirect in vivo 
targets of YopM produced by the infecting parent strain. 
 
A. Recapitulation of the main findings in this work 
Previous in vivo studies done in our laboratory excluded the importance of the 
adaptive immune system in the YopM virulence mechanism and revealed a YopM-
associated depletion of NK cells from the spleen and blood accompanied by decreased 
production of several proinflammatory cytokines (159). However, in the present study the 
absence of NK cells in mice exerted no influence on growth of either the parent Y. pestis 
or the yopM mutant strain, and YopM did not cause NK cells to be depleted in liver. In 
contrast, ablation of Gr1
+ 
cells significantly relieved the growth defect of the yopM 
mutant in both spleen and liver, and the mutant and parent strains caused similar necrotic 
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lesions in livers of Gr1-depleted mice. These findings pointed toward Gr1
+
 cells, which 
include PMNs and MDMs (macrophages/monocytes/DCs), as the true cellular targets of 
YopM in vivo, instead of NK cells. 
However, YopM in the infecting bacteria had no effect on the recruitment of PMNs 
into organs, or ROS and NO production by splenic or peritoneal PMNs. Further, ablation 
of PMNs from Y. pestis-infected mice relieved the growth limitation of the yopM 
mutant only in liver, instead of both spleen and liver, indicating that YopM modulates the 
immune responses differently in spleen and liver, and PMNs are the major cell type 
counteracted by YopM in liver but not in spleen.  
In addition to the different effects of YopM on the accumulation of NK cells in spleen 
and liver, we also found that YopM compromised recruitment of MDMs into the spleen, 
but not in liver. The greater recruitment of splenic MDMs in mice infected with the 
yopM mutant disappeared when the mice were treated with anti-Gr1 antibody, 
accompanied by uncontrolled growth of the yopM mutant in spleen. Therefore Gr1+ 
cells (potentially inflammatory monocytes and inflammatory DCs) became promising 
candidates modulated by YopM to favor bacterial growth in spleen.  
Clodronate treatment, which depleted both resident macrophages/DCs as well as 
circulating monocytes from mice (4, 321), compromised the growth of both parent and 
mutant strains in the mice, but the growth limitation of the yopM-1 mutant was 
maintained. Therefore the clodronate-sensitive resident macrophages/DCs could act as a 
niche to protect both the parent and mutant strains from the immune attack, whereas the 
MDMs resistant to clodronate may be responsible for the maintenance of growth 
limitation of the yopM-1 mutant. 
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However, the growth limitation of the yopM mutant was relieved in spleen and liver 
of mice lacking CCR2, the receptor recognizing CCL2/MCP-1 and mediating the 
recruitment of inflammatory monocytes and TipDCs (151), indicating that CCR2
+
 Gr1
+
 
inflammatory monocytes and DCs are critical for the control of the yopM mutant in 
spleen. Meanwhile, studies of the distribution of these cells in bone marrow, blood and 
spleen showed that YopM inhibited their recruitment at the level of infiltration from 
blood into spleen. Further, the uncontrolled growth of the yopM mutant in the liver of 
CCR2
-/-
 mice could be explained by a compromised function of PMNs because PMNs are 
also Gr1
+
CCR2
+
 and their differentiation and adherence are enhanced by CCR2 (144, 
262). This finding is consistent with the PMN ablation data in liver. In the bubonic 
plague model, in which YopM is also necessary for the full virulence of Y. pestis, absence 
of CCR2 in mice relieved the growth limitation of the yopM mutant in skin at an early 
stage of infection, indicating that YopM’s capacity to disable host defenses in skin is 
mediated by CCR2.  
A model with different innate immune cell types modulated by YopM in spleen and 
liver was supported further by the outcome of co-infection experiment of the parent and 
yopM mutant strains. The growth defect of the yopM mutant was relieved in the spleen, 
but not in liver, of the mice infected with the mixture of the two strains, because YopM in 
the parent Y. pestis protected both strains in spleen despite inhibiting the influx of iDCs 
into the whole spleen. In livers, however, the parent strain favored only its own growth 
by compromising the function of immediately adjacent PMNs. 
In most of the experiments in this study, the infecting bacteria were grown at a 
temperature mimicking that in the flea gut (26ºC). However, when the bacteria received 3 
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hours of pre-induction at mammalian temperature (37ºC), an unexpected delay in the 
appearance of the growth defect of the yopM mutant strain as well as the attenuated 
virulence of this mutant were found, accompanied by postponed yopM-associated influx 
of inflammatory monocytes and iDC into spleen. These findings supported further the 
importance of these cells in the YopM mechanism in spleen, without changing the model 
for 26ºC grown bacteria, because the effects of PMN ablation and CCR2 KO on the 
infection of pre-induced bacteria were the same as those of non-induced Y. pestis. 
In conclusion, CCR2
+
Gr1
+
 PMNs and CCR2
+
Gr1
+
 inflammatory monocytes/DCs 
were identified as the major cell types affected by YopM in spleen and liver, respectively, 
in the systemic plague model. Meanwhile, signals mediated by the chemokine receptor 
CCR2 are critical in YopM-mediated virulence in both systemic and bubonic plague. 
Thus, these findings provide a framework for focusing future research to identify the 
direct molecular targets of YopM.  
 
B. The adaptive immune system is not critical in the YopM virulence mechanism 
There is in vitro evidence that Y. pestis can inhibit T cell activation and induce 
apoptosis of T cells, probably through YopH, an effector Yop with tyrosine phosphatase 
activity (6, 52). Meanwhile, in vivo studies showed the possible importance of T cells in 
the defense against Y. pestis (239, 247). Serum collected from mice inoculated IP
 
showed 
protective function against plague in mice (240); and two major immunogenic proteins, 
F1 antigen and LcrV, were shown to provide a high degree of protection in small animal 
models (11, 184, 227), which indicates that
 
antibodies secreted by plasma cells play an 
important role against Y. pestis.
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In previous work done in our lab, infection in lymphocyte-deficient SCID mice 
(C57BL/6 background) were compared to that in WT mice to determine whether YopM 
functions primarily at the level of the adaptive immune system or on innate immune 
defenses (159). After infection with a low dose (100CFU) of either KIM5 or yopM-1 Y. 
pestis, SCID and C57BL/6 mice displayed similar patterns of bacterial burden in both 
spleen and liver (159) (Figure 10.1), as well as similar histopathological manifestations in 
liver until day 4 p.i. (159), indicating that YopM only counteracts innate immunity at the 
early stage of infection. However, after day 4 p.i. the number of yopM-1 Y. pestis 
remained at high levels in the liver and declined slightly in the spleen of SCID mice, 
whereas yopM-1 Y. pestis were cleared in C57BL/6 mice by day 10. Both of the mouse 
strains infected with parent strain Y. pestis were killed by day 5 p.i., and no differences 
were found between the two mouse strains (159) (Figure 10.1). Therefore, the adaptive 
immune response is only required for efficient clearance of the yopM-1 mutant beyond 
day 4 p.i.. The presence of YopM in the KIM5 strain renders the infecting bacteria fully 
virulent to kill the mice before the adaptive immune system exhibits the ability to clear Y. 
pestis. Thus, the modulation of the immune response by YopM must occur at the early 
phase of the infection and the innate immune system would be the primary target of 
YopM.  
 
C. YopM does not modulate innate immune responses through NK cells 
a) NK cell function and previous model about the role of NK cells in YopM-
mediated immune modulation 
When our lab initially tried to identify the innate immune cell types that may be 
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affected by YopM, a YopM-associated depletion of NK cells from spleen and blood of 
mice infected IV was found by flow cytometric analysis (159). NK1.1
+
 cells were 
depleted dramatically from day 3 p.i. in spleen from mice infected with Y. pestis KIM5, 
but not in mice infected with the yopM-1 mutant. Staining with another pan-NK marker, 
CD49b, similarly showed YopM-associated depletion. Meanwhile, staining of blood 
leukocytes showed that the percentage of NK1.1
+
_ lymphocytes was reduced 5-fold at day 
5 p.i. in mice infected with parent strain KIM5, while no change in NK cell percentage 
was found in mice infected with the yopM-1 mutant. Further, the mice infected with a Y. 
pestis strain lacking another major effector Yop, YopH, displayed the same depression of 
NK cell numbers that was seen in mice infected with the parent strain KIM5. Therefore, 
it is YopM, not other effector Yops, in the infecting Y. pestis that causes a systemic 
reduction in NK cells during infection, instead of a localized inhibition of the infiltration 
of NK cells into spleen. 
As one of the major cell types to form the first line of defense against infection, NK 
cells function as an interface between the innate and adaptive immune systems. They 
originate in the bone marrow and are derived from the same lymphoid progenitor as T 
and B cells. They comprise 5–10% of the lymphocyte population in the blood, spleen and 
liver (189).  
There are two sets of cytokines that induce the proliferation and activation of NK 
cells. The first set is IL-2 and IL-15. It was believed that both of IL-2 (127) and IL-15 
(216, 355) were critical for NK development. However, studies on mice lacking the IL-
2R γ-chain, which is shared by the IL-2R and IL-15R, and on IL-2 KO mice showed that 
IL-15, but not IL-2, played the critical role in NK cell development (88, 166). Meanwhile, 
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differentiation of bone-marrow-derived precursors of murine uterine NK (uNK) cells into 
mature cells, which expressed NK surface markers and effector molecules, was found to 
depend on IL-15, instead of IL-2 (362).  
Another set of cytokines related to NK cell proliferation includes IL-12 and IL-18, for 
which importance was proven by the impaired NK cell activity in IL-18 and IL-12 KO 
mice (327). In addition to a strong synergistic proliferation and activation of NK cells 
induced by IL-12 and IL-18, three major differences in NK development between IL-
12/IL-18 and IL-2/IL-15 treatment were also found (176). As shown in Table 10.1, 
IL2/IL15 treatment induced the proliferation of both NK and NKT cells, as well as the 
expression of NK1.1 on the cell surface. However, although IL-12/IL-18 treatment failed 
to induce differentiation of NKT cells and expression of NK1.1, it did stimulate the 
production of cytokines, such as IFN-γ, IL-3, IL-6 and TNF, which were absent in 
IL2/IL15 treatment (176). NK cells derived in response to IL-12/IL-18 were much more 
cytotoxic than NK cells grown in IL-2 or IL-15, which may be explained by a Fas-
independent pathway in the first NK cell group (175). 
Current theory about the activation of NK cells is the “missing-self” hypothesis: NK 
cells are activated when their potential target cells have downregulated MHC-I as well as 
some abnormal surface molecules, which frequently happens in cells infected with certain 
viruses (156, 189). That means that NK cells use two sets of cell surface receptors, 
inhibitory and activating receptors, to distinguish between normal healthy cells and 
abnormal cells and control their activation, proliferation, and effector functions. 
Inhibitory receptors, whose ligand is self-MHC class I on potential targets, function to 
inhibit the activation of NK cells. These receptors include Ly49 receptors (rodent), killer 
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cell immunoglobulin-like receptors (KIR, human), and conserved heterodimers of the 
CD94/NKG2 receptor family (expressed by both species) (128). Activating receptors, 
whose function is to activate NK cells, are more diverse than inhibitory receptors. The 
best studied activating receptor, NKG2D, recognizes MHC-I-like surface glycoproteins, 
most of which are not encoded by genes in the MHC complex and do not function as 
peptide-binding structures for the presentation of antigens (260). Other activating 
receptors such as the NKR-P1 Receptors, CD244 and CD226, whose ligands are not 
MHC related, cannot directly trigger cytotoxicity and cytokine production but appear to 
function primarily as “costimulatory” receptors or to overcome the inhibitory NK cell 
receptors (189, 225).  
After being activated, NK cells share a common killing mechanism with CTL (i.e., 
using perforin and granzymes) to lyse infected cells directly, as well as secrete many 
cytokines, such as IFN-γ, which can activate macrophages (189). The previous studies 
about production of proinflammatory cytokines in our lab also pointed toward NK cells 
as the major target of YopM (159). mRNA expression of the pro-inflammatory and Th1 
cytokines IL-1β, IL-6, TNF-α, IFN-γ, IL-12 and IL-18, especially the last two, in spleen 
as early as d 2 p.i. was compromised by YopM in the infecting bacteria. This was a direct 
effect on expression, as opposed to being an indirect effect of increased expression of 
suppressive Th2 cytokines such as IL-10 and IL-4, which in fact were not detectable until 
d 4 p.i.. Expression of mRNA for these cytokines in purified splenic F4/80
+
 macrophages 
and monocytes (IL-1β, IL-6, TNF-α, IL-12 and IL-18) and NK cells (IFN-γ only) showed 
a pattern similar to that in the whole spleen, indicating that YopM was modulating 
immune function early in infection and that macrophages and monocytes as well as NK 
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cells were important sources for the observed changes in whole spleen. Meanwhile, the 
levels of IL-15 mRNA in purified F4/80
+
 macrophages/monocytes and IL-15R mRNA in 
purified NK1.1
+
 NK cells were much lower in mice infected by Y. pestis KIM5 than ones 
infected by the yopM-1 mutant. Therefore, YopM could inhibit the proliferation of both 
NK and NKT cells, as well as their functions in cytotoxicity and cytokine production. 
And lacking the signal from NK cell-secreted IFN-γ, macrophages failed to be fully 
activated, and the growth of the YopM containing Y. pestis would be unchecked (Figure 
10.2) (159). 
 
b) NK cell ablation did not relieve the growth defect of the yopM-1 mutant 
If the above hypothesis reflects the true role of NK cells in the YopM mechanism, the 
growth limitation of the yopM-1 mutant should be relieved if NK cells are depleted 
from the infected mice. There are two traditional antibodies to deplete NK cell in vivo, 
anti-NK1.1 (PK136) and anti-asialo-GM1 (157, 158), which are usually used to ablate 
NK cells from NK1.1 expressing mouse strain such as C57BL/6 mice and other mice 
strains, respectively.  
As described in Table 10.1, NK cells induced by IL-12/IL-18 express no NK1.1 as 
well as produce large amount of IFN-γ; and the IL-2 or IL-15-induced NK cells act in the 
opposite way. These observations raised a concern that the anti-NK1.1 susceptible 
NK1.1
+
 cells were not responsible for the IFN-γ production on days 2-4 of infection by 
the yopM Y. pestis, and thus not important in the YopM virulence mechanism. However, 
the above results about cytokine-induced NK cell development came from in vitro 
cytokine-treated splenocytes, and the failure in expression of IFN-γ by those IL2/IL-15 
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induced NK1.1
+
 cells could be due to the absence of stimulation from activating receptor 
ligands (175, 176). Meanwhile, there is
 
compelling evidence from anti-NK1.1 mediated 
NK depletion  that NK1.1
+
 cells play a central role in early
 
IFN-γ synthesis in response to 
infection by a number of protozoal and
 
bacterial pathogens (83, 90, 172), and purified 
splenic NK1.1
+
 cells show robust production of IFN-γ after anti-NK1.1 treatment (14).  
Since it is reported that a freshly isolated murine spleen CD8+ T cell population  
contains 20% to 30% asialo-GM1
+
 cells, which were distinct from asialo-GM1
+
 NK1.1
+ 
NK cells (179), we utilized anti-NK1.1 to deplete NK cells in our experiments. Actually, 
our preliminary experiments showed that both anti-NK1.1 (PK136) and anti-asialo-GM1 
displayed similar ability to ablate NK cells (data not shown). However, although 90% of 
the NK1.1
+
 NK cells were depleted from spleen and liver, anti-NK1.1 antibody treatment 
in the present study failed to cause any change in the bacterial growth and 
histopathological appearance in infections by either strain until day 5 p.i. (Figure 4.3). 
 
c) YopM depletes traditional splenic NK cells, but not hepatic NK cells or NKT 
cells in either organs 
This unexpected result made us check our model again. In previous work, we used 
anti-NK1.1 to stain NK cells as a single cell type. However, NK cells contain several 
subgroups which may have different functions and YopM may not affect all of them. To 
address this issue, we used three antibodies to define NK subgroups. NK1.1 or NKR-P1C 
(natural killer cell receptor P1C) is a type II transmembrane C-type lectin receptor 
belonging to the family of activating NK receptors (112, 277) and is only expressed by 
some mouse strains, including C57BL/6 (292). The antigen recognized by mAb DX5 is 
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CD49b (15), belonging to α2 integrin, which is known to bind to collagen or laminin 
(249). DX5 is a useful reagent because it stains NK cells from all mouse strains examined; 
however, the cells detected by DX5 include a small group of T cells (224), which are not 
NKT cells (243). Therefore, DX5 is only used as a supplemental antibody in the 
identification of NK cells in this study. The third antibody was anti-CD3, which is not 
specific for NK cell detection. Always associating with the TCR, CD3 is a member of a 
complex comprised of 5 proteins, which transduce activation signals to the cell following 
antigen interaction with the TCR. This surface marker was used to define a subgroup of 
NK cells, NKT cells. NKT cells are narrowly defined as a T cell lineage expressing NK 
lineage receptors, including NK1.1 in the C57BL/6 background, in addition to semi-
invariant (Vα14-Jα18) CD1d-restricted αβ TCRs (34, 113). The traditional way to define 
NKT cells is that they are CD3
+
NK1.1
+
 (or DX5
+
) cells (175) and the newest definition is 
that they are CD1d-dependent and Vα14-Jα18+ (NK1.1+ or NK1.1-)CD3+ cells (113). 
Upon stimulation, NK1.1
+
 NKT cells express high levels of IFN-γ and TNF, some IL-4, 
IL-13, granulocyte–macrophage colony-stimulating factor (GM-CSF) and IL-2; whereas 
NK1.1
-
 NKT cells produce higher levels of IL-4 and lower levels of IFN-γ than their 
NK1.1
+ 
counterparts (113). In our study, a simple combination of CD3 and NK1.1 
markers was used to define NKT cells, i.e., as NK1.1
+
CD3
+ 
cells, because IFN-γ 
producing NK1.1
+
 NKT cells were our interest in defense against Y. pestis, and mCD1d-
PBS57
+
 cells were mainly CD3
+
NK1.1
+
 in our study (Figure 4.1B).  Our studies of the 
effects of YopM on the subgroups of NK cells in spleen showed that YopM only depleted 
NK1.1
+
CD3
-
 cells, but had no effect on the NK1.1
-
DX5
+ 
cells or NKT cells, which would 
remain as potentially a great source of IFN-γ in the infection.  
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Our previous work had mainly analyzed immune cell populations in spleen. However, 
liver is the other organ predominantly infected in the first 3 days of systemic plague, and 
growth dynamics in liver for Y. pestis are similar to those in spleen despite the distinct 
immune microenvironments in these two organs. For example, liver, more than spleen, is 
a focus for immune surveillance by NKT cells, which can release IL-4 explosively and 
other key Th2 cytokines such as IL-13, in addition to massive amounts of IFN-γ, as 
described previously (34, 113, 219). In our previous study (159), we had not evaluated 
leukocyte population dynamics in liver, due to the difficulty of separating leukocytes 
from hepatocytes. In this work, we combined and modified protocols originally 
developed for obtaining leukocytes from colon (257) to obtain high-purity preparations of 
leukocytes from liver, and these were analyzed by flow cytometry alongside leukocytes 
from spleen in mice infected with Y. pestis KIM5 or KIM5-3002. Several tissue-specific 
changes were found. Contrary to the depletion of NK1.1
+
CD3
-
 NK cells in spleen by 
YopM-containing Y. pestis, there was little to no depletion of either classic NK cells 
(NK1.1
+
 CD3
-
) or NKT cells in liver of mice infected by either the parent or yopM-1 Y. 
pestis strains. This finding indicated that the virulence effect of YopM in liver was not 
manifested as a net loss of NK cells but did not rule out the possibility that these cells 
were lost and rapidly replenished. Combined with the results from NK cell ablation 
experiments, we concluded that NK cells are redundant for YopM’s pathogenic 
mechanism or that NK cell depletion by YopM is an irrelevant secondary effect of YopM.    
 
D. YopM affects the dynamics of DCs in both spleen and liver, but does not 
compromise host defense through DCs 
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We next examined populations of DCs for changes that might correlate with YopM’s 
effect on bacterial growth, because of the well-established frontline surveillance function 
of DCs for invading microorganisms or microbial products (24). It was reported that 
human monocytes could differentiate into mature DCs, which expressed IFN-α and 
stimulated cytotoxic T cell responses, after in vitro infection with Y. pestis strain CO92 
(pgm pla) (279). There is evidence that Y. pestis selectively engages macrophages, 
DCs and PMNs for Yops injection through the T3SS (197), and the migration of DCs to 
draining lymph nodes is inhibited when the infecting Y. pestis strain contains the Yops-
encoding virulence plasmid (347).  
We monitored the numbers of all major subgroups of DCs in mice infected by the 
parent or the yopM-1 Y. pestis. There are at least three subtypes of DCs in mouse spleen: 
CD8
+
DCs (lymphoid DCs), CD11b
+
DCs (myeloid DCs, mDCs), and B220
+
DCs (pDCs) 
(16, 299). Although it was believed that CD8
+
DCs derived from lymphoid-restricted 
precursors, and all CD8
−
DCs derived from myeloid-restricted precursors, recent evidence 
showed that both precursors could produce all the mature splenic and thymic DC 
subtypes (299). The distribution, development and function in innate immunity of the 
three subsets are listed in Table 10.2.  
In spleen, only the numbers of CD8
+
 DCs displayed a YopM-specific change, 
decreasing 4-fold by d 4 p.i.. These DCs are located in the T cell area, where they can 
internalize apoptotic cells, selectively present antigens to both CD4
+
 and CD8
+
 T cells, 
and elicit a Th-1 response through production of IL-12 and IFN-gamma (16, 147). In liver, 
all three subgroups of DCs decreased in numbers when the infecting Y. pestis strain 
contained YopM. However, the YopM-related changes in numbers of CD8
+ 
DCs in spleen 
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or DCs in liver only became significant relatively late in infection (d 4 to 5 p.i.) compared 
to the time when the growth difference between the two Y. pestis strains was significant 
(d 2 or 3 p.i.). Meanwhile, the mean fluorescence intensity (MFI) of CD86 and MHC-II, 
two major DC maturation and activation markers (187), showed no difference between 
the infection of two strains.  
There is cross-talk between NK cells and DCs, especially pDCs. As listed in Table 
10.2, after activation by virus or CpG-ODN, pDCs expressed the ligand for the 
glucocorticoid-induced TNF receptor (GITRL), which was shown to promote NK cell 
cytotoxicity and IFN-γ production in synergy with IL-2, IFN-α and NKG2D triggering 
(124). Further, a B220
+
CD11c
+
NK1.1
+
 population, which is capable of producing higher 
levels of IFN-γ than conventional NK cells, was identified recently to functionally 
overlap with NK cells and pDCs (38). Therefore, the dynamics of all three DC subsets in 
NK cell-ablated mice were studied, but no effect of NK cell ablation on the distribution 
of these DCs in either spleen or liver was found (Figure 5.2). Meanwhile, our preliminary 
DC ablation experiments by using CD11c-DTR transgenic mice (155) also did not 
support CD11c
+
 DCs as the target cells for YopM, despite that both the parent and 
yopM-1 mutant strains grew much better in DC-ablated mice (done by Annette 
Uittenbogaard, data not shown). Accordingly, although DCs likely are important in 
plague and YopM may have a role in modulating the function of these cells, an inhibitory 
effect of YopM on another cell type is likely to be responsible for promoting early 
bacterial growth.   
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E. Gr1
+
 cells are responsible for controlling the yopM-1 mutant 
Since both NK cells and DCs are unlikely to be early cellular targets of YopM in vivo, 
we turned our focus to other cell types in innate immunity. In previous studies, there was 
no YopM-associated recruitment of PMNs (Gr1
+
 cells) and macrophages (F4/80
+
 cells) 
found in the systemic plague model (159). However, defining PMNs as Gr1
+
 only is not 
correct since the anti-Gr1 antibody detects not only Ly6G, a PMN surface marker, but 
also Ly6C (229), which is expressed on monocytes and pDCs in addition to PMNs. 
Meanwhile, F4/80 is highly expressed on macrophages but low or intermediate on 
monocytes (325, 329). These cells not only differentiate into macrophages and DCs but 
also produce cytokines including TNF and IFN-γ (293). 
Unlike PK136, which successfully ablated NK cells in vivo but exhibited no effect on 
growth of either the parent Y. pestis or the yopM-1 mutant strain, RB6-8C5 (anti-Gr1) 
depleted Gr1
+
 cells and showed strong effects on bacterial growth. 90% of the Ly6G
+
 
PMNs were ablated from spleen and liver, the growth defect of the yopM-1 mutant was 
significantly relieved, and the mutant and parent strains caused similarly necrotic lesions 
in liver. These findings showed that Gr1
+
 cells are important in restricting the growth of 
yopM-1 Y. pestis. Depletion of these cells also allowed some increased growth of the 
parent Y. pestis, likely because even the YopM-containing parent strain does not 
neutralize 100% of the Gr1
+
 cells. 
Initially we thought that PMNs were the single key cellular player in the YopM 
virulence mechanism because the specificity of anti-Gr1 (RB6-8C5) was misunderstood 
for a long time. RB6-8C5 was believed to detect PMNs only and had been used 
extensively to deplete PMNs in murine disease models, and even was called anti-Ly6G in 
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some papers (93, 206, 208, 332, 373). However, RB6-8C5 also depletes Ly6C
+
 cells in 
vivo. It has been determined that Ly6C
+
 blood monocytes are precursors of inflammatory 
macrophages (110, 320, 321). RB6-8C5 detects this subpopulation of blood monocytes as 
well as monocytes from early peritoneal exudates, which maintain Gr-1 expression as 
they differentiate into macrophages (130). Therefore, systemic administration of this 
antibody could eliminate these cells along with PMNs. In addition, in vivo administration 
of RB6-8C5 has already been shown to deplete pDCs (25). Thus, results of our studies 
with RB6-8C5 treatment reflected not only the loss of PMNs but also the loss of other 
Gr-1-expressing cells. 
 
F. YopM favors the growth of Y. pestis in liver through inhibiting the function of 
PMNs 
a) YopM does not affect the recruitment of PMNs into infected tissue 
PMNs and inflammatory monocytes have received little in vitro study compared to 
macrophages for their role in the pathogenic mechanisms of Yops, although PMNs are 
thought to be important in controlling bacterial numbers early in plague (146, 290). In 
vitro, Y. pestis KIM5 selectively injects Yops into PMNs as well as macrophages and DCs 
among splenic leukocytes (197). We already knew that Gr1
+
 cells are dominant in 
restricting the growth of yopM-1 Y. pestis. Since PMNs were strongly depleted by the 
anti-Gr1 treatment, they became a prime candidate for a cell type that is important for 
controlling bacterial proliferation in both liver and spleen.  
The recruitment of PMNs under normal homeostatic  and inflammatory conditions 
involves a multistep process (310) (Figure 10.3 A). In an initial step, PMNs adhere 
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weakly to the endothelial cell layer but are still allowed to roll along the venular wall. 
This rolling is promoted by vasodilation and by expression of selectins on PMNs (L-
selectin; CD62L) and endothelial cells (E and P-selectins; CD62P and CD62E). Then 
these PMNs are stimulated by many mediators, which include TNF-α, IL-1, complement 
fragment C5a, platelet-activating factor (PAF), leukotriene B4 (LTB4), and chemokines 
(286). These stimulated PMNs attach firmly to the endothelial layer and change in shape 
through interaction of their surface integrins, mainly Mac-1 (CD11b/CD18) with 
adhesion molecules on the endothelial cell (Figure 10.3 B). Integrin adhesiveness is 
enhanced by chemokines produced by leukocytes (e.g., IL-8) as well as by endothelial 
and tissue cells. Chemoattractive mediators, such as C5a, PAF, chemokines and the 
bacterial mediator fMLP, activate PMNs through specific recognition of their 
corresponding G protein-coupled receptor (GPCR) so that PMNs migrate through the 
endothelial cell layer into the underlying tissue to the chemoattractant source. Activation 
of PMNs by chemokines also provokes the secretion of proteases, such as gelatinases 
(matrix metalloproteinase-2 and -9 (MMP-2 and -9)) which can degrade the 
subendothelial extracellular matrix and facilitate the migration of leukocytes (263). 
Members of the chemokine family fall into two major groups, based on the position 
of one or two cysteine residues located near the N terminus of the protein: CC chemokine 
ligands (CCL) with two adjacent cysteines, e.g., MCP-1/CCL2, and CXC chemokine 
ligands (CXCL), for which the two cysteine residues are separated by another amino acid, 
e.g., IL-8/CXCL8 (207, 274). All chemokine receptors are integral membrane proteins 
containing seven membrane-spanning helices and belong to the family of GPCR.  
IL-8, a CXC chemokine, is the major human chemokine to induce recruitment and 
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activation of PMNs by binding CXCR1 and CXCR2 expressed on the PMN surface (274, 
291). However, murine PMNs express only CXCR2, and the rodents lack a direct 
homologue of IL-8; but the chemokines CXCL1/KC, CXCL2/MIP-2, and CXCL5-6/LIX 
are regarded as murine functional homologues of IL-8 (140, 200). CC chemokines, e.g. 
macrophage-inflammatory protein-1α (MIP-1α), may also participate in PMN migration 
in different models of inflammation (45, 259, 313). MIP-1α promotes PMN recruitment 
by interacting with CCR1 probably on CD4
+
 T cells and inducing the sequential release 
of TNF-α and LTB4, which are potent chemoattractants for PMNs (259).  
We found no difference in numbers of PMNs in livers and spleens of mice infected 
with the parent strain of Y. pestis or the yopM-1 mutant (Figure 7.1), indicating that 
YopM does not affect the recruitment of PMNs in the systemic plague model. Meanwhile, 
study of the PMNs in blood and spleen in the early stage of infection in this model also 
showed that YopM did not affect efflux of PMNs into circulation or their infiltration into 
spleen (Figure 8.4). This result is consistent with our observations from liver and spleen 
infected with Y. pestis KIM5 or the ΔyopM-1 strains and also with studies using a 
peritoneal infection model to quantify PMN influx (Figure 7.3). 
In pneumonic plague, recruitment of PMNs to the lungs and local production of 
proinflammatory cytokines and chemokines are delayed and do not occur for 36 to 48 h 
(53). We confirmed this result for influx of inflammatory cells (Figure 3.3). In contrast, 
we found that there was a robust inflammatory response in skin as early as 8 h following 
ID infection mimicking fleabite. Consistent with an early difference in inflammatory 
character between the two types of plague, there is a growing number of pathogenic 
properties that are required for full virulence in bubonic, but not pneumonic, plague (61, 
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79, 104). YopM also was required for virulence of Y. pestis CO92 in experimental 
bubonic, but not pneumonic, plague in mice (LD50 data, Table 4, CO92.S6 and CO92.S19, 
ID and IN routes), consistent with our hypothesis that YopM functions to counteract the 
effect of PMNs on bacterial growth. However, there was no large difference in the 
magnitude of PMN recruitment to the infected dermis between mice infected with the 
parent strain or the yopM-2 mutant.  
Accordingly, we thought that YopM’s major effect on PMNs, if there was any, was 
not on their influx into infected organs but on their inflammatory function. A recent study 
has shown that in vitro, Y. pestis KIM5 shows the same timecourse of killing by human 
PMNs as does Y. pestis KIM6 (lacking the virulence plasmid that encodes the T3SS and 
Yops) (308), indicating that YopM and other Yops may not function directly to enhance 
survival within PMNs.  
 
b) YopM dose not compromise the activation of PMNs 
In response to
 
pathogens, PMNs move from the bloodstream into infected tissues,
 
where they are activated and start to produce ROS, a response which is known as the 
oxidative burst
 
(20, 64). The generation of microbicidal oxidants by PMNs
 
starts from the 
activation of NADPH oxidase, which reduces O2 to an oxygen free radical and then H2O2. 
PMNs and monocytes utilize myeloperoxidase to further combine H2O2 with Cl
-
 to 
produce hypochlorite, which plays a critical role in destroying bacteria (64). 
This multicomponent
 
enzyme system is inactive in resting cells, in which various
 
components are distributed between the cytosol and membranes.
 
The major membrane 
component, cytochrome b558, is located in specific
 
granules or the plasma membrane of 
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resting
 
PMNs. The cytosolic components consist of four major
 
proteins: p47
phox
, p67
phox
, 
p40
phox
 and Rac 2  (19). When PMNs are activated by stimuli such as N-formyl peptide
 
derived from bacteria (fMLP) or PMA, some
 
of the cytosolic components, especially 
p47
phox
, become phosphorylated and migrate
 
to the membrane, where they assemble as an 
active complex (19).  
PMNs can exist in three different activation states, namely,
 
the resting, primed, and 
activated states. The priming process
 
occurs upon stimulation of PMNs by a number of 
inflammatory mediators,
 
including TNF-α, GM-CSF, and LPS, and subsequently 
enhances the PMN response to a second stimulus such as fMLP (78, 81, 86). The 
mechanisms underlying the priming
 
process may include partial p47
phox
 phosphorylation 
induced by priming agents such as TNF-α, GM-CSF, and LPS (78, 81, 86), increased 
membrane
 
expression of cytochrome b558 (81), as well as up-regulation of fMLP
 
receptors (331).
 
 
Another sign of the activation in PMNs is the production of NO. Derived from the 
oxidation of the terminal guanidine nitrogen atom of LI-arginine by the enzyme NO 
synthase (NOS), NO has been implicated in various physiological and pathological 
processes including cell injury and apoptosis. Two general classes of NOS have been 
identified (220, 221). Constitutive NO synthase (cNOS) is a Ca
2+
/calmodulin and 
NADPH-dependent enzyme. Mainly involved in physiological processes in the 
cardiovascular and nervous systems, cNOS is expressed in vascular endothelium, brain 
and platelets.  
We used two models to analyze the production of ROS and NO by PMNs. The 
staining reagents used in both models were the same: DCFDA, which becomes 
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fluorescent when acetate groups are removed by intracellular esterases and oxidation by 
ROS occurs within the cell, and DAF, which becomes fluorescent when it reacts with NO. 
The first model was IV infection (systemic plague model), and the production of ROS 
and NO by the splenocytes was measured by flow cytometric analysis. The advantage of 
this model was that the cell types, such as macrophages and PMNs which made ROS and 
NO, could be distinguished by their surface markers from DCFDA- and DAF-negative 
cells, e.g. lymphocytes.  
However, only ca. 10% of leukocytes in spleen are cell types related to the YopM 
virulence mechanism. Therefore, we used the IP infection model as an alternative 
approach. A high dose of bacteria was injected IP, peritoneal cells were harvested after 
several hours, and ROS and NO production were measured immediately by microplate 
reader. Most of the peritoneal cells were relevant, being PMNs (60% of total peritoneal 
cells) and macrophages (40% of total peritoneal cells). The infecting bacteria (Y. pestis 
KIM5 and yopM-1 KIM5) were pgm and they needed iron from blood to support 
extensive growth. Therefore we infected the mice with a high dose (10
6
CFU/mouse, 
between the LD50s of the two strains) of pre-induced bacteria, which could inject Yops 
into the host cells as soon as stable contact was established. Peritoneal cells were 
harvested at a very early stage of infection (before the bacteria would have depleted their 
iron stores) and the early responses of these cells to YopM could be captured.   
However, as with the systemic model, there were still some concerns about the IP 
model. This model was not a mimic of any natural plague model, although YopM was 
required for the full virulence of Y. pestis (Table 3.1, LD50 of IP). This IP model exhibited 
the MDR, best documented as a physiological response to both acute nonspecific 
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inflammatory and specific delayed immune hypersensitivity processes (26). This 
phenomenon enriched these peritoneal cells for PMNs at the expense of ca. half of the 
macrophages and probably accounted for our inability to recover even 10% of the 
bacteria form the peritoneal cavity. The lost Y. pestis could attach to the peritoneal wall 
or be conveyed as intracellular bacteria via the migrating macrophages. Under either 
condition, those bacteria failed to contact and deliver the Yops into the harvested PCs. 
Therefore, we may have lost some signals of DCFDA and DAF by losing these bacteria.  
Another disadvantage of peritoneal infection is the presence of B1 cells, which 
constitute a minor fraction of the spleen but are enriched in the peritoneal and pleural 
cavities (125, 171) and express IL-10, an anti-inflammatory cytokine (121). However, the 
main drawback of this method was that the source of ROS and NO, i.e., PMNs and 
macrophages, cannot be distinguished because these cells were not stained with 
antibodies against surface markers. Therefore, the amount of ROS and NO detected in 
this model reflected the activation of all recoverable peritoneal cells. 
Although neither model was perfect, they were complementary to each other and no 
YopM-dependent activation was found either in splenic PMNs or peritoneal cells (Figure 
7.2 and 13). To test whether YopM affected the priming process of these cells, their 
stimulability was measured after one hour of in vitro treatment with PMA or pCD1-
negative Y. pestis, which lacks the T3SS and all of the effector Yops. YopM showed no 
effect on the stimulation of cells in either model (Figure 7.2 and 13, and data not shown 
for the in vitro infection).  
Another possible effect of YopM on PMN function was to inhibit the directed 
migration of PMNs. Two in vitro migration experiments were done with peritoneal cells 
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after IP infection; the migration of neither PMNs nor macrophages toward the bacterial-
derived chemoattractant fMLP was influenced by the presence of YopM in the infecting Y. 
pestis (done by Annette Uittenbogaard and data not shown). 
Therefore, we concluded that YopM does not modulate the host immune responses 
through inhibiting the function or recruitment of splenic or peritoneal PMNs. However, 
PMNs from infected liver were not tested for effects of YopM on function because their 
in vivo status would have decayed by the time they could be obtained. 
 
c) PMN ablation only relieved the growth limitation of the yopM-1 strain in 
liver, but not in spleen 
A commercial anti-Ly6G (IA8) was developed recently and made selectively in vivo 
depletion of PMNs possible. It was reported that unlike anti-Gr1 antibody (RB6-8C5), 
which ablates blood PMNs and Gr-1
+
 monocytes, in vivo administration of 1A8 only 
reduced blood PMNs but not Gr-1
+
 monocytes (77). In our experiments, IA8 depleted 
over 90% of the Ly6G
+
CD11b
+
 PMNs from both spleen and liver, and growth of yopM-
1 Y. pestis was disproportionately enhanced in liver compared to the parent strain, 
showing that PMNs are selectively involved in controlling growth of the mutant in that 
organ.  In contrast, there was no effect of the ablation on growth of the yopM-1 strain in 
spleen (Figure 7.5). These findings indicate that YopM directly or indirectly undermines a 
function of PMNs in liver, but not in spleen where these cells are not a critical target of 
YopM’s pathogenic mechanism, or they are a redundant target.  
It needs to be noted that the PMNs investigated here were defined as Ly6G
+
CD11b
+
 
cells, which represent the major portion of PMNs. However, according to recent studies, 
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PMNs can be divided into several subgroups by two different ways. Where PMNs were 
distinguished based on patterns of cytokine and chemokine production, TLR expression, 
and surface CD49d and CD11b expression, three subsets were identified as PMN-I, 
PMN-II, and PMN-N (Table 10.3) (340). PMN-Ns are quiescent circulating PMNs and 
can convert to the other two subsets under certain circumstances (340).  Another way to 
classify PMNs depends on the expression of the surface marker Gr1. Both Gr1
high
 and 
Gr1
low
 cells were harvested from the peritoneal cavity in C57BL/6 mice that were 
infected IP with Haemophilus influenzae. The Gr1
high
 cells were found to be the major 
source of IL-15, which is important in the clearance of intracellular bacteria through 
activating NK cells (218). However, the expression of Gr-1 surface marker on PMNs is 
not correlated to the properties that distinguish PMN-I, PMN-II, and PMN-N cells (217) 
and therefore Gr-1 PMNs cannot be classified as any of those three PMN subsets. Thus, 
in our work only the importance of Ly6G
+
CD11b
+
 PMNs, which may belong to the 
CD11b
+
 PMN-II or Gr1
high
 PMN classification, was studied. Further investigation of the 
role of other PMN subsets in the YopM virulence mechanism can be done in the future. 
However, the importance of these PMN subsets in the control of yopM-1 Y. pestis will 
not be determined until efficient methods to specifically ablate these PMN subsets are 
developed.  
 
G. Subgroups of MDMs play different roles in the YopM-mediated virulence 
mechanism  
a) YopM inhibits the recruitment of MDMs into spleen but not liver through a 
PMN-independent pathway 
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We already identified Gr1
+
 PMNs in liver as the major cell type whose function is 
modulated by YopM. However, the cellular target of YopM in spleen still needed to be 
determined. Early in infection, the first immune cells encountered in spleen by Y. pestis 
are resident macrophages and myeloid DCs at the infection site. Within a short time, 
PMNs also are involved. These cell types express CD11b on their surface. CD11b, also 
known as macrophage-1 antigen (Mac-1) or complement receptor 3 (CR3), is expressed 
at low or undetectable levels in myeloid precursors, and its expression increases steadily 
during myeloid differentiation, reaching highest levels in mature phagocytes, such as 
PMNs, monocytes, and macrophages (120, 273, 335). Upon exposure to degranulation 
stimuli such as the bacterial peptide fMLP, stored Mac-l, an integrin heterodimer, rapidly 
mobilizes to the cell surface and serves as an important adhesion molecule mediating 
many functions, including firm adhesion of these leukocytes onto the endothelium 
(Figure 10.3) (352). 
Combined with the PMN-specific marker Ly6G, CD11b was used to distinguish 
PMNs from other phagocytes. PMNs were defined as Ly6G
+
CD11b
+
, whereas the rest of 
the phagocytes are Ly6G
-
CD11b
+
. Since Ly6G
-
CD11b
+
 cells include macrophages, 
monocytes and some DCs, we named them MDMs. 
Interestingly, MDMs failed to be recruited as robustly into spleens of mice infected 
with parent Y. pestis as in mice infected by the yopM-1 mutant after d 2 p.i.. This effect 
did not occur in liver (Figure 8.1). However, the same number of MDMs was induced by 
both strains in bone marrow and they effused into the circulation equally by d 2 p.i.. 
Taken together, these findings indicated that YopM produced by the parent strain acts 
locally to prevent those MDMs from reaching extravascular tissue in spleen at an early 
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stage of infection.  
The anti-Gr1 treatment eliminated the yopM-1 Y. pestis-induced influx of MDMs 
into spleen and delayed that influx into liver, accompanied by relief of the growth defect 
of yopM-1 Y. pestis in both organs (Figure 6.1). This anti-Gr1-mediated effect on the 
MDM infiltration could be due to the depletion of inflammatory monocytes in MDMs 
directly by this antibody because of the robust expression of Ly6C on these cells (110, 
321).  
Meanwhile, the absence of PMNs caused by anti-Gr1 treatment may be responsible 
for inhibiting recruitment of MDMs since in inflammatory situations where PMNs serve 
as early responders; and the cytokines and chemokines they produce elicit the influx of 
monocytes as a secondary wave of the acute inflammatory response (143, 305, 306). 
However, the role of PMNs in the recruitment of MDMs is questionable in plague models. 
In a rat model of bubonic plague, macrophages began to appear in primary swollen 
lymph nodes (bubo) 18 h before PMN numbers increased; and in spleen, PMNs and 
macrophages were noted to appear at about the same time (287). In our systemic plague 
model, influx of PMNs and MDMs peaks at the same time in both spleen and liver 
(Figure 7.1 and 15). The depletion of PMNs by anti-Ly6G did not delay or diminish the 
influx of MDMs (Figure 7.5). These findings indicate that recruitment of MDMs in 
plague is independent of PMNs, raising the potential for YopM directed modulation of 
influx of MDMs through pathways not involving PMNs.   
 
b) Clodronate-sensitive resident macrophages and DCs provide a protective 
environment for Y. pestis in a YopM-independent manner 
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We previously showed that there is a YopM-associated decrease in net message 
expression for pro-inflammatory cytokines in splenic F4/80
+
 cells 
(macrophages/monocytes) as early as d 2 p.i. (159). This could have reflected a smaller 
contribution of inflammatory monocytes to the F4/80
+
 population analyzed from mice 
infected by the parent Y. pestis KIM5 compared to the yopM-1 mutant. However, it may 
also reflect an early effect of YopM delivered to resident macrophages/DCs. In a sterile 
peritonitis model in rat, it was reported that mobilization and chemotaxis of PMNs were 
regulated by macrophages (162). Thus, YopM could favor the growth of the parent strain 
in liver through indirectly affecting the function of PMNs by compromising cytokine 
production of macrophages and DCs.  
In order to determine whether those MDMs played a critical role in YopM-mediated 
virulence, we used clodronate-liposomes to deplete macrophages/DCs. 
Dichloromethylene-bisphosphonate (CI2MBP or clodronate) is not a toxic drug in itself 
because the free drug does not easily cross cell membranes and has an extremely short 
half life in circulation and body fluids. However, after being delivered into phagocytes by 
liposomes, which enter by phagocytosis, clodronate is released because the phospholipid 
bilayers of the liposomes are disrupted under the influence of lysosomal phospholipases. 
The intracellular free clodronate accumulates in the phagocytes and induces apoptosis of 
these cells probably through depletion of intracellular iron (222, 345) or a direct effect on 
the ATP metabolism (269, 345). 
Clodronate is safe to non-phagocytic cells because it cannot enter those cells and has 
an extremely short half life in the circulation and body fluids when released into the 
circulation from dead macrophages or by leakage from liposomes (346). In our 
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experiments, 80% of the MDMs were depleted in spleen and liver after clodronate 
treatment 18 h prior to the infection; and MDMs and DCs remained at the same level in 
spleen, or their influx was delayed in liver, after infection (Figure 8.2). However, in 
contrast to the effect of anti-Gr1, treatment of mice with clodronate-liposomes to deplete 
MDMs curtailed growth of both Y. pestis strains accompanied by significantly fewer, 
smaller, and less necrotic lesion sites in liver. As reported by other groups (31, 154) and 
shown in our result (Figure 8.2), treatment with clodronate-liposomes did not deplete 
PMNs.  
Since MDMs include resident macrophages/DCs and Gr1
+
 inflammatory monocytes 
and all of them could be susceptible to clodronate treatment, it was difficult to determine 
which cell type(s) favored the growth of Y. pestis. Considering that the growth limitation 
of yopM-1 Y. pestis was relieved in the mice lacking CCR2, a chemokine receptor 
which mediates the recruitment of inflammatory monocytes into organs, we concluded 
that during the first few days of systemic plague resident macrophages/DCs provide a 
protected environment for the
 
Y. pestis to survive and proliferate, in which the bacteria 
avoid contact with other components of the host
 
immune system, as previously suggested 
(192, 253, 254, 319). 
Although the growth of both strains was inhibited in clodronate-treated mice 
compared to the mock treated groups, the bacteria kept multiplying in the first two days 
in both organs (Figure 8.2, panel G). This could have been due to the incomplete ablation 
of the resident macrophages and DCs. Ca. 20% of this population was left at the time of 
infection (Figure 8.2, panel G), and these cells may offer enough protective niches for 
early growth.  
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c) CCR2
+
 cells played a critical role in YopM-mediated virulence in spleen 
Inflammatory monocytes became the next candidate among MDMs as cells may that 
play an essential role in controlling growth of ΔyopM Y. pestis.  
In humans, circulating monocytes are divided into two subsets based on their surface 
expression of CD14, a component of the LPS receptor complex, and CD16, the FcγRIII 
receptor (242). 90% of the circulating monocytes are CD14
+
, whereas CD16
+
 monocytes 
only constitute 10% of circulating monocytes. The CD16
+
 population expands during 
infections (102, 333) and produces high levels of proinflammatory cytokines such as 
TNF (32), and is therefore referred to as proinflammatory monocytes. 
Monocytes in mice fall into two subsets, which are distinguished by differences in 
expression of their surface markers Ly6C, CCR2 and CX3CR1 (110, 238, 321) (Table 
10.4 and Figure 10.4). The CX3CR1
low
CCR2
+
Ly6C
+
 are most similar to human CD16
+
 
monocytes, whereas CX3CR1
+
CCR2
−
 Ly6C
low
 monocytes are most similar to human 
CD14
+
 monocytes according to their morphological characters and surface chemokine 
receptors (293).  
CX3CR1
+
 (CX3CR1
+
CCR2
−
 Ly6C
low
) monocytes remain in the circulation for longer 
periods than Ly6C
+
 (CX3CR1
low
CCR2
+
Ly6C
+
) and traffic into peripheral tissues under 
noninflammatory conditions (110). These cells, referred to as resident monocytes, serve 
as the major precursor for tissue macrophages and DCs (110), except in spleen where 
MDPs (macrophage-DC progenitor) and pre-DCs reconstitute resident macrophages and 
conventional DCs most effectively (293) (Figure 10.5). Although CX3CR1
+
 monocytes 
may descend from Ly6C
+
 monocytes (321, 326), their recruitment is mediated by a 
CX3CR1 signal and independent from the CCR2-mediated pathway by which Ly6C
+
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cells are recruited into tissues (110, 256). 
Ly6C
+
 monocytes have a short transit time in the bloodstream and are not recovered 
from peripheral tissues in the absence of inflammation (110). In response to 
inflammatory stimuli, Ly6C
+
 monocytes home to peripheral tissues, produce high levels 
of TNF-α and IL-1β during infection or tissue damage, and thus are named inflammatory 
monocytes (18, 110). These monocytes differentiates into active macrophages. Another 
destiny of Ly6C
+ 
monocytes is to become DCs. However, they develop into different 
DCs under different conditions. In adoptive transfer experiments,  the recipient mice are 
irradiated, and transferred Ly6C
+
 bone marrow monocytes give rise to splenic CD11c
high
 
conventional DCs as well as F4/80
+
 splenic macrophages (181). In the setting of systemic 
inflammation Ly6C
+
 monocytes differentiate into splenic CD11b
+
CD11c
int
Mac-3
+
 cells 
(230), which are similar to TNF- and iNOS-producing DCs (TipDCs) in systemic 
listeriosis (294) (Figure 10.5).  
We already knew that Gr1 (Ly6G/Ly6C)
+
 cells were critical in the control of yopM-
1 Y. pestis in both spleen and liver (Figure 6.1). The stable accumulation of Ly6G
-
CD11b
+
 
MDMs in spleen was also found to be inhibited in the infection by the parent Y. pestis, in 
contrast to infection by the yopM-1 mutant (Figure 8.1). When Gr1+ cells were ablated, 
the influx of Ly6G
-
 CD11b
+
 MDMs was abolished in the infection by both strains (Figure 
6.1), indicating that those cells potentially were Gr1 (or Ly6C)
+
 cells. Once we found that 
PMNs were not required to control the yopM-1 mutant in spleen (Figure 7.5) and 
excluded resident macrophages and DCs as cells that control growth of ΔyopM Y. pestis 
(Figure 8.2), Ly6C
+
 inflammatory monocytes/DCs became the prime candidates for Gr1
+
 
cells that selectively control the growth of the yopM-1 Y. pestis in spleen. 
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The recruitment of those Ly6C
+
 inflammatory monocytes depends primarily on the 
signaling pathway mediated by the chemokine receptor CCR2 on their surface (293). The 
major ligand of CCR2 is CCL2/MCP-1, a member of the C-C chemokine family and a 
potent chemotactic factor for monocytes. There are additional CCL family members that 
signal through CCR2 in mice (CCL8, CCL7, CCL12/MCP-5). These peptides are 
approximately 70% homologous with CCL2/MCP-1 (344).  
The expression of CCL2/MCP-1 can be induced in many cell types, including 
endothelial, fibroblasts, epithelial, smooth muscle, mesangial, astrocytic, monocytic, and 
microglial cells (85, 270).  However, monocyte/macrophages are found to be the major 
source of CCL2/MCP-1 (365, 366). CCL2/MCP-1 is a potent chemoattractant for 
monocytes in vitro. CCL2/MCP-1 binds to its receptor, CCR2, and produces directional 
cell motion through several signaling pathways (Figure 10.6) (207). Meanwhile, as part 
of its migration program in monocytes, CCL2/MCP-1 induces the expression of integrins 
required for chemotaxis (152, 342). In addition, CCL2/MCP-1 attracts memory T 
lymphocytes, DCs, NK cells, and even activates NK cells and CD8
+
 T cells (60, 190, 194, 
293).  
As shown in Figure 10.6, CCL2/MCP-1 mediates its effects through its receptor 
CCR2, a G-protein coupled receptor (207). After binding to their ligand, CCR2 
undergoes a conformational change, which modifies its function to that of a GEF. Then 
the associated G-protein is activated by exchanging its bound GDP for a GTP, which 
causes the dissociation of its α subunit from the β and γ subunits. The α subunit activates 
phospholipase C and hydrolyzes phosphatidylinositol-bisphosphate (PIP2) in the 
cytoplasmic membrane. Two products from this reaction, diacylglycerol (DAG) and 
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inositol trisphosphate (IP3) activate intracellular calcium release and protein kinase C 
(PKC)-dependent NF-κB pathways, respectively. The released intracellular calcium 
activates calmodulin (CaM) kinase pathway, in which CaM binds calcium and activates 
CaM kinase II. This kinase then phosphorylates target enzymes and regulates their 
activities. This GPCR signaling pathway ultimately regulates directional motion of the 
cell. Meanwhile, Rho family proteins, which are GTP-binding proteins with the capacity 
to influence cell motility through regulation of actin-dependent processes, are also 
activated by CCR2-mediated signal. 
Because inflammatory monocytes/DCs largely depend on CCR2 for recruitment to 
foci of infection, we could test their involvement by comparing growth of parent and 
mutant Y. pestis in CCR2
-/-
 mice.  It is reported that KO mice for CCL2/MCP-1 or its 
receptor CCR2 are viable but have abnormalities in monocyte recruitment and cytokine 
expression (167, 191). Indeed, spleens of CCR2
-/-
 mice had greatly reduced recruitment 
of Ly6G
-
CD11b
+
 cells, and the yopM-1 mutant grew nearly as well as the parent strain 
(Figure 8.5), thereby directly implicating cells recruited through CCR2 in controlling 
growth of yopM-1 Y. pestis. We concluded that YopM selectively inhibits recruitment of 
inflammatory monocytes/DCs into spleen; when YopM is absent, those cells accumulate 
at foci of infection and limit growth of the bacteria. 
In contrast to CCR2 KO, parent and yopM-1 Y. pestis strains were similarly 
enhanced in growth in mice lacking CCL2/MCP-1, although the growth difference 
between the parent and mutant Y. pestis strains was slightly decreased (Figure 8.7). 
CCL2/MCP-1 acts on many cell types, including monocytes, memory T lymphocytes, 
natural killer (NK) cells and PMNs (85, 264), as well as interacting with receptors other 
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than CCR2 (284). Therefore, CCL2/MCP-1 KO may favor the growth of both parent and 
mutant strains by compromising the immune system broadly. Meanwhile, CCR2
+
 cells 
could still be recruited or activated via other ligands of CCR2 such as CCL3 and CCL7 
(85, 151, 235). Thus, this finding supports that CCR2
+
 cells, other than the cells recruited 
by CCL2/MCP-1, play the key role in YopM-mediated virulence mechanism.  
 
d) CCR2
+
 PMNs played a critical role in the YopM-mediated virulence in liver 
Gr1
+
 cells dependent on CCR2 function were required to control growth of the 
yopM-1 mutant in liver (Figure 6.1). We have identified PMNs as critical cells that 
control growth of yopM-1 Y. pestis in liver, and these cells should be Gr1+ and CCR2+.  
However, although there has been little information about the expression and function of 
CCRs in PMNs, it was reported that bone marrow PMNs are capable of expressing 
functional CCR2 under the stimulation of G-CSF (144). The role of CCR2-mediated 
signals on the recruitment of PMNs is controversial. Christoph Reichel et al. found a 
CCR2-mediated PMN recruitment to postischemic tissue (262), whereas another group 
reported that in CCR2 KO mice early accumulation and delay clearance of PMNs in the 
peritoneal cavity after thioglycollate injection could be enhanced (168), and we may have 
observed this latter effect in livers of CCR2
-/-
 mice (Figure 8.5 C, right panel). A possible 
explanation for the different findings may come from a difference in the isoforms of 
CCR2 in these experiments.  
Unlike CCL2/MCP-1, CCR2 expression is relatively restricted to certain types of 
cells, mainly monocytes. There are two alternatively spliced forms of CCR2, namely, 
CCR2A and CCR2B, which differ only in their C-terminal tails (270). In addition to their 
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amino acid sequences, these two isoforms are also different in their tissue distribution and 
signaling pathway. For example, CCR2A was found to be expressed by vascular smooth 
muscle cells  and some mononuclear cells (27), and Ca
2+
 flux was not stimulated when 
CCL2/MCP-1 interacted with CCR2A (280). It has been reported that activated 
monocytes, NK cells,
 
and dendritic cells expressed abundant amounts of the CCR2B 
isoform
 
and, to a lesser extent, the CCR2A isoform (250), and Ca
2+
 flux was induced in 
the CCR2B-positive cells (280). Thus, the CCR2 mediating PMN recruitment to 
postischemic tissue may be CCR2A isoform, whereas the one in peritoneal inflammation 
model is CCR2B. 
Currently there is no information about the CCR2 isoform on PMNs; however, it 
would be reasonable to assume that it is CCR2B, because CCR2B mainly appears on 
inflammatory cells. Therefore, it is unlikely that the CCR2-mediated signaling pathway 
governs PMN recruitment into infection sites. However, it does promote PMN 
differentiation and adherence (144, 264).  
Therefore, YopM’s mechanism in liver, like that in spleen, results in downregulation 
of expression of ligands for CCR2 but not of other chemokines, e.g. KC/IL-8, that are 
sufficient for recruitment of inflammatory cells. During capture of PMNs from 
circulation, signaling through CCR2 by chemokines bound to proteoglycans on 
endothelial cells (354) might promote subsequent PMN antibacterial function. Consistent 
with this speculation, even though CCR2
-/-
 mice responded to infection by yopM-1 Y. 
pestis with enhanced recruitment of PMNs (Figure 8.5C), these PMNs apparently were 
not functional, because the yopM-1 mutant grew better in these mice than in WT mice 
in which fewer PMNs were present in organs (Figure 8.5D).  
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 In the co-infection experiment (Figure 8.12), the presence of the parent strain 
(i.e.,YopM being delivered to cells in the infection sites) in liver did not relieve the 
growth limitation of the yopM-1 mutant, despite the fact that both of the strains grew 
similarly in the co-infected spleen. The importance of CCR2-mediated PMN function in 
YopM virulence in liver may explain this difference. It is likely that parent and mutant Y. 
pestis would bind to different Kupffer cells (KCs), and only the KCs that bind the 
yopM-1 Y. pestis could retain their ability to present CCR2-binding chemokines to 
activate surrounding PMNs, which in turn could kill some of the bacteria. However, the 
parent Y. pestis modulated nearby KCs and protected itself from PMN anti-bacterial 
activity. Thus, the parent strain would maintain its growth advantage over the yopM-1 
mutant after d 2 p.i.    
 
e) CCR2
+
 cells played a critical role in the YopM-mediated virulence in the 
bubonic plague model 
In our studies, Y. pestis was grown at ambient temperature (26
 o
C) so that the host 
responses might resemble those in skin during bubonic plague, in which the infecting 
bacteria grow at 26
 o
C in the flea gut. Meanwhile, the major innate defense cells in skin 
are Langerhans cells (DCs) and macrophages, which are differentiated from 
Ly6C
+
CCR2
+
 inflammatory monocytes (Figure 10.5) (293). Because CCR2 function was 
critical for limiting growth of the yopM-1 mutant in both liver and spleen, we 
hypothesized that this would also be the case when mice were challenged ID with 
ambient-temperature-grown Y. pestis.   
Indeed, the yopM-2 Y. pestis CO92.S19 showed delayed growth in skin compared to 
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the fully virulent parent Y. pestis CO92.S6 in WT mice at d 4 p.i. (Figure 8.6).  Further, 
the yopM-2 mutant grew as well in CCR2-/- mice as the parent strain did in skin of WT 
mice.  As seen in liver and spleen in systemic plague, growth of the parent strain in skin 
was not altered in the CCR2
-/-
 mice compared to in WT mice, likely because YopM was 
present to neutralize CCR2-related functions in WT mice. Therefore, our findings show 
that signals through CCR2 are important for defense against both bubonic and systemic 
plague. 
 
f) CD11b
+
CD11c
int
CCR2
+
 Gr1
+
 inflammatory DCs are the key cell type in 
controlling the yopM-1 Y. pestis in spleen 
According to the Figure 10.5, in response to infection, blood inflammatory monocytes 
in spleen differentiate into DCs with a CD11b
+
CD11c
int
Mac-3
+
 phenotype, distinct from 
the conventional DC subsets (CD11c
high
). In the spleen of yopM-1 infected mice,  we 
identified a population of inflammation-induced DCs whose phenotype, Gr1
+
 
CD11b
+
CD11c
int
 iNOS
+
 Mac3
+
 (Figure 8.8), is similar to TNF- and iNOS-producing DCs 
(TipDCs) that infiltrate the spleen of Listeria monocytogenes-infected mice (17, 294). As 
the downstream differentiation product of Gr1 (Ly6C)
+
 monocytes, TipDCs only exist in 
peripheral organs and their presence depends on the CCR2-mediated recruitment of blood 
inflammatory monocytes (293, 328), which was also confirmed in our experiments with 
CCR2
-/-
 mice (Figure 8.10).  
These inflammatory DCs were differentially recruited into spleen by yopM-1 and 
parent Y. pestis and may underlie at least part of the mechanism for the growth limitation 
of the yopM-1 mutant (Figure 8.9). At foci of infection their major bactericidal product, 
 224 
NO, could be responsible for limiting net growth of the yopM-1 mutant. Even though 
the bacteria would be predominantly extracellularly located in spleens by 2 d of infection 
(192), NO can be an effective antibacterial mechanism, as indicated in studies of bubonic 
and septicemic plague where free NO is available for killing extracellular bacteria and 
nitrosative stress is a prominent driving force shaping Y. pestis gene expression and 
metabolism (290).   
The parent Y. pestis could decrease its exposure to this antibacterial agent by limiting 
influx of the NO-producing cells into spleen, and all the bacteria growing in this spleen 
should benefit from this microenvironment. Consistent with this idea, the presence of the 
parent strain conferred partial protection on the yopM-1 mutant in spleen after d 2 in the 
co-infection experiment. Interestingly, there was a reciprocal but detrimental effect of the 
mutant strain on net growth of the parent strain prior to d 3 of infection (Figure 8.12). 
This likely is a distinct phenomenon, as it happened in both liver and spleen. We 
speculate that resident and early-responding inflammatory cells are stimulated in the 
focus of infection by pro-inflammatory cytokines induced in expression by the yopM-1  
strain (159), and these cells have heightened anti-bacterial activity that affects both Y. 
pestis strains in the co-infection. 
 
H. The molecular targets of YopM 
In mice infected with the yopM-1 mutant, inflammatory DCs were recruited and 
retained by spleen (Figure 8.9). In contrast, PMNs were captured in similar numbers by 
the two strains in spleen (Figure 7.1). These findings imply that YopM affects recruitment 
mechanisms in spleen, which are distinct between PMNs and inflammatory monocytes 
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(the circulating precursors of inflammatory DCs). The greatest distinction between the 
two cell types in the recruitment process lies in the chemokines that bind corresponding 
GPCRs.   
Two prominent chemokines that elicit migration of monocytes but not PMNs are 
CCL2/MCP-1 and CCL5/RANTES, which are produced by cytokine-stimulated platelets, 
endothelial cells, mast cells and resident macrophages (85, 151, 168, 236, 293, 351) as 
well as stimulated PMNs (305). Current evidence points toward the signaling pathway of 
CCR2, the receptor for CCL2/MCP-1, CCL7/MCP-3, and CCL13/MCP-4 (85) as one of 
the major molecular target of YopM. In our studies, absence of CCR2 was sufficient to 
relieve the growth defect of yopM-1 Y. pestis (Figure 8.5). Inflammatory DCs, which we 
found to be selectively accumulated in spleens infected with yopM-1 Y. pestis, are 
defective for recruitment to spleen in CCR2
-/-
 mice (Figure 8.9 and 8.10). YopM could 
indirectly influence production of chemokines that signal through CCR2 in spleen by 
downregulating expression of cytokines such as IL-1 and TNF (159) that activate 
endothelial cells (196, 271) or by directly downregulating a cell biological pathway that 
leads to chemokine expression. 
Our recent mRNA expression analysis also supports the importance of the CCR2 
signaling pathway in YopM-mediated virulence. Harvested 1 hour after high-dose IV 
infection, splenic CD11b
+
Ly6G
-
CD5
-
 macrophages were purified by magnetic beads, and 
their mRNA was subjected to microarray analysis. We found that the expression of 
CCL2/MCP-1 and CCL3 in the yopM-1 strain infection was higher than that in parent 
strain infection. This difference was even larger when we analyzed those mRNA samples 
by quantitative real-time RT-PCR. (Done by Tanya Myers and Annette Uittenbogaard, 
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data not shown). 
There are new findings about the molecular targets of YopM in host cell cytosol. 
Reported by two independent groups, YopM was confirmed to bind RSK1 through its C-
terminal domain (from LRR12 to the C-terminus), and such binding contributes to 
virulence in a systemic infection model of Y. pseudotuberculosis grown at ambient 
temperature (201, 204).  
Because of numerous differences in surface molecules expressed by Y. 
pseudotuberculosis and Y. pestis grown at 26
o
C (e.g., the former has flagella and the latter 
does not), the cell-biological context in which YopM acts will be different in infections 
by the two Yersinia species. We do not yet know whether this interaction is involved in 
the CCR2 mediated pathways in spleen discussed earlier. 
 
I. 3 hour pre-induction at 37
 o
C induces some virulence property of Y. pestis to 
compensate the loss of YopM in
 
the yopM strain in the spleen at an early stage of 
the infection  
We observed an interesting phenomenon in spleen when we tried to improve our 
systemic model by pre-inducing the infecting bacteria, which had been cultured at 
ambient temperature, for 3 hours at 37°C, the internal temperature of a mammal. Pre-
induction initiated the expression of thermo-regulated virulence factors, including the 
T3SS and Yops. Therefore, the infecting bacteria encountered the microenvironment in 
the spleen and liver with a status close to that in natural septicemic plague.  
The length of time for the pre-induction was decided based on our current 
understanding of the phenotypic changes of Y. pestis during temperature transition.  
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Once shifted to 37°C, expression of T3SS and Yops, encoded by the virulence 
plasmid pCD1, is upregulated. The injectisomes start to be assembled and the synthesis 
of Yops is upregulated, probably via thermoinduction of the pCD-encoded transcriptional 
activator LcrF (6, 226). yopM is one of genes expressed at the highest level discovered 
among the components of the T3SS during thermoregulation (226).  
Another important factor regulated by temperature is the F1 pilus capsule, which 
contributes to the ability of Y. pestis to block uptake by phagocytes in concert with the 
T3SS. The anti-phagocytosis function of the F1 capsule was seen only after 4-5 h pre-
induction at 37°C (89) but the phagocytosis-resistance was gained by ambient 
temperature-grown Y. pestis 3-5 h after temperature shifting (21, 63) and correlated with 
detectable production of V antigen (i.e., LcrV a component of the T3SS) (21) .  
Therefore, we chose 3 hours for the pre-induction because the T3SS would be 
strongly expressed, the anti-phagocytosis function of the F1 capsule would not be strong 
and the bacteria could efficiently bind to host cells and delivers Yops. The idea was to 
maximize the early delivery of Yops and (hopefully) produce a stronger YopM 
phenotype that could be analyzed earlier than d 2 of infection. 
Although the growth limitation of the yopM-1 mutant strain was retained in the 
infection with the pre-induced bacteria, its appearance was postponed by the 3 hours pre-
induction from d 2 p.i. to d 3 p.i., accompanied by similarly delayed YopM-associated 
influx of MDMs and iDCs into spleen (Figure 9.1). Influx of PMNs into spleen was not 
affected by the pre-induction. Meanwhile, the effects of YopM on the dynamics of 
infection and the recruitment of relevant leukocytes in liver were not affected by this pre-
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induction (Figure 9.1). Further, the pre-induction showed very little effect on the lethality 
of the yopM-1mutant strain (Table 3.1), or on the pattern of bacterial growth in PMN-
ablated (Figure 9.2) or CCR2-KO mice (Figure 9.3). 
The observation that the pre-induction could relieve the growth defect of the yopM-
1 mutant in spleen on day 2 p.i. therefore indicated that the temperature transition of Y. 
pestis induced some early thermo-regulated properties of the infecting bacteria that 
compromise the immune system in spleen in a  manner that is similar to that used by 
YopM. However, this compensation for the loss of YopM held only until d 2 p.i.. This 
means that the accumulation of the immune responses specifically evoked by the yopM-
1 mutant, as opposed to the YopM
+
 strain, eventually overcame the negative effects on 
host defenses from those unknown thermo-induced properties. After d 2 p.i., the infection 
dynamics of pre-induced Y. pestis were similar to those of ambient temperature-grown 
bacteria. This observation supported our conclusion that different immune responses 
were responsible for the control of yopM-1 mutant in spleen and liver. 
The entire genome of Yersinia pestis has been studied by DNA microarrays to 
characterize global regulatory changes during temperature transition (226). 235 
chromosomal genes and open reading frames (ORFs) were thermally upregulated and 274 
were thermally downregulated, most of which are related to the metabolism of the 
bacteria. The changes of these genes may influence the growth of the bacteria but would 
not obviously affect the modulation of host immune system.  
Fifty one, four, and thirteen ORFs on major virulence plasmids, pCD1, pPCP, and pMT, 
respectively, were thermoinduced. These genes are strongly induced by the temperature 
transition, for example, the caf operon encoding the F1 capsule components and the 
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transcriptional regulator (caf1R) became upregulated by 100-fold at 10 h and is the 
strongest upregulation value in the entire genome. However, the only immunomodulatory 
effect of F1 capsule documented so far is to activate peritoneal macrophages (297). The 
activated macrophages should control the growth of Y. pestis. It is unlikely that 
thermoinduced expression of F1 capsule would compensate the loss of YopM in ΔyopM 
Y. pestis.  
LPS is a potential candidate to explain this compensation.  LPS is found in the outer 
membrane of Gram-negative bacteria, acts as an endotoxin and elicits rapid and strong 
innate immune responses in animals. LPS consists of three portions: O-antigen, core 
oligosaccharide and lipid A. O-antigen is a repetitive glycan polymer attached to the core 
oligosaccharide, and comprises the outermost domain of the LPS molecule. The presence 
or absence of O chains determines whether the LPS is considered rough or smooth, terms 
that derive from the appearance of colonies on agar medium. Full-length O-chains would 
render the LPS smooth, whereas the absence or reduction of O-chains would make the 
LPS rough (267). Y. pestis has a rough-type LPS that lacks an O-specific chain (301), 
which favors efficient plasminogen activation by Pla (165). The lipid A component is a 
phosphorylated glucosamine disaccharide decorated with multiple fatty acids. These 
hydrophobic fatty acid chains anchor the LPS into the bacterial membrane. The lipid A 
domain is the endotoxic part of LPS and is responsible for much of the toxicity of Gram-
negative bacteria. When bacterial cells are lysed by the immune system, fragments of 
membrane containing lipid A are released into the circulation, causing fever, diarrhea, and 
possibly fatal endotoxic shock (also called septic shock). Lipid A interacts with the host 
LPS receptor complex consisting of TLR4 and its coreceptor MD-2 to induce cellular 
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responses. 
The number and length of acyl side chains are critical
 
for TLR4 signaling in humans 
and mice. Hexa-acylated Lipid A maximally stimulates immunological
 
responses, 
whereas altering the number or length of
 
the attached fatty acids reduces the magnitude of 
the signal (215). Lipid A of Y. pestis differs in the degree of acylation, depending on the 
temperature at which Y. pestis is grown. The lipid A obtained from bacteria cultivated at 
ambient temperature is normally a typical
 
hexa-acylated LPS, which is a strong activator 
for the TLR-4 mediated signaling pathway for TNF-α production in macrophages.  
TNF-α, a cytokine involved in systemic inflammation, is mainly produced by 
macrophages, but also by a broad variety of other cell types including TipDCs. TNF-α is 
a multi-functional cytokine which is able to activate macrophages, to induce apoptotic 
cell death, and to inhibit tumorigenesis and viral replication. It is also a potent 
chemoattractant for PMNs, and helps them to stick to the endothelial cells for migration.  
After the temperature transition from
 
26°C to 37°C, Y. pestis
 
immediately begins to 
produce LPS with tetra-acylated Lipid A, which is not
 
only nonstimulatory for TLR4 but 
also acts as an antagonist
 
for the stimulatory hexa-acylated form of LPS (91, 223). It is 
also reported that tetra-acylated LPS (37°C) can inhibit stimulation of DCs not only via 
TLR4 signaling but also via TLR2 and TLR9 (330).  
The change of LPS from the hexa-acylated to the tetra-acylated form occurs rapidly 
after the temperature transition. The modification of Lipid A stimulated by a 3-h pre-
induction might not seem like much, but the TLR-mediated anti-bacterial response is 
potent: Y. pestis that is modified to stably produce hexa-acylated due to a plasmid-borne 
E. coli acyltransferase is completely avirulent (223). We hypothesize that the 
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downregulation of cytokine and chemokine production caused by the inhibition of TLRs 
via tetra-acylated Lipid A favors the growth of the yopM-1 mutant in spleen before d 3 
p.i.. 
 
J. Current Model of the YopM virulence Mechanism 
a) Spleen and liver respond differently to YopM 
Due to difficulty in separating leukocytes from hepatocytes, the immune responses to 
Y. pestis in liver has not been studied as much as in spleen. In our systemic plague studies, 
we found that spleen and liver respond to Y. pestis infection differently with regard to 
recruitment of NK cells（Figure 4.1）and pDCs (Figure 5.1) as well as Ly6G-CD11b+ 
MDMs (Figure 8.1). Meanwhile, in contrast to spleen, liver did not respond with 
differential inflammatory DC recruitment in mice infected with parent and yopM Y. 
pestis (Figure 8.9), and the parent strain did not complement the yopM  mutant in trans 
after d 2 p.i. in liver (Figure 8.12).  These findings suggest that YopM does not exert a 
dominant effect on chemokine pathways in liver; or, that YopM’s effect on chemokine 
pathways is redundant for recruitment of inflammatory cells. The importance of CCR2 
for recruitment of cells into spleen but not liver during systemic plague and a selective 
inhibitory effect of YopM
+
 Y. pestis on this recruitment may explain our previous finding 
that NK cells, which are also recruited via CCR2 (190, 250), are differentially recruited to 
spleen by the parent and YopM- strains, whereas there is no difference in recruitment of 
NK cells by the two Y. pestis strains in liver (Figure 4.1).   
In the spleen, the blood-borne pathogens leave the bloodstream and enter the external 
rim of the white pulp through a transit area called the marginal zone and reach the venous 
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sinus of the red pulp from the penicillar arteries that form terminal branches of the central 
arterioles. The marginal zone contains a large number of resident cells including 
macrophages and DCs. Two subsets of macrophages, marginal zone-macrophages and 
marginal-zone metallophillic macrophages, can be found there. Marginal zone-
macrophages form the outer macrophage ring and express specific ICAM-3 grabbing 
nonintegrin-related 1 (SIGNR1), a C-type lectin, and macrophage receptor with a 
collagenous structure (MARCO), a type I scavenger receptor. Marginal-zone 
metallophillic macrophages are close to the white pulp to form the inner macrophage ring. 
The adhesion molecule sialic-acid-binding immunoglobulin-like lectin 1 (SIGLEC1) is 
present on the surface of these cells. Marginal zone B cells and DCs are located between 
these two rings (Figure 10.7) (205). 
In addition to TLR-4, the specific receptors on those macrophages play a critical role 
in the trapping of blood-borne pathogens. The SIGNR1 and MARCO on marginal-zone 
macrophages synergistically mediate uptake of pathogens through recognition of their 
surface molecules, such as mannosylated lipoarabinomannan on the surface of 
Mycobacterium tuberculosis. SIGLEC1 on the marginal-zone metallophilic macrophages 
can bind sialic-acid residues at the cell surface of some pathogens, which may 
concentrate blood-borne pathogens in this area, leading to their subsequent clearance 
through phagocytosis (205). In response to the ingested pathogens, these macrophages 
produce different proinflammatory cytokines, e.g., IFN, TNF and IL-1. In the red pulp, 
macrophages actively migrate in and out of the venous sinuses and phagocytose 
pathogens they encounter there.  
Liver structure, function, and response to infection are distinct from those in spleen 
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(145, 232). As the largest reticulo-endothelial cell network in the body, the liver is a 
major source of many components of the innate immune response including acute-phase 
and complement proteins as well as inflammatory cytokines and chemokines. The liver 
receives a dual blood supply from the hepatic portal vein and hepatic arteries. Supplying 
approximately 75% of the liver's blood supply, the hepatic portal vein carries venous 
blood drained from the spleen, gastrointestinal tract, and its associated organs. The 
hepatic arteries supply arterial blood to the liver, accounting for the remainder of its 
blood flow. The reticulo-endothelial cell network in liver displays a sinusoidal structure 
with fenestrated, discontinuous endothelium and serves as a mixing chamber for the 
oxygen-rich blood from the hepatic artery and the nutrient-rich blood from the portal vein. 
Endothelial cells, KCs, hepatic stellate cells, Pit cells and some DCs are located in 
sinusoids and called as “hepatic sinusoidal cells”. As shown in Figure 10.8, the 
endothelial cells have pores or fenestrations through which solutes can apparently move 
freely into the perisinusoidal space. 
Unlike most of the splenic macrophages which are localized in the marginal zone and 
splenic cords and trap pathogens that filter out of the central arterioles, KCs are located 
within the lumen of the sinusoids (145). KCs are the first defense line to be exposed to 
pathogens that come with blood. Actually, liver sinusoidal KCs constitute 80~90% of the 
tissue macrophages in the body. As the resident macrophages, KCs are the principal liver 
cells for phagocytosis, antigen presentation, and production of pro-inflammatory 
cytokines. 
KCs express a variety of TLRs, including TLR4 which is involved in uptake and 
clearance of LPS and production of cytokines, as well as TLR2 that leads to production 
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of pro-inflammatory cytokines (145). In response to LPS or some pro-inflammatory 
bacterial products, KCs are activated and  produce large amount of inflammatory 
mediators including cytokines (e.g. TNF- and IFN-), ROS and NO, and chemokines 
(CCL2/MCP-I, IL-8), while KCs  in the non-inflamed liver secrete anti-inflammatory 
mediators, such as IL-10 and TGF-β (161, 258).  
The interaction between KCs and PMNs is prominent in the response to bacterial 
infection (117, 119, 141). KCs themselves are not potent antibacterial cells, but they bind 
bacteria avidly and present them to PMNs for killing (117-119, 182). In response to 
stimulation of TLRs, KCs do produce IL-1, IL-6, and TNF (119) that activate 
endothelial cells to produce CCL2/MCP-1. KCs also produce CCL3/MIP-1, which 
recruits DC precursors to liver (364).   
 
b) Model of ambient-temperature grown YopM-mediated immune modulation 
in spleen  
As shown on Figure 10.7, our findings for spleen in systemic plague are incorporated 
to generate a model for the sequence of events in wt mice.  , the IV-injected ambient-
temperature grown Y. pestis reach the marginal zone sinus and pass through 
discontinuous endothelium and interact with resident DCs and macrophages. Initially, 
hexa-acylated lipid A (flea version) stimulates resident cells through TLR4-mediated 
pathways (223, 261) and creates a local pro-inflammatory environment. Meanwhile, the 
phagocytosis resistance and other inhibitory effects on host defense caused by major 
virulence factors, such as T3SS, Caf1, and PsaA, are not manifested yet because the 
expression of these genes has not been fully induced. Y. pestis could bind to and be 
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ingested by resident macrophages and DCs through Pla and Ail, the adhesions expressed 
at both 26
 o
C and 37
 o
C. Within the phagocytosome, the bacteria inhibit acidification (255) 
and may have access to the cytosol (254), where they potentially promote 
proinflammatory cytokine expression through stimulation of intracellular molecular 
pattern receptors such as NOD1 and NOD2 (213, 298). This intracellular incubation step 
is critical for the growth of the Y. pestis in vivo because removal of these resident 
phagocytes by clodronate caused the failure of both strains to multiply. The 
thermoregulated genes of Y. pestis start to be expressed while the bacterium resides 
intracellularly and support the survival of bacterium by dampening the bactericidal 
function of those phagocytes. Once released, the bacterium would be fully adapted to 
37
o
C and able to resist phagocytosis by PMNs.   
, YopM delivered to resident cells by extracellular Yersinia would curtail expression 
of proinflammatory cytokines and some chemokines that may already exist and would 
have been activating cells locally or serving as homing factors for inflammatory 
monocytes. This downregulation constitutes the induction phase of YopM’s pathogenic 
effect.  It is the outcome of molecular cell biological interactions mediated by YopM 
within resident cells that have yet to be defined. If the infecting Y. pestis are pre-induced 
for 3 hours, their lipid A changed from the hexa-acylated form to the tetra-acylated form, 
which is not
 
only nonstimulatory for TLR4 but also acts as an antagonist
 
for the 
stimulatory hexa-acylated form of LPS. Pre-induction is assumed to inhibit some early 
immune responses that overlap with those compromised by YopM in spleen because the 
pre-induction compensates for the loss of YopM in the very early stage of the infection of 
the yopM mutant in spleen. 
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, before YopM carries out its inhibitory effects on the resident cells, the initial 
proinflammatory condition would have attracted PMNs and inflammatory monocytes 
(iMOs)/DCs from blood by activating local endothelial cells and more of these cells 
would have been recruited from the bone marrow. They are recruited in parallel, through 
separate chemokine pathways. 
, YopM compromises the accumulation of CCR2+ iDCs in spleen; however, PMNs 
are recruited similarly whether YopM is present or absent from the infecting Y. pestis. 
Therefore, the initial capture and rolling steps mediated on endothelial cells by selectins 
are unlikely affected by YopM because those selectins interact with both PMNs and 
inflammatory monocytes. The defective influx of CCR2
+
 iMOs and CCR2
+
 NK cells into 
spleen infected by the YopM-containing parent strain could result from YopM’s inhibitory 
effect on activation of the endothelial cells (ECs) and nearby resident cells to express 
chemokines such as CCL2/MCP-1 () that support recruitment of CCR2+ cells to the 
focus of infection. 
If the infecting Y. pestis strain lacks YopM, CCR2
+
 iMOs develop into CCR2
+
 iDCs 
that persist in spleen and reduce net growth of the bacteria by releasing NO (). Neither 
the recruitment nor activation of PMNs, in which the signal from CXCL1() may be 
critical, is affected in spleen by the presence of YopM in the infecting bacteria, which 
indicates that YopM does not modulate the innate immune responses in spleen through 
affecting PMNs. Although YopM inhibits the recruitment of NK cells into spleen, NK 
cells are not critical in the YopM mediated virulence (). 
c) Model of ambient-temperature grown YopM-mediated immune modulation in 
liver  
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Figure 10.8 describes a possible model for the sequence of events in liver of systemic 
plague of WT mice. , the input ambient-temperature grown Y. pestis reach the sinusoid 
of liver via the blood and interact with KCs in liver. The hexa-acylated lipid A of the 
infecting bacteria may induce early pro-inflammmatory responses by stimulating KCs 
through the same mechanism as in splenic resident macrophages. However, after pre-
induction, YopM injected into host cells does not compromise this early pro-
inflammatory response () because the growth limitation of the yopM mutant in liver 
was maintained despite the dampening effect on pro-inflammmatory responses due to the 
nonstimulatory LPS with tetra-acylated Lipid A.  
Although YopM uses the same molecular mechanisms to modulate immune responses 
in spleen and liver, the affected pathways have different cellular components between 
spleen and liver. However, the global systemic responses to the infecting Y. pestis is 
universal and YopM plays no important role in these responses ().  
, CCR2+ PMNs, CCR2+ iMOs/iDCs and CCR2+ NK cells are recruited similarly 
into liver between the parent and yopM Y. pestis, indicating that the recruitment of those 
cells is independent of the CCR2-CCL2 signaling pathway. However, PMN function is 
undermined by YopM in some CCR2-related way, perhaps indirectly at the level of an 
interaction of PMNs with KCs or endothelial cells. This is a downstream response to 
YopM in liver. If YopM is not present in the infecting strain, PMNs reduce net growth of 
the bacteria () through production of bactericidal compounds probably including ROS 
and defensins. 
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K. conclusion 
In this study, we used a systemic plague model to identify the cells and pathways that 
are undermined by the virulence protein YopM of the plague bacterium Yersinia pestis. 
YopM favors the growth of Y. pestis through modulating the innate immune responses.  
Gr1
+
 cells are required to selectively limit growth of YopM- Y. pestis, and the virulence 
mechanism of YopM involves different subsets of Gr1
+
 cells in spleen and liver. Gr1
+
 
PMN ablation relieved the growth defect of YopM- Y. pestis only in liver, showing that 
PMNs are critical for controlling growth of YopM- Y. pestis in liver but not spleen. In 
spleen, the Gr1
+
 CD11b
+
 CD11c
lo-int
 MAC3
+
 iNOS
+
 iDCs are differentially recruited by 
parent and YopM- Y. pestis infections, and their recruitment to spleen from blood was 
blocked when YopM was present in the infecting strain.  
Both Gr1
+
 PMNs and Gr1
+
 iDCs express CCR2, the chemokine receptor for 
CCL2/MCP-1, on their surface and YopM- Y. pestis grows as well as the parent strain if 
mice lack CCR2. Therefore, CCR2 is identified as a critical node in the chemokine 
communications network that YopM disables. Taken together, the data show that YopM 
modulates the host immune system by disabling the recruitment of CCR2
+
 Gr1
+
 iDCs 
into spleen, while undermining the function of CCR2
+
 Gr1
+
 PMNs in liver. 
Meanwhile, YopM is indispensable for the full virulence of Y. pestis in bubonic 
plague because the absence of YopM significantly increased the LD50 in the ID infection 
model. CCR2 was found to be responsible for controlling growth of YopM- Y. pestis in 
skin, indicating that YopM’s molecular targets in skin ultimately act through CCR2 and 
showing that CCR2-mediated functions are important in host defense against bubonic 
plague. Thus, the findings provide a framework for focusing future research to identify 
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YopM’s direct molecular targets. 
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Table 10.1 Differences between NK cells derived from splenocytes in response to IL-
12/IL-18 and those derived in the presence of IL-2 or IL-15 （Summarized from 
References (175, 176)） 
   
 
 
 
 
 
 
 
 
 
 
 IL12/IL18 treatment IL2 treatment IL15 treatment 
Cell type(s) 
produced 
NK NK and NKT NK and NKT 
 
Expression of 
Surface 
NK1.1 
None Yes
 
 
Yes 
Cytokine 
production  
IFN-γ 
IL-3 
IL-6 
TNF 
IL-4 and IL-10 
IL-5 
IL-9 
IL-13 
 
none 
Cytotoxicity Strong weak weak 
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Table 10.2 Characteristics of DC subsets  
 
 
 CD11b+DC 
(Myeloid DCs) 
CD8+DCs 
(Lymphoid DCs) 
B220+DCs 
(Plasmacytoid 
DCs) 
Early 
Haematopoie
tic Precursors 
Although there are myeloid-restricted and lymphoid-restricted 
precursors, they can develop to all of the three subsets (299) 
 
Factors that  
Promote 
Differentiation 
 
 
Transcription Factor 
RelB (361) 
Transcription Factor 
Id2 (122) and ICSBP 
(IFN consensus 
sequence binding 
protein) (5) 
 
Flt3L (68) 
 (CD135 ligand) 
Chemokines  
or their 
Receptors  
CCR1 and 5  
(recognize MIP-1α 
from Kuffer Cells)  
(364) 
 
CCL19 and CCL21(69) 
CCL3 
 
CCL19 and 
CCL21(69) 
CXCR3 (68),  
CCR7 (244) 
CCR1, CCR2 and 
CCR5 (68) 
 
 
Distribution 
in Spleen 
Marginal zone 
(migrate into T-cell 
zones on stimulation 
with microbial 
products) (299) 
 
T cell zone
 
 
T cell zone and 
scattered in 
marginal zone and 
red  pulp (68) 
Maturation 
Markers 
 
CD80, CD86, CD40, MHC-II (187, 295) 
Major 
Surface 
Markers 
High CD11c  
CD11b(299) 
 
High CD11c  
CD8 
CD205(299) 
Moderate CD11c 
B220 (CD45RA) 
Ly6C (68) 
Function in 
Innate 
Immunity 
Induce a 
TH2-biased response 
(299) 
 
 
 
 
IL-12p40 and TNF-
α ?(153) 
Produce IL-12 
and IFN-γ to 
induce a TH1-
biased cytokine 
response (16) 
 
IL-12p40 and 
TNF-α (153) 
Produce IFN-α and β 
(upon bacterial 
or viral infection) (68) 
 
IFN-γ 
(upon IL-4 
stimulation) (324) 
 
Activate NK cells 
through GITRL (124) 
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Table 10.3 Characters of PMN subsets  
 
 
a. MRSA, methicillin-resistant Staphylococcus aureus; b. SIRS, systemic inflammatory 
response syndrome 
All the information comes from reference (340) unless denoted.  
 PMN-I PMN-II PMN-N 
Source  
 
MRSA
a
- resistant hosts 
(SCIDbg mice with 
mild SIRS
b
) 
 
MRSAsusceptible 
hosts 
(SCIDbg mice with 
severe SIRS) 
 
SCIDbg mice 
without SIRS 
 
Shape of the 
nucleus 
Multilobular Ring-form Round 
MPO positive 
granules in 
cytosol 
 
High Level Minimal Level 
 
Minimal Level 
Surface 
Antigen 
Expression 
CD49d
+
 
CD11b
-
 
CD49d
-
 
CD11b
+
 
CD49d
-
 
CD11b
-
 
TLR 
Expression 
 
TLR 2,4,5 and 8 TLR 2,4,7 and 9 TLR 2,4 and 9 
Cytokine 
Production 
IL-12 
TNF-α 
IL-1β 
 
IL-10 
TNF-α 
IL-1β 
No 
Chemokine  
Production  
 
CCL3  
CXCL1 
CCL2 
CXCL1 
No 
 
H2O2 
production 
 
Yes Yes No 
Activate 
Macrophage 
Classically Activated 
Macrophage 
(anti-bacteria effector 
cells) 
Alternatively 
Activated Macrophage 
(promote fibrosis, 
wound healing, 
neovascularization and 
granuloma formation 
(336) ) 
 
No 
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Table 10.4 Characteristics of monocytes subsets (Summarized from References (18, 
293)  
 
 
Common markers of bone marrow and blood monocytes: CD115 (M-CSF-R), CD11b and 
F4/80 (low) 
 
 
 
 
 
 
 
 Ly6C
+
 
(human: CD14
+
, 90% in 
circulation) 
 
CX3CR1
+
 
(human: CD16+,10% in 
circulation) 
Chemokine 
Receptor 
CCR2 
 
 
(ligand: CCL2, 7, 8, 13 and 16) 
(CCL2 produced by endothelial, 
fibroblast, epithelial, smooth 
muscle cells) (85) 
 
CX3CR1  
 
 
(ligand: CX3CL1/fractalkine: 
produced by endothelial cells, 
monocytes, T cells and NK cells) 
 
% in 
Circulation 
50% 50% 
Surface 
Marker at 
High Level 
CD11b, CD62L  MHC-II, CD11c 
Size  Large (10-14uM) Small (8-12uM) 
Development  Inflammatory monocyte  
(highly phagocytic) 
 
 
DCs, macrophages  
Long lived in blood 
                    Steady-state 
 
Resident Macrophages and DCs 
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Figure 10.1 the relationship between YopM and adaptive immunity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time course of infection with Y. pestis KIM5 and the yopM-1 mutant in BL/6 and SCID 
mice. BL/6 mice (open symbols) and SCID mice (solid symbols) were infected with 100 
CFU of Y. pestis KIM5 (squares) or Y. pestis KIM5-3002 (yopM-1, circles). A, CFU in 
spleens  and B, CFU in livers. The horizontal dotted lines indicate the lowest numbers of 
CFU per organ detected with at least 30 CFU per plate. The mice infected with the parent 
strain KIM5 were all morbid by day 5 and had died several hours prior to preparation for 
CFU analysis (indicated by the parentheses). (NS, not significantly different; *, P < 0.05; 
**, significantly different at P < 0.01). (159) 
 245 
Figure 10.2 Previous model of virulence mechanism of YopM  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YopM injected into macrophages by the T3SS inhibits the expression of all three major 
cytokines for NK cell development, IL-12, IL-18, and IL-15. Meanwhile, IL-15R 
expression on the NK cell surface is also inhibited by the YopM delivered into NK cells.  
The effects of YopM on both cell types promote systemic depletion of NK cells and 
compromise the production of IFN-γ by NK cells, which causes deficient activation of 
macrophages. The growth of the yopM-1 mutant is limited because of the subsequently 
reduced innate and Th1 immunity. (159) 
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Figure 10.3 Leukocyte Extravasation  
 
A. 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. the model for leukocyte recruitment (285). Blood flow is from the left to the right as 
indicated. Free flowing leukocytes (1) are captured by activated endothelial cells and 
begin to roll along the vessel wall on endothelial selectins (2). The rolling leukocytes 
sense chemoattractive signals, i.e. chemokines, and become activated for firm adherence 
to the endothelium mediated by b2 integrins (3). Firmly adhering leukoctyes transit into 
the extravasacular space through intercellular endothelial gaps (4), where they migrate 
along chemoattractive gradients to the inflammatory focus. B. adhesion molecules and 
respective ligands involved in transendothelial migration of PMNs (352). PSGL-1, P-
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selectin glycoprotein ligand-1; ESL-1, E-selectin ligand 1; LFA-1, lymphocyte associated 
function antigen-1; PECAM, platelet-endothelial cell adhesion molecule, Mac-1, 
macrophage antigen-1. 
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Figure 10.4 Phenotype of monocyte subsets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inflammatory (left) and resident (right) monocytes differentially express cell adhesion 
molecules and chemokine receptors, thus implying distinct recruitment mechanisms(305). 
 
 
 
 
 
 
 
 
 
 
Lo
w 
Hi 
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Figure 10.5 Development of monocytes (Summarized from Reference (18, 293)  
 
A. Spleen 
 
 
                          
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
B. Skin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue damage (e.g. UV light, inflammation) 
Need circulation myeloid precursor 
 
Ly6C
+
 
LCs F4/80
+
 macrophage  
 
Inflammation induces the release of 
MCP-1, which binds to skin-draining 
lymph nodes and recruits Ly6C
+
CCR2
+
 
monocytes  
Bone  
Marrow  
Spleen 
Blood 
Steady State 
Local pre-DC 
LCs (Langerhans cells) 
Local 
Pre-DCs MDP 
Resident 
macrophages 
and DCs  
recruited by 
CCL2-CCR2  
TipDCs  
 
macrophage  
Inflammation  
Steady state 
MDP (macrophage-DC 
progenitor) 
Ly6C
+
 
CX3CR1
+
 
(after depletion of circulating 
monocyte ,  
7 day to replenish) 
 
Ly6C
+
 
(after depletion of 
circulating monocytes, 
 3-4 day to replenish) 
Common myeloid progenitor cells (CMP) 
(CD117+ Lin-(linage associated marker, e.g. CD3, NK1.1)) 
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Figure 10.6 The signaling pathways activated upon CCL2/MCP-1 ligation to CCR2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCR2 is a GPCR. Interaction between CCL2 and CCR2 activates the G protein and 
induces the PLC-IP3 pathway, which stimulates intracellular calcium release. In addition 
to inducing IP3, PLC causes the activation of PKC that activates PKC-dependent NF-κB. 
NF-κB upregulates several genes that produce directional cell motion. Rho is also 
activated, which results in induction of cell mobility. DAG, diacylglycerol; IP3, inositol 
trisphosphate; NF-κB, nuclear factor-kappa B; PIP2, phosphatidylinositol-bisphosphate; 
PKC, protein kinase C; PLC, phospholipase C. (207) 
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Figure 10.7 Model for how YopM affects cells and cytokines in systemic plague caused 
by Y. pestis (Spleen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The flow of events following IV infection of WT mice is indicated by the numbers.  Red 
arrows and text denote YopM-specific effects. See the Discussion for a narrative 
description. （The cartoon of the structure of the spleen marginal zone is modified from 
reference (205)） 
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Figure 10.8 Model for how YopM affects cells and cytokines in systemic plague caused 
by Y. pestis (Liver) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The flow of events following IV infection of WT mice is indicated by the numbers.  Red 
arrows and text denote YopM-specific effects. See the Discussion for a narrative 
description. （The cartoon of the structure of the sinusoid in liver is modified from 
reference (252)） 
Copyright © Zhan Ye 2010
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APPENDICES 
(LIST OF ABBREVIATIONS) 
 
ABC              ATP-binding cassette 
Ail                  attachment-invasion locus 
APC               allophycocyanin  
apoB                apolipoprotein B 
CaM               calmodulin 
Cb                  carbenicillin 
CCL2             Chemokine (C-C motif) ligand 2 
CCR2             Chemokine (C-C motif) Receptor 2 
CFU              colony forming unit 
cNOS            constitutive nitric oxide synthase  
DAF               4-amino-5-methylamino-2',7'-difluorofluorescein 
DC                 Dendritic cell 
DCF               2',7'-dichlorofluorescein  
DCFDA          2',7'-dichlorodihydrofluorescein diacetate 
EMA               ethidium monoazide 
ERK                extracellular signal-related kinase 
ESL-1             E-selectin ligand 1 
F1 protein       fraction 1 proteins 
FITC               fluorescein isothiocyanate 
Fur                  ferric uptake regulation 
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GAP               GTPase-activating protein 
GEF               Guanine nucleotide-Exchange Factors 
GITRL            ligand for the glucocorticoid-induced TNF receptor 
GM-CSF        granulocyte–macrophage colony-stimulating factor 
GPCR             G protein-coupled receptor 
HIB                Heart Infusion Broth 
hms                 hemin storage locus 
HPI                 high-pathogenicity island  
ICAM-1         intercellular adhesion molecule-1 
ID                   intradermal 
IKK               inhibitor-κB kinase 
IN                   intranasal 
IP                   intraperitoneal  
irp                  iron-regulated proteins 
KC                Kupffer cells 
KO                knock-out  
LcrV             low calcium response protein V 
LFA-1           lymphocyte associated function antigen-1 
LPS               lipopolysaccharide 
LRR              leucine-rich repeat 
Mac-1           macrophage antigen-1 
MaFIA          Macrophage Fas-induced apoptosis 
MAPK          mitogen-activated protein kinase 
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MARCO       macrophage receptor with a collagenous structure 
MCP-1         Monocyte Chemoattractant Protein-1 
mDC             myeloid DC  
MDM           inflammatory monocytes/DC, myeloid DC and macrophage 
MDP             macrophage-DC progenitor  
MDR            macrophage disappearance reaction  
MFI              mean fluorescence intensity 
MHC            major histocompatibility complex 
MKK            mitogen-activated protein kinase kinase 
MT               Murine Toxin  
NF-κB          nuclear factor-κB 
NK cell         natural killer cell 
NO               nitric oxide 
NOS             NO synthase  
ORF             open reading frames 
PC                peritoneal cell 
pCD1           Calcium Dependence 
pDC             plamacytoid DC 
PE                phycoerythrin 
PECAM       platelet-endothelial cell adhesion molecule 
pgm             the pigmentation locus 
p.i.                post infection  
Pim               pesticin immunity protein 
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Pla                plasminogen activator 
Plg                plasminogen 
Pln                plasmin 
PMA            Phorbol Myristate Acetate  
PMN            polymorphonuclear leukocyte 
pPCP1         Pesticin, Coagulase, Plasminogen activator 
PRK2           protein kinase C-related kinase 2 
PSGL-1        P-selectin glycoprotein ligand-1 
Pst                bacteriocin pesticin 
PTP               protein tyrosine phosphatase 
RANTES      regulated on activation, normal T cell expressed and secreted 
RFU               relative fluorescence unit 
ROS              Reactive Oxygen Species 
RSK1             ribosomal S6 protein kinase 1 
SC                  subcutaneous 
SCID mice      severe combined immunodeficiency mice 
SIGLEC1        sialic-acid-binding immunoglobulin-like lectin 1 
SIGNR1         specific ICAM-3 grabbing nonintegrin-related 1 
TBA                 tryptose blood agar 
TCR                  T cell antigen receptor 
TLR                  Toll-like receptor 
TNF-α              tumor necrosis factor-α  
T3SS                Type III Secretion System 
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WT                   wild-type 
Yap                   Yersinia Autotransporter Protein 
Yop                   Yersinia outer protein 
YSA                  Yersinia selective agar 
Ysc                    Yop secretion 
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